Neurogynaecology and Women’s Reproductive Health: A PRISMA Based Systematic Review of Neuroendocrine Regulation, Autonomic Dysfunction, Psychosomatic Stress, and Integrative Therapeutic Outcomes

Neurogynaecology and Women’s Reproductive Health: A PRISMA Based Systematic Review of Neuroendocrine Regulation, Autonomic Dysfunction, Psychosomatic Stress, and Integrative Therapeutic Outcomes | Research Square window.SnipcartSettings = { analytics: { enabled: false } }; (function() { var accessVector = localStorage.getItem('access_vector') || ''; window.dataLayer = window.dataLayer || []; if (accessVector) { window.dataLayer.push({ user: { profile: { profileInfo: { snid: accessVector } } } }); } })(); (function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start':new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0],j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src='https://www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f);})(window,document,'script','dataLayer','GTM-K279D39R'); Browse Preprints In Review Journals COVID-19 Preprints AJE Video Bytes Research Tools Research Promotion AJE Professional Editing AJE Rubriq About Preprint Platform In Review Editorial Policies Our Team Advisory Board Help Center Sign In Submit a Preprint Cite Share Download PDF Systematic Review Neurogynaecology and Women’s Reproductive Health: A PRISMA Based Systematic Review of Neuroendocrine Regulation, Autonomic Dysfunction, Psychosomatic Stress, and Integrative Therapeutic Outcomes Dr Harshu Sharma, Lovlish Gupta This is a preprint; it has not been peer reviewed by a journal. https://doi.org/ 10.21203/rs.3.rs-9181695/v1 This work is licensed under a CC BY 4.0 License Status: Posted Version 1 posted You are reading this latest preprint version Abstract Background Neurogynecology is a rapidly evolving interdisciplinary field that elucidates bidirectional interactions between the nervous system and the female reproductive system. Disorders including polycystic ovarian syndrome (PCOS), dysmenorrhea, endometriosis, chronic pelvic pain, and stress-related infertility are increasingly recognised as biopsychoneuroimmune conditions in which neuroendocrine dysregulation, autonomic imbalance, psychosomatic stress, and neuro-immune signaling function as central pathogenic mechanisms. Objectives To systematically synthesise evidence on neuro-gynaecological mechanisms, evaluate clinical correlations, and assess integrative therapeutic outcomes across key gynaecological conditions. Methods A PRISMA-guided systematic review was conducted. PubMed, Scopus, and Google Scholar were searched using predefined Boolean operators. Peer-reviewed clinical, observational, experimental, neuroimaging, and psychosomatic studies published primarily between 2000 and 2026 were included, for neurological, neuroendocrine, autonomic, or psychosomatic relevance to gynaecological pathology. Results Eighty-nine studies met inclusion criteria. Four principal neuro-gynaecological pathogenic domains were identified: (1) HPA–HPO axis dysregulation mediating stress-induced reproductive suppression; (2) autonomic nervous system imbalance characterised by sympathetic hyperactivity and reduced vagal tone, measurable by heart rate variability; (3) psychosomatic stress driving central sensitisation and disproportionate pain perception; and (4) bidirectional neuro-immune crosstalk sustaining neurogenic inflammation in chronic pelvic conditions. Conclusion Gynaecological disorders represent complex, centrally driven biopsychoneuroimmune conditions requiring multidimensional diagnostic and therapeutic frameworks. Adopting an integrative neuro-gynaecological model has significant potential to improve diagnostic precision, reduce symptom chronicity, and deliver personalised, patient-centered women's healthcare. Neurogynecology is positioned to become an essential and standard pillar of modern gynaecological practice. Neurology Endocrinology & Metabolism Sexual & Reproductive Medicine Psychology Neurogynecology neuroendocrine regulation autonomic nervous system psychosomatic stress central sensitisation neuro-immune interactions Figures Figure 1 Figure 2 Figure 3 1. Introduction Gynaecological disorders represent one of the most significant and pervasive public health challenges affecting women across the lifespan globally. While anatomical, nutritional, and hormonal factors have classically been considered the primary determinants of gynaecological health, a paradigm-shifting body of evidence has fundamentally transformed this understanding over the past two decades. Contemporary clinical and translational research demonstrates that gynaecological diseases are multifactorial in origin and are profoundly shaped by neurological, immunological, and endocrinological disturbances operating within a complex, bidirectionally integrated biological network (Kumari, 2013 ; Sankaranarayanan & Ferlay, 2006 ). The emergence of neurogynecology as a recognised interdisciplinary field reflects this scientific evolution. Central and peripheral neural systems are now understood to not merely regulate reproductive physiology but to actively determine the pathophysiology of gynaecological diseases through neuroendocrine, autonomic, and neuroinflammatory mechanisms (Hwang et al., 2014 ; Douglas, 2010 ). This understanding challenges the traditional organ-centric model of gynaecological care, which focused principally on anatomical abnormalities, hormonal assays, and structural pathology (França et al., 2017 ). Table 1 presents the five principal neuro-gynaecological biological systems and their respective reproductive roles. Table 1 Neuro-Gynaecological Biological Systems and Their Reproductive Roles Biological System Key Components Mechanism of Action Reproductive Functions Affected Associated Disorders Clinical Significance Neurological System Brainstem, limbic system (amygdala, hippocampus), hypothalamus, peripheral nerves Neural modulation of reproductive hormones and end-organ function via neuroendocrine signalling Menstrual cycle regulation, ovulation, and fertility PCOS, stress-related infertility, irregular menstruation Central to neuroendocrine coordination; disruption triggers reproductive dysfunction Endocrine System Hypothalamic–Pituitary–Ovarian (HPO) Axis and Hypothalamic–Pituitary–Adrenal (HPA) Axis Pulsatile hormonal signalling via GnRH, FSH, LH, oestrogen, and progesterone; cortisol modulation under stress Ovulation, follicular development, menstrual cyclicity, steroidogenesis Ovulatory disorders, PCOS, functional hypothalamic amenorrhea Core regulatory axis; HPA–HPO crosstalk is a primary mechanism in stress-induced reproductive failure Autonomic Nervous System Sympathetic and parasympathetic (vagal) divisions; pelvic plexus Neural control of pelvic vascular tone, ovarian steroidogenesis, and uterine contractility via adrenergic/cholinergic pathways Uterine contractility, ovarian blood flow, cervical function Dysmenorrhea, chronic pelvic pain, PCOS Sympathetic hyperactivity and vagal withdrawal are measurable and targetable contributors to gynaecological pathology Immune System Cytokines (IL-1β, IL-6, TNF-α), mast cells, macrophages, T lymphocytes, neuropeptides Bidirectional neuro-immune signalling; inflammatory cascade amplified by neurogenic mediators Tissue homeostasis, inflammatory regulation, wound healing Endometriosis, pelvic inflammatory disease, infertility Neuro-immune crosstalk sustains chronic inflammation and drives therapeutic resistance Psychosomatic System Limbic stress circuits (amygdala, prefrontal cortex), HPA axis, pain-processing networks Brain–body interaction via cortisol, central sensitisation, and autonomic dysregulation Menstrual regularity, pain perception, fertility, quality of life Anxiety-related infertility, central sensitisation syndromes Psychosomatic factors are independent pathogenic drivers, not secondary symptoms — their assessment is clinically mandatory Note. Sources : Brocca & Garcia-Segura ( 2019 ); Nicolopoulou ( 2001 ); Yu et al. ( 2024 ); Nepomnaschy et al. ( 2007 ); Lal ( 2009 ). Conditions including PCOS, primary and secondary dysmenorrhea, endometriosis, chronic pelvic pain, and stress-related menstrual irregularities are now understood as biopsychoneuroimmune disorders , conditions in which stress-mediated neural signalling, autonomic nervous system dysregulation, and neuroendocrine disruption are central, not peripheral, pathogenic factors (Licht et al., 2013 ; Van den Akker, 2011 ; Murck et al., 2025 ). Failure to recognise and address these dimensions within routine clinical practice is a primary contributor to treatment resistance, unexplained symptom persistence, and reduced quality of life in women with chronic gynaecological conditions. Despite the accumulating evidence base, neuro-gynaecological assessment remains substantially underrepresented in clinical gynaecology. Most evaluations continue to rely predominantly on hormonal assays and imaging, systematically overlooking neurological, autonomic, and psychosomatic contributors. This diagnostic gap partly explains the high prevalence of women with chronic gynaecological conditions who fail to achieve sustained symptom relief with conventional therapies alone. The present systematic review was therefore designed to consolidate and critically appraise the existing evidence on neuro-gynaecological mechanisms, evaluate their clinical significance, and provide a structured framework for integrative assessment and management of women's reproductive health conditions. Table 2 highlights the key conceptual and practical distinctions between traditional gynaecology and the neuro-gynaecological framework, illustrating the rationale for this paradigm shift. Table 2 Conceptual Comparison: Traditional Gynaecology versus the Neuro-Gynaecological Framework Dimension Traditional Gynaecology Neuro-Gynaecological Framework Conceptual Basis Organ-centric; disease arises from localised anatomical or hormonal pathology Biopsychoneuroimmune; disease arises from convergent dysfunction across neural, endocrine, immune, and reproductive systems Diagnostic Approach Pelvic imaging (ultrasound, MRI) and hormonal assays (FSH, LH, oestrogen, AMH) Expanded multimodal assessment: neuroendocrine profiling + autonomic function (HRV) + pain centralisation index + psychological screening + inflammatory biomarkers Disease Model Single-system, peripherally localised pathology Multisystem; central neural dysregulation drives peripheral manifestations Explanation for Treatment Resistance Inadequate hormonal suppression or surgical completeness Unaddressed central sensitisation, psychosomatic contributors, and neuro-immune inflammation Treatment Paradigm Hormonal pharmacotherapy, surgical correction, analgesics Integrative multidisciplinary: pharmacological + neuromodulatory + psychological + autonomic-regulating + neuro-immune modulating Pain Explanation Proportional to observable peripheral pathology (lesion size, inflammation) Pain severity reflects central sensitisation status — may far exceed anatomical findings Expected Outcomes Symptom reduction through peripheral correction Holistic improvement: reproductive function + pain relief + psychological wellbeing + quality of life Patient Stratification By hormonal profile and imaging stage By autonomic balance, stress biomarkers, pain sensitisation score, and psychosocial risk profile Note. This comparison illustrates the expanded conceptual and clinical scope that the neuro-gynaecological framework offers over conventional gynaecological practice. 2. Rationale, Objectives and Hypothesis 2.1 Rationale and Significance: The rationale for this systematic review arises from two converging clinical imperatives. First, neurogynecology remains substantially underrepresented in routine clinical practice despite a growing evidence base linking neurological processes to gynaecological disorders. Second, the organ-centric model of gynaecological care has demonstrably failed a significant proportion of patients, those with treatment-resistant chronic pain, unexplained infertility, and disproportionate symptom severity, precisely because it does not account for the central neural, autonomic, and psychosomatic determinants of disease. A comprehensive, methodologically rigorous synthesis of evidence is therefore urgently needed to support the clinical translation of neuro-gynaecological science into routine practice. 2.2 Objectives To systematically review and synthesise peer-reviewed literature on neuro-gynaecological interactions in women's reproductive health. To critically analyse neuroendocrine, autonomic, psychosomatic, and neuro-immune mechanisms implicated in the pathophysiology of gynaecological disorders. To evaluate the clinical efficacy of integrative, multidisciplinary neuro-gynaecological therapeutic approaches. To identify current research gaps and propose evidence-informed priorities for future neuro-gynaecological investigation and clinical translation. 2.3 Central Hypothesis This review is guided by the central hypothesis that gynaecological disorders are not isolated peripheral reproductive conditions but complex, centrally mediated biopsychoneuroimmune disturbances, and that their diagnosis and treatment require systematic integration of neurological, psychological, immunological, and reproductive assessments within a multidisciplinary clinical framework. 3. Methodology This systematic review was conducted in strict accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) 2020 guidelines to ensure methodological rigour, transparency, and reproducibility of the evidence synthesis process. A narrative systematic review design was adopted in preference to meta-analysis, given the methodological heterogeneity of available studies across outcome measures, populations, and study designs. 3.1. Data Source Systematic database searches were conducted across three major electronic bibliographic databases: PubMed/MEDLINE, Scopus , and Google Scholar. Reference lists of all included systematic reviews and relevant primary studies were additionally screened manually to capture eligible studies not retrieved through database searches. 3.2. Search Strategy Structured searches employed MeSH terms and free-text keywords combined with Boolean operators (AND, OR, NOT). Principal search terms included: "Neurogynecology," "neuroendocrine regulation," "hypothalamic–pituitary–ovarian axis," "hypothalamic–pituitary–adrenal axis," "autonomic nervous system," "heart rate variability," "psychosomatic stress," "central sensitisation," "PCOS," "polycystic ovarian syndrome," "dysmenorrhea," "endometriosis," "chronic pelvic pain," "neuro-immune interactions," "neurogenic inflammation," "integrative women’s healthcare," and "mind–body intervention." 3.3. Inclusion and Exclusion Criteria Inclusion (1) Peer-reviewed original research articles, systematic reviews, and narrative reviews in the English language; (2) Clinical, observational, experimental, neuroimaging, heart rate variability, and psychosomatic studies; (3) Studies examining neurological, neuroendocrine, autonomic, psychosomatic, or neuro-immune aspects of gynaecological disorders; (4) Studies reporting quantitative or qualitative outcomes relevant to neuro-gynaecological mechanisms or integrative therapeutic interventions; (5) Published primarily between 2000 and 2026, with foundational earlier studies included where relevant. Exclusion (1) Case reports or case series with insufficient data for systematic appraisal; (2) non-peer-reviewed literature, conference abstracts, and grey literature without verifiable methodology; (3) Animal studies without demonstrated translational relevance to human gynaecological pathology; (4) Duplicate publications from the same dataset. 3.4. PRISMA Study Selection The study selection process followed PRISMA 2020 recommendations. A total of approximately 1,840 records were identified across the three databases. After deduplication, approximately 1,210 records were screened by title and abstract. Full-text review was conducted for approximately 186 records, with 89 studies ultimately meeting all inclusion criteria and contributing to the qualitative evidence synthesis. The PRISMA selection summary is presented below in Table 3 . Table 3 PRISMA Study Selection Summary PRISMA Selection Stage Record Count / Description Database Search (PubMed, Scopus, Google Scholar) Preliminary records identified: ~1,840 After deduplication Records screened: ~1,210 After title and abstract screening Full-text articles assessed for eligibility: ~186 After full-text exclusion (case reports, non-English, non-peer-reviewed, no clinical relevance) Studies included in qualitative synthesis: 89 Publication year range 2000–2026 (with emphasis on post-2015 literature) Study designs included Systematic reviews, RCTs, observational studies, experimental studies, neuroimaging studies, HRV studies, and psychosomatic research Note. Precise record counts are approximate, reflecting the systematic search conducted across PubMed, Scopus, and Google Scholar using the described search strategy. 4. Findings: Neuroendocrine Regulation in Gynaecological Disorders The hypothalamic–pituitary–ovarian (HPO) axis constitutes the central neuroendocrine architecture of female reproductive physiology, coordinating hormonal signals that govern menstrual cyclicity, ovulation, follicular maturation, and steroidogenesis. Critically, the HPO axis does not function in isolation: it is intimately integrated with the hypothalamic–pituitary–adrenal (HPA) axis, the autonomic nervous system, and higher cortical and limbic brain structures. The reviewed evidence confirms that disruption of this integrated neuroendocrine architecture underlies a spectrum of common gynaecological conditions (Josimovich, 2013 ; Wu et al., 2025). Table 4 comprehensively delineates the principal neuroendocrine components, their mechanisms of dysregulation, and gynaecological consequences. Table 4 Neuroendocrine Components: Physiological Roles, Mechanisms of Dysregulation, and Gynaecological Consequences Neuroendocrine Component Physiological Role Mechanism of Dysregulation Hormonal Consequences Gynaecological Significance HPO Axis (GnRH–LH–FSH cascade) Central regulator of menstrual cyclicity, folliculogenesis, and ovulation Disruption of pulsatile signalling between hypothalamus, anterior pituitary, and ovaries under chronic stress or metabolic load Altered GnRH amplitude and frequency; aberrant LH:FSH ratio Menstrual irregularities, ovulatory dysfunction, unexplained infertility; core regulatory axis for all reproductive outcomes HPA Axis (CRH–ACTH–Cortisol) Stress response, systemic homeostasis, anti-inflammatory regulation Chronic stress-induced hyperactivation; excess cortisol suppresses hypothalamic GnRH neurones via direct negative feedback Elevated CRH, ACTH, and cortisol; suppressed gonadotropins Functional hypothalamic amenorrhea, anovulation, PCOS exacerbation; stress is a primary, reversible cause of reproductive failure Limbic–Hypothalamic Pathway Integration of emotional, behavioural, and environmental signals into endocrine output Amygdala and hippocampal hyperactivation under psychological stress directly modulates GnRH neurone firing Dysregulated GnRH secretion patterns Direct anatomical and functional link between emotional states and menstrual regularity; explains stress-induced cycle disruption Ovarian Steroidogenesis Under Stress Production of oestrogen and progesterone essential for cycle maintenance and endometrial preparation Cortisol directly inhibits follicular development and gonadal steroid biosynthesis via glucocorticoid receptors Reduced oestradiol and progesterone; impaired folliculogenesis Delayed ovulation, luteal phase defects, implantation failure; identifiable through integrated hormonal profiling Neuroendocrine Basis of PCOS Regulation of ovarian androgen production through gonadotropin balance Elevated GnRH pulse frequency preferentially drives LH over FSH; sympathetic hyperactivity amplifies androgen production Elevated LH:FSH ratio; excess theca cell androgen output Hyperandrogenism, anovulation, polycystic morphology; PCOS is fundamentally a neuroendocrine — not solely ovarian — disorder Prolactin and Neurohormonal Modulation Modulates lactation, reproductive hormone balance, and neuroimmune function Stress-induced hyperprolactinaemia suppresses GnRH via ultra-short feedback loop Reduced LH and FSH; disrupted ovulatory surge Infertility, luteal phase defects; elevated prolactin functions as a neurohormonal stress biomarker in reproductive evaluation Kisspeptin Signalling Upstream gatekeeper of GnRH secretion; integrates metabolic and stress signals into reproductive regulation Impaired kisspeptin neurone activity under chronic stress, nutritional deficit, or metabolic disorder Reduced GnRH release; suppressed gonadotropin cascade Delayed puberty, amenorrhea, stress-induced infertility; kisspeptin is an emerging translational diagnostic and therapeutic target Beta-Endorphin Pathway Endogenous opioid modulation of pain perception and hypothalamic neuroendocrine activity Stress- and pain-induced beta-endorphin release inhibits hypothalamic GnRH neurones and modulates descending pain pathways Suppressed GnRH and gonadotropin secretion under chronic pain or stress Ovulatory dysfunction in chronic pain syndromes; directly links dysmenorrhea and chronic pelvic pain to hormonal dysregulation Note. Sources : Petraglia et al. ( 2008 ); Chrousos et al. ( 1998 ); Reznikov ( 2023 ); Tsutsumi & Webster ( 2009 ); Pinilla et al. ( 2012 ); Valera et al. ( 2025 ); Ruddenklau & Campbell ( 2019 ). 4.1. Hypothalamic Control and GnRH Pulsatility The hypothalamus functions as the principal neuroendocrine integrator of the reproductive axis, translating neural signals, emotional stimuli, metabolic cues, and environmental stressors into coherent, timed endocrine responses. GnRH neurones in the arcuate nucleus and preoptic area release GnRH in a critically timed pulsatile pattern that is indispensable for normal pituitary gonadotropin secretion. Alterations in GnRH pulse frequency or amplitude directly impair LH and FSH release, disrupting ovarian function. Limbic inputs from the amygdala and hippocampus directly modulate hypothalamic GnRH neurones, establishing a direct and clinically measurable link between emotional states and reproductive function (George et al., 2012 ). 4.2. Stress-Induced HPA Axis Activation and Reproductive Suppression Chronic psychological or physiological stress triggers sustained HPA axis activation, generating sequential secretion of CRH, ACTH, and cortisol. Excess cortisol exerts potent inhibitory effects on the HPO axis by suppressing GnRH pulsatility and impairing ovarian steroidogenesis via glucocorticoid receptor-mediated inhibition of follicular development (Toufexis et al., 2014 ; Kaiser et al., 2023). This neuroendocrine cascade produces functional hypothalamic amenorrhea, menstrual irregularities, delayed ovulation, and unexplained infertility in women without primary ovarian pathology — demonstrating the primacy of central neuroendocrine regulation in reproductive health. 4.3. Neuroendocrine Dysregulation in PCOS PCOS is characterised by a fundamentally neuroendocrine pathogenesis. Aberrant GnRH pulse frequency preferentially drives LH secretion over FSH, stimulating ovarian theca cells to produce excess androgens and resulting in hyperandrogenism, anovulation, and polycystic ovarian morphology. Sympathetic nervous system hyperactivity and enhanced stress responsiveness exacerbate these neuroendocrine disturbances (Ruddenklau & Campbell, 2019 ). Elevated cortisol and aberrant beta-endorphin signalling further disrupt HPO axis feedback. These findings establish PCOS as a complex neuroendocrine condition centrally driven by dysregulated eural regulation, not a primary ovarian disorder (Solorzano et al., 2012 ; Garg et al., 2022 ). 4.4. Neurohormonal Modulation: Prolactin, Kisspeptin, and Beta-Endorphins Neurohormones including prolactin, kisspeptin, and beta-endorphins exert critical modulatory roles across the reproductive axis. Stress-induced hyperprolactinaemia suppresses GnRH secretion, contributing to luteal phase defects and infertility. Kisspeptin neurones function as upstream gatekeepers of GnRH release and are exquisitely sensitive to metabolic and stress signals — their dysregulation underlies amenorrhea and stress-induced infertility, positioning kisspeptin as an emerging diagnostic and therapeutic biomarker (Al-Fahham & Al-Nowainy, 2016 ; Nappi et al., 2021 ). Beta-endorphins released during chronic pain suppress hypothalamic activity, directly linking dysmenorrhea and chronic pelvic pain to hormonal dysregulation. 5. Findings: Autonomic Nervous System Dysfunction in Gynaecological Disorders The autonomic nervous system (ANS) comprising sympathetic, parasympathetic, and enteric divisions, plays an indispensable and clinically underappreciated role in female reproductive physiology. Via adrenergic and cholinergic innervation of pelvic organs, the ANS directly regulates ovarian steroidogenesis, uterine contractility, cervical secretion, and pelvic vascular tone (Stanković et al., 2021 ). A growing body of neurophysiological evidence demonstrates that autonomic dysregulation — characterised by sympathetic hyperactivity and reduced parasympathetic (vagal) tone — is a measurable, reproducible, and clinically significant contributor to the pathophysiology of multiple gynaecological conditions. Heart rate variability (HRV), a validated non-invasive biomarker of sympathovagal balance, has emerged as a key diagnostic and monitoring tool in neuro-gynaecological research (Agorastos et al., 2023 ). Table 5 systematically presents the ANS abnormalities identified across major gynaecological conditions and their clinical implications. Table 5 Autonomic Nervous System Dysregulation in Gynaecological Disorders: Mechanisms, Biomarkers, and Clinical Implications ANS Component Gynaecological Condition Mechanism of ANS Dysregulation Measurable Biomarker / Finding Clinical Implication Sympathetic hyperactivity PCOS Elevated catecholamine tone drives ovarian noradrenergic signalling, increasing ovarian androgen production and disrupting folliculogenesis Increased muscle sympathetic nerve activity (MSNA); elevated plasma norepinephrine; abnormal HRV (reduced HF power) ANS-targeted therapies (e.g., moxibustion, exercise, alpha-blockers) improve hormonal profiles; HRV monitoring guides treatment response Sympathetic hyperactivity + reduced vagal tone Dysmenorrhea Adrenergic stimulation increases uterine vascular resistance and prostaglandin-mediated myometrial hypercontractility; reduced vagal tone impairs endogenous analgesia Reduced RMSSD and HF/LF ratio on HRV analysis; elevated prostaglandin F2α; increased pain catastrophising HRV-guided biofeedback and parasympathetic-activating interventions (yoga, controlled breathing) reduce menstrual pain intensity and duration Autonomic imbalance (sympathetic dominance) Chronic pelvic pain Sustained sympathetic activity amplifies nociceptive afferent signalling from pelvic viscera; reduced vagal tone diminishes endogenous pain inhibition via cholinergic anti-inflammatory pathway Impaired HRV; elevated salivary alpha-amylase (sympathetic marker); allodynia on quantitative sensory testing Vagal nerve stimulation and parasympathetic activation reduce pelvic pain intensity; HRV serves as treatment monitoring tool Autonomic neuropathy of pelvic innervation Endometriosis-associated pain Abnormal sympathetic and sensory nerve innervation of ectopic lesions creates aberrant neural microenvironment sustaining neurogenic inflammation Dense SP- and CGRP-positive nerve fibres in lesions on immunohistochemistry; elevated neuropeptides in peritoneal fluid Targeting neural components of lesions alongside hormonal suppression; neuromodulatory approaches address pain refractory to standard therapy Impaired HPA–ANS integration Stress-related menstrual disorders Chronic stress simultaneously activates HPA and SNS, resulting in compounded suppression of HPO axis and sensitisation of visceral pain pathways Blunted cortisol awakening response; reduced HRV; disrupted menstrual cycle regularity Integrated stress management (MBSR, biofeedback) simultaneously targets HPA and ANS dysregulation; more effective than isolated hormonal intervention Note. Sources : Yu et al. ( 2024 ); Yun et al. ( 2004 ); Wei et al. ( 2020 ); Agorastos et al. ( 2023 ); Stanković et al. ( 2021 ). 5.1. Sympathetic Hyperactivity in PCOS Multiple lines of evidence converge in establishing sympathetic nervous system hyperactivity as a pathogenic contributor to PCOS beyond the classically described hormonal and metabolic features. Elevated ovarian sympathetic nerve density, increased catecholamine levels, and reduced HRV, indicative of impaired parasympathetic tone, have been documented in women with PCOS (Yu et al., 2024 ). Noradrenergic signalling within the ovary directly stimulates theca cell androgen production and inhibits follicular maturation, providing a mechanistic link between ANS dysregulation and the endocrine phenotype of PCOS. Interventions targeting sympathetic hyperactivity, including aerobic exercise, electroacupuncture, and alpha-adrenergic receptor modulation, have demonstrated improvements in both hormonal profiles and metabolic parameters. 5.2. ANS Dysregulation in Dysmenorrhea and Chronic Pelvic Pain Primary dysmenorrhea is associated with measurable autonomic imbalance, characterised by sympathetic dominance and reduced vagal tone during the menstrual phase. This autonomic shift increases uterine vascular resistance, promotes prostaglandin-mediated myometrial hypercontractility, and reduces the activation threshold of pelvic nociceptors. HRV analysis consistently demonstrates reduced parasympathetic indices — including RMSSD and HF power — in women with severe dysmenorrhea compared with controls, with the degree of autonomic imbalance correlating significantly with pain severity and psychological distress (Park & Watanuki, 2005 ). In chronic pelvic pain, sustained sympathetic activity amplifies nociceptive afferent signalling from pelvic viscera, while concurrent vagal withdrawal diminishes the cholinergic anti-inflammatory pathway, perpetuating a self-reinforcing cycle of inflammation and pain. 5.3. Autonomic Dysfunction and Endometriosis Endometriosis is characterised by aberrant autonomic innervation of ectopic lesions, including elevated densities of sympathetic and sensory nerve fibres (Wei et al., 2020 ). This neural microenvironment perpetuates neurogenic inflammation through neuropeptide release, while the adrenergic overstimulation of immune cells within lesions promotes cytokine production and further neural sensitisation. The co-existence of peripheral autonomic dysfunction and central sensitisation in endometriosis explains the characteristic dissociation between lesion burden and pain severity that is frequently encountered clinically. 5.4. Heart Rate Variability as a Neuro-Gynaecological Biomarker HRV analysis offers a clinically accessible, non-invasive, and validated window into ANS function in gynaecological patients. Reduced HRV — specifically low frequency/high frequency (LF/HF) ratio elevation and suppressed RMSSD — has been documented across PCOS, dysmenorrhea, endometriosis, and chronic pelvic pain populations. HRV correlates significantly with pain severity, psychological distress, and hormonal dysregulation, positioning it as a multidimensional biomarker of neuro-gynaecological dysfunction. HRV-guided biofeedback, which uses real-time autonomic feedback to train resonance breathing and vagal tone enhancement, functions as both a diagnostic and therapeutic tool in neuro-gynaecological practice (Agorastos et al., 2023 ). 6. Psychosomatic Stress and Central Sensitisation Psychosomatic stress is a critical and increasingly well-evidenced determinant of women's reproductive health, operating through complex bidirectional interactions between psychological processes, neural circuitry, endocrine regulation, and immune function. Psychological stress, anxiety, depressive disorders, and emotional trauma are robustly established as significant contributors to the onset, persistence, and severity of gynaecological disorders (Chorna, 2024 ). Within the neuro-gynaecological framework, these psychosocial factors exert pathophysiological influence primarily through dysregulation of central neural pathways and the development of central sensitisation — a condition characterised by amplified pain perception, lowered pain thresholds, and maladaptive neuroplastic remodelling of spinal and supraspinal pain-processing circuits (Delanerolle et al., 2025 ). Figure 1 illustrates the integrated psychosomatic–neuroendocrine pathways converging on gynaecological dysfunction. Chronic psychosomatic stress activates limbic structures including the amygdala and hippocampus, which communicate directly with the hypothalamus to modulate neuroendocrine output (Jankord & Herman, 2008 ). Sustained HPA axis activation results in prolonged cortisol secretion that disrupts GnRH pulsatility, impairs ovarian steroidogenesis, and progressively destabilises the HPO axis (Tsigos & Chrousos, 2002 ). As a consequence, oestrogen and progesterone synthesis become irregular, contributing to menstrual disturbances, ovulatory dysfunction, and heightened vulnerability to stress-sensitive gynaecological conditions. These findings establish psychosomatic stress not as a secondary co-morbidity but as a primary, centrally acting driver of reproductive dysregulation. Figure 2 depicts the integrated model through which psychosomatic stress drives central sensitisation and chronic gynaecological pain. Central sensitisation involves heightened excitability within the central nervous system, wherein repeated or prolonged nociceptive input leads to maladaptive neuroplastic changes in the spinal dorsal horn and supraspinal pain-processing regions. Psychological stress accelerates this sensitisation by enhancing excitatory neurotransmission (glutamate, substance P) while simultaneously impairing inhibitory pathways mediated by GABA and serotonin (Ciranna, 2006 ). Functional neuroimaging studies have demonstrated altered activation in the anterior cingulate cortex, insular cortex, thalamus, and prefrontal cortex in women with chronic pelvic pain, confirming the central neural origin of disproportionate gynaecological pain (As-Sanie et al., 2016 ; Yu et al., 2021 ). Table 6 . provides a systematic overview of psychosomatic mechanisms and their clinical dimensions. Table 6 Psychosomatic Mechanisms in Gynaecological Disorders: Neural, Endocrine, and Clinical Dimensions Psychosomatic Factor Neural Mechanism Neuroendocrine Effect Neurophysiological Change Gynaecological Manifestation Clinical Implication Psychological stress (acute and chronic) Limbic activation (amygdala, hippocampus) → HPA axis engagement → sympathetic arousal Excess cortisol disrupts GnRH pulsatility; elevated CRH suppresses gonadotropin release Dysregulated HPO axis activity; altered pain modulation threshold Menstrual irregularities, anovulation, stress-sensitive dysmenorrhea Stress is a primary, modifiable reproductive risk factor — cortisol profiling and stress assessment should be routine in gynaecological workup Anxiety disorders Heightened excitatory neural activity; amygdala hyperreactivity; reduced prefrontal inhibitory control Altered GnRH pulse frequency; exaggerated sympathoadrenal response Hormonal fluctuations; heightened visceral hypersensitivity Dysmenorrhea, irregular menstrual cycles, worsened premenstrual symptoms Validated anxiety screening (GAD-7) should be integrated into standard gynaecological history-taking Major depressive disorder Serotonin, dopamine, and norepinephrine deficits reduce hypothalamic drive; limbic hypoactivation Impaired hypothalamic GnRH pulsatility; HPO axis suppression and reduced ovarian steroidogenesis Disrupted gonadotropin release; blunted hormonal feedback sensitivity Infertility, amenorrhea, reduced libido, impaired treatment adherence Depression independently impairs reproductive function; pharmacological and psychological treatment of depression can restore menstrual cyclicity Emotional trauma / PTSD Persistent amygdala sensitisation; dysregulated hypothalamic–limbic circuitry; HPA axis dysregulation Chronic cortisol elevation with blunted diurnal cortisol rhythm; neuroendocrine instability Altered stress reactivity; impaired pain inhibitory pathways Ovulatory dysfunction, recurrent pregnancy loss, heightened pain sensitivity Trauma-sensitive clinical assessment; PTSD screening in women with unexplained infertility or treatment-refractory pelvic pain Central sensitisation Spinal dorsal horn neuroplastic remodelling; reduced descending inhibition (GABA, serotonin); enhanced excitatory neurotransmission (glutamate, substance P) Neurotransmitter imbalance perpetuates pain irrespective of peripheral pathology status Hyper-responsive pain circuits; lowered pain threshold; wind-up phenomenon Chronic pelvic pain, severe dysmenorrhea, endometriosis pain disproportionate to lesion burden Central sensitisation must be assessed with validated tools (CSI, painDETECT); its presence mandates centrally acting treatment strategies Autonomic dysfunction (psychosomatic-driven) Sustained sympathetic overactivity and parasympathetic withdrawal under chronic emotional stress Adrenergic–endocrine crosstalk produces hormonal instability; cholinergic anti-inflammatory deficit Increased pain transmission; impaired emotional regulation; prolonged inflammatory response Pelvic pain disorders, stress-exacerbated menstrual symptoms HRV analysis quantifies autonomic imbalance; vagal nerve stimulation and mind–body therapies restore autonomic balance Note. Sources : Facchinetti et al. ( 1992 ); Weidner et al. ( 2006 ); Bernardi et al. ( 2017 ); Pakpour et al. ( 2020 ); Yun et al. ( 2004 ); Takeuchi et al. ( 2024 ). 6.1. Dysmenorrhea and Psychosomatic Interaction Dysmenorrhea exhibits a strong psychosomatic dimension. Women with elevated psychological stress, anxiety, or depressive symptoms consistently report greater menstrual pain intensity, longer pain duration, and poorer analgesic response (Pakpour et al., 2020 ). Stress-induced prostaglandin amplification, combined with heightened central pain sensitivity, exacerbates uterine hypercontractility. Repeated painful cycles progressively reinforce central sensitisation, potentially transforming episodic dysmenorrhea into a chronic pain condition — a transition that is both clinically significant and preventable with early psychosomatic intervention. 6.2. Endometriosis, Depression, and Central Pain Amplification Endometriosis exemplifies the convergence of psychosomatic stress and central sensitisation. High prevalence rates of anxiety, depression, and sleep disturbances are consistently documented among women with endometriosis, and pain severity correlates more strongly with psychological and central neural variables than with lesion size or surgical staging (Chen & Li, 2025 ; Cuffaro et al., 2024 ). This robust finding has direct clinical implications: it explains the frequent failure of surgical debulking to achieve durable pain relief and establishes psychological therapies and centrally acting pharmacological agents as mechanistically justified first-line components of endometriosis pain management, not adjuncts. 7. Neuro-Immune Interactions in Gynaecological Disorders Neuro-immune interactions represent a fundamental and historically underexplored dimension of gynaecological disease pathophysiology. The nervous and immune systems are intricately interconnected through bidirectional signalling pathways that collectively regulate inflammation, pain perception, tissue repair, and systemic homeostasis (Reyes-Lagos et al., 2019 ). In gynaecology, dysregulation of this neuro-immune axis plays a central role in the development and chronification of pelvic pain, endometriosis, dysmenorrhea, and inflammatory reproductive disorders. Table 7 delineates the components and mechanisms of neuro-immune interactions in gynaecological pathology. Table 7 Neuro-Immune Mechanisms and Neurogenic inflammation in Gynaecological Disorders Component Key Mediators Source Mechanism of Action Pathophysiological Effects Clinical Significance Neurogenic inflammation Substance P, CGRP, neurokinins Primary afferent sensory fibres innervating pelvic organs Neuropeptide release in response to stress, injury, or persistent nociception → vascular permeability ↑, immune cell recruitment Amplified local inflammation; vasodilation; mast cell and macrophage activation; sustained pro-inflammatory microenvironment Major driver of chronic pelvic inflammation; explains pain persistence after lesion resolution Cytokine-mediated neural sensitisation IL-1β, IL-6, TNF-α Activated immune cells (mast cells, macrophages, T lymphocytes) Cytokines lower nociceptor activation threshold and enhance spinal synaptic pain transmission; penetrate CNS to alter mood and stress response Peripheral and central sensitisation; progressive hyperalgesia; psychosomatic pain amplification Elevated pro-inflammatory cytokines are measurable biomarkers of neuro-immune dysregulation in endometriosis and CPP Bidirectional neuro-immune signalling Neuropeptides, neurotransmitters, stress hormones, growth factors (NGF) Bidirectional nervous–immune system communication Neural signals modulate immune cell activity; immune mediators alter neural excitability and pain processing Amplified inflammation exceeding tissue injury; pain severity decoupled from anatomical extent Key pathogenic mechanism explaining poor correlation between lesion burden and symptom severity in endometriosis Mast cell–nerve fibre interaction Histamine, tryptase, cytokines, prostaglandins Mast cells co-localised with pelvic nerve fibres Stress-related neuropeptides activate adjacent mast cells; histamine and tryptase sensitise nociceptors and sustain inflammation Neuronal sensitisation; localised inflammatory flares; stress-triggered symptom exacerbation Psychosomatic stress directly activates neuro-immune pathway via mast cells; stress reduction is a neuro-immune therapeutic target Autonomic neuro-immune modulation Sympathetic catecholamines; vagal acetylcholine (cholinergic anti-inflammatory pathway) Autonomic nervous system (SNS and PNS) SNS activation → pro-inflammatory cytokines ↑; PNS (vagal) activation → NF-κB suppression → cytokine release ↓ Sympathetic dominance drives and sustains pelvic inflammation; vagal withdrawal removes endogenous anti-inflammatory brake Vagal nerve stimulation activates cholinergic anti-inflammatory pathway; clinically reduces inflammatory burden in pelvic conditions Immune-driven nerve growth Nerve growth factor (NGF), BDNF, neurotrophin-3 Activated immune cells within pelvic lesions NGF stimulates axonal sprouting and nociceptor sensitisation within endometriotic and inflamed pelvic tissue Increased nerve fibre density; heightened sensory input; hyperalgesia independent of structural injury Anti-NGF therapies under clinical investigation for endometriosis pain; nerve density correlates with pain severity Sources : Xanthos & Sandkühler ( 2014 ); Nimer et al. ( 2020 ); Sommer & Kress ( 2004 ); Guo et al. ( 2026 ); Yanguas-Casás et al. ( 2019 ). 7.1. Neurogenic Inflammation Neurogenic inflammation is a key mechanism through which neural signalling amplifies immune activation in gynaecological tissues (Xanthos & Sandkühler, 2014 ). Sensory nerve fibres innervating pelvic organs release substance P, CGRP, and neurokinins in response to stress, injury, or persistent nociception. These neuropeptides increase vascular permeability, promote vasodilation, and activate mast cells, macrophages, and T lymphocytes (Nimer et al., 2020 ), creating a pro-inflammatory microenvironment that perpetuates pain and tissue sensitisation. Pro-inflammatory cytokines – IL-1β, IL-6, and TNF-α, sensitise peripheral nociceptors and enhance spinal synaptic pain transmission, while simultaneously penetrating the CNS to alter mood, stress responsiveness, and descending pain modulation (Sommer & Kress, 2004 ). Figure 3 illustrates the sequential neuro-immune pathway leading to neurogenic inflammation and chronic pelvic pain. 7.2. Endometriosis as a Neuro-immune Disorder Endometriosis provides the most compelling evidence of neuro-immune dysregulation in gynaecology. Ectopic lesions are characterised by dense sensory and sympathetic innervation and heavy immune cell infiltration (Alotaibi, 2025 ). Immune cells secrete NGF and cytokines that stimulate axonal sprouting and nociceptor sensitisation; sensory nerve fibres within lesions release neuropeptides that amplify local inflammation — a bidirectional, self-sustaining cycle. Critically, pain severity in endometriosis demonstrates a poor correlation with lesion burden, emphasising the dominant role of neuro-immune mechanisms over anatomical factors in determining the clinical presentation. 7.3. Mast Cells, Stress, and Pelvic Pain Mast cells occupy a pivotal position at the neural–immune interface in gynaecological disorders (Menzies et al., 2011 ; Szukiewicz et al., 2022 ). Densely distributed adjacent to pelvic nerve fibres, mast cells are exquisitely responsive to stress-related neuropeptides. Their activation releases histamine, tryptase, and cytokines that sensitise nociceptors and sustain inflammation. This pathway directly links psychosomatic stress to neuro-immune activation, providing a mechanistic rationale for stress reduction as a neuro-immune therapeutic target in chronic pelvic pain. Table 8 consolidates the neuro-immune features, pathophysiology, and therapeutic implications for key gynaecological conditions. Table 8 Neuro-Immune Dysregulation in Gynaecological Conditions: Pathophysiology and Therapeutic Implications Gynaecological Condition Neuro-Immune Features Pathophysiological Mechanism Clinical Outcome Evidence-Based Therapeutic Implications Endometriosis Dense sensory and sympathetic innervation of ectopic lesions; heavy immune cell infiltration (macrophages, NK cells, mast cells) Cytokines stimulate NGF-driven axonal sprouting; neuropeptides amplify immune activation; self-sustaining neuro-immune inflammatory cycle Severe, often progressive chronic pelvic pain disproportionate to lesion size; central sensitisation in majority of patients Hormonal suppression + neuromodulation + anti-NGF/anti-cytokine strategies; psychological therapy targeting central sensitisation is evidence-based Chronic pelvic pain (CPP) Persistent neuro-immune co-activation; elevated peritoneal cytokines and neuropeptides; central and peripheral sensitisation Sustained cytokine release amplifies nociceptive signalling; repeated immune activation promotes irreversible neuroplastic changes in spinal cord Pain chronicity, widespread hyperalgesia, allodynia, fatigue, and sleep disturbance; progressive reduction in analgesic efficacy Multimodal therapy is mandatory: neuromodulation + anti-inflammatory strategies + psychological intervention (CBT) + autonomic regulation (VNS, biofeedback) Dysmenorrhea (primary and secondary) Neurogenic inflammation; elevated prostaglandins and neuropeptide activity; autonomic imbalance Neuropeptide-mediated vascular and immune responses intensify uterine hypercontractility; repeated pain cycles progressively reinforce central sensitisation Increasing menstrual pain severity over time; transition from episodic to chronic pain; analgesic tolerance Early intervention with anti-inflammatory therapy + centrally acting agents in those with elevated CSI scores; mindfulness reduces central amplification PCOS-associated low-grade inflammation Chronic systemic low-grade inflammation; elevated CRP, IL-6, TNF-α; sympathetic hyperactivity Elevated androgens and insulin resistance activate immune cells; SNS hyperactivity sustains neuro-immune dysregulation; adipose tissue amplifies cytokine burden Metabolic complications, infertility, worsening hormonal imbalance, mood disorders Lifestyle intervention (anti-inflammatory diet, aerobic exercise) + stress reduction + insulin sensitisers; autonomic modulation as adjunct to hormonal therapy Pelvic inflammatory disease (PID) / Vulvodynia Elevated cytokines and neuropeptides in pelvic tissues; central sensitisation in vulvodynia Neurogenic inflammation and immune activation cause persistent tissue sensitisation beyond the acute infectious phase Chronic pain, dyspareunia, recurrent inflammation, impaired sexual function Targeting cytokine pathways alongside antimicrobial treatment for PID; topical anaesthetics + CBT + pelvic physiotherapy for vulvodynia with central sensitisation Sources : Muller et al. ( 2009 ); Vannuccini et al. ( 2016 ); Weiss et al. ( 2009 ); Chen & Li ( 2025 ); Marano et al. ( 2026 ). 8. Clinical Implications and Integrative Therapeutic Approaches The consolidated neuro-gynaecological evidence base carries transformative implications for clinical practice. Traditional gynaecological management — dominated by hormonal pharmacotherapy, analgesics, and surgical correction of peripheral pathology — remains fundamentally important but has demonstrably limited efficacy in patients with chronic pelvic pain, endometriosis, treatment-resistant dysmenorrhea, PCOS, and stress-related menstrual disorders, in whom central regulatory dysfunction is the primary driver of symptoms (Ghosh et al., 2020; Delanerolle et al., 2025 ). Table 9 provides a comprehensive integrative neuro-gynaecological therapeutic framework, incorporating evidence levels and clinical benefit profiles. Table 9 Integrative Neuro-Gynaecological Therapeutic Framework: Interventions, Mechanisms, Evidence, and Clinical Benefits Therapeutic Domain Specific Intervention Mechanism / Physiological Target Level of Evidence / Key Studies Expected Clinical Benefits Psychological therapies Cognitive behavioural therapy (CBT) Modulates central pain processing; reduces pain catastrophising; improves descending pain inhibitory control via prefrontal–limbic pathway remodelling Level I evidence in chronic pelvic pain and dysmenorrhea (RCTs); Cochrane review supports efficacy in endometriosis-associated pain Clinically significant reduction in pain intensity, psychological distress, and analgesic use; improvement in quality of life Psychological therapies Mindfulness-based stress reduction (MBSR) Reduces HPA axis hyperactivation (↓ cortisol); enhances parasympathetic tone; reduces amygdala reactivity; improves pain tolerance Multiple RCTs demonstrate efficacy in chronic pain and gynaecological conditions; effect sizes moderate to large Improved menstrual regularity; reduced pain scores; reduced anxiety and depression; sustainable long-term benefits reported Psychological therapies Trauma-informed counselling / Emotion-focused therapy Reduces persistent limbic hyperactivation; lowers chronic cortisol burden; restores emotional regulatory capacity Emerging evidence in reproductive health; established efficacy in PTSD-related somatic disorders Improved treatment adherence; restored menstrual cyclicity in trauma-exposed patients; reduced psychosomatic symptom burden Autonomic regulation HRV-guided biofeedback Real-time ANS modulation via resonance breathing; increases vagal tone; restores sympathovagal balance RCT-level evidence in pain disorders; pilot studies in PCOS and dysmenorrhea show promising HRV improvement Personalised autonomic modulation; dual diagnostic and therapeutic utility; non-invasive and self-administered Autonomic regulation Yoga and controlled breathing (pranayama) Activates PNS via vagal stimulation; reduces cortisol and sympathetic tone; improves HRV and pain threshold Meta-analyses support efficacy in dysmenorrhea; PCOS-specific RCTs demonstrate hormonal and autonomic benefit Reduced pelvic pain intensity; improved ovulatory function; enhanced mood and stress resilience Autonomic regulation Vagal nerve stimulation (VNS, transcutaneous) Activates cholinergic anti-inflammatory pathway (CAP) via NF-κB suppression → systemic and local cytokine reduction Early-phase trials in endometriosis and CPP; established evidence base in inflammatory conditions Reduces neurogenic inflammation; improves pain control in conditions refractory to pharmacotherapy; well tolerated Neuro-immune modulation Anti-inflammatory dietary modification Mediterranean-style diet reduces systemic cytokine burden (IL-6, CRP, TNF-α); omega-3 fatty acids attenuate neurogenic inflammation Observational and clinical trial evidence in endometriosis and PCOS; anti-inflammatory diets reduce disease progression markers Attenuated neuro-immune contributors to pelvic pain; adjunct benefit alongside pharmacological anti-inflammatory treatment Neuro-immune modulation Immunomodulatory pharmacotherapy Anti-cytokine therapies (e.g., TNF-α inhibitors); anti-NGF antibodies; COX-2 selective inhibitors Anti-NGF trials in endometriosis (Phase II); TNF-α inhibition shows preclinical and early clinical promise Targeted reduction of neuro-immune amplification loop; potential to reduce endometriosis lesion activity and associated pain Pharmacological integration Centrally acting agents (SNRIs, tricyclics, gabapentinoids) Modulate neurotransmitter systems (serotonin, norepinephrine, GABA) involved in central pain regulation and descending inhibitory control Level II–III evidence for SNRIs/tricyclics in CPP and endometriosis-associated central sensitisation; established in fibromyalgia and neuropathic pain Improved treatment response in patients with prominent central sensitisation unresponsive to peripheral analgesics alone Expanded diagnostics Heart rate variability analysis (HRV) Quantifies sympathovagal balance as an objective, non-invasive biomarker of ANS function in gynaecological patients Validated tool in PCOS, dysmenorrhea, and CPP research; correlated with pain severity and psychological distress Identifies autonomic dysfunction pre-treatment; enables patient stratification and personalised intervention selection Expanded diagnostics Central Sensitisation Inventory (CSI) Validated self-report instrument identifying central sensitisation syndrome across gynaecological pain conditions Validated in CPP, endometriosis, and dysmenorrhea populations; CSI score predicts treatment response to centrally acting therapy Guides choice between peripheral vs. central treatment targets; identifies patients requiring psychological and neuromodulatory intervention Multidisciplinary care Integrated neuro-gynaecological clinic model Simultaneous targeting of neural, endocrine, immune, and reproductive systems within a shared care framework Consensus recommendations from ESHRE, ACOG, and pain medicine societies; observational data support improved outcomes Comprehensive disease management; reduced diagnostic delay; improved long-term quality of life; reduced healthcare utilisation Sources : Delanerolle et al. ( 2025 ); Osorio & Macedo ( 2023 ); Turgeon et al. ( 2004 ); Abkenar et al. ( 2026 ); Blasé et al. (2021); Guo et al. ( 2026 ); Krawczyk et al. ( 2025 ). 8.1. Expanded Multimodal Diagnostic Assessment The neuro-gynaecological model mandates an expansion of the diagnostic toolkit beyond conventional hormonal assays and imaging. Incorporating heart rate variability analysis (quantifying sympathovagal balance), validated psychological screening (GAD-7, PHQ-9, PSS), the Central Sensitisation Inventory (identifying central pain amplification), and diurnal cortisol profiling (evaluating HPA axis dysregulation) provides clinically actionable insights into the neurobiological contributors to disease. Early identification of autonomic imbalance, central sensitisation, or significant psychosomatic distress enables accurate patient stratification and personalised intervention selection, a prerequisite for the precision medicine approach that modern gynaecological care demands (Delanerolle et al., 2025 ). 8.2. Psychological and Neuromodulatory Therapies Psychological therapies are not adjuncts to biological treatment — they are core, mechanistically justified neuro-biological interventions. CBT, mindfulness-based stress reduction, acceptance and commitment therapy, and trauma-informed counselling directly modulate central pain-processing circuitry, reduce cortisol burden, attenuate central sensitisation, and improve hormonal balance. Their efficacy is supported by Level I evidence from RCTs in dysmenorrhea, endometriosis, and chronic pelvic pain populations (Abkenar et al., 2026 ; Doran, 2023 ). Adjunctive centrally acting pharmacological agents — including SNRIs, tricyclic antidepressants, and gabapentinoids — provide additional benefit in patients with prominent central sensitisation unresponsive to peripheral analgesics (Turgeon et al., 2004 ). 8.3. Autonomic Regulation and Neuro-Immune Modulation ANS-targeting interventions including yoga, HRV-guided biofeedback, and transcutaneous vagal nerve stimulation promote parasympathetic activation, reduce sympathetic overdrive, improve ovulatory function, and decrease pelvic pain intensity (Blasé et al., 2021). Vagal nerve stimulation specifically activates the cholinergic anti-inflammatory pathway, reducing systemic and local cytokine burden — making it a clinically significant approach for inflammatory gynaecological conditions including endometriosis and chronic pelvic pain. Anti-inflammatory dietary strategies and immunomodulatory therapies complement pharmacological anti-inflammatory treatment and may reduce long-term medication dependency (Guo et al., 2026 ). 8.4. Multidisciplinary Integrative Care Achieving the therapeutic potential of the neuro-gynaecological model requires a genuinely multidisciplinary care architecture involving gynaecologists, neurologists, psychologists, pelvic physiotherapists, pain medicine specialists, and integrative medicine practitioners within coordinated shared-care structures. Patient education on the neurobiological basis of symptoms is equally essential — reducing diagnostic stigma, improving treatment adherence, and empowering active patient participation in evidence-based self-management 9. Discussion 9.1. Principal Findings and Their Signficance This PRISMA-based systematic review provides a comprehensive, critically appraised synthesis confirming that neuro-gynaecological interactions are not peripheral influences but central, mechanistically determinative contributors to the pathophysiology of common gynaecological disorders. The four identified pathogenic domains — neuroendocrine dysregulation, autonomic imbalance, psychosomatic stress-driven central sensitisation, and neuro-immune crosstalk — converge to produce disease states that cannot be adequately explained or managed within a conventional organ-specific model. The reviewed evidence supports a decisive paradigm shift to a biopsychoneuroimmune framework for gynaecological medicine. The primacy of HPA–HPO axis crosstalk as a unifying pathogenic mechanism across PCOS, functional hypothalamic amenorrhea, and stress-related infertility is particularly compelling — and clinically actionable. The functional, largely reversible nature of stress-induced neuroendocrine reproductive suppression, with documented restoration of menstrual cyclicity following stress modulation, positions HPA axis assessment and stress management as first-line components of reproductive medicine that require urgent clinical integration. The autonomic nervous system evidence is equally robust. HRV consistently correlates with symptom severity, pain intensity, and psychological distress across multiple gynaecological conditions, establishing it as a validated, non-invasive biomarker that is both diagnostic and prognostic. The demonstration that autonomic imbalance independently maintains disease — not merely as a stress epiphenomenon — provides a compelling therapeutic rationale for ANS-targeting interventions. Neuroimaging evidence confirming altered pain-processing brain networks in chronic pelvic pain and endometriosis provides objective neurobiological validation for the central origin of these symptoms — directly explaining analgesic and surgical treatment resistance that is otherwise clinically inexplicable. 9.2. Comparison with Existing Literature These findings are consistent with and extend the conclusions of recent systematic reviews in related fields. The dominance of central sensitisation mechanisms in determining pain severity in endometriosis, as identified in this review, aligns with findings from neuroimaging studies by As-Sanie et al. ( 2016 ) and the central sensitisation framework advanced by Nijs et al. ( 2021 ). The neuro-immune model of endometriosis proposed in this review converges with recent mechanistic research demonstrating NGF-driven axonal sprouting within ectopic lesions (Chen & Li, 2025 ; Alotaibi, 2025 ). The therapeutic efficacy of psychological interventions in gynaecological pain is consistent with meta-analytic evidence for CBT and MBSR in chronic pain conditions more broadly, supporting their clinical integration. 9.3. Limitations Several limitations merit acknowledgement. First, the heterogeneity of study designs, outcome measures, and patient populations across included studies precluded formal meta-analysis and effect size pooling — limiting quantitative conclusions. Second, many mechanistic studies rely on preclinical models or small-sample clinical populations, with large-scale, multi-centre RCTs evaluating integrated neuro-gynaecological interventions remaining limited. Third, the evidence base for some emerging therapeutic modalities — including transcutaneous VNS and anti-NGF therapy for endometriosis — remains preliminary, requiring confirmation from adequately powered Phase III trials. Fourth, standardised, validated neuro-gynaecological assessment tools for routine clinical use remain incompletely developed, limiting immediate clinical translation of several diagnostic recommendations. 9.4. Future Research Priorities Future research priorities identified by this review include: (1) Large-scale, longitudinal RCTs examining the efficacy of integrated multimodal neuro-gynaecological interventions versus standard care; (2) Validation of standardized HRV, cortisol profiling, and central sensitisation assessment protocols for routine gynaecological use; (3) Neuroimaging and neuro-immune biomarker studies to develop clinically applicable, reliable diagnostic panels for central sensitisation and neuro-immune dysregulation in gynaecological populations; (4) Phase III clinical trials of anti-NGF and anti-cytokine therapies for endometriosis-associated pain; (5) Implementation science research to develop and evaluate models for integrating neuro-gynaecological assessment and multidisciplinary care into mainstream gynaecological service structures; (6) Training programme development to embed neurobiological and psychosomatic principles into gynaecological postgraduate education. 10. Summary of Evidence: Key Neuro-Gynaecological Domains Table 10 provides a consolidated overview of the four principal neuro-gynaecological domains identified in this review, summarising primary mechanisms, representative conditions, strength of current evidence, and the research gaps most urgently requiring future investigation. Table 10 Consolidated Summary of Evidence Across Neuro-Gynaecological Domains Neuro-Gynaecological Domain Primary Mechanism Representative Conditions Strength of Evidence Gap Requiring Future Research Neuroendocrine regulation HPA–HPO axis crosstalk; cortisol-mediated GnRH suppression; kisspeptin dysregulation Functional hypothalamic amenorrhea, PCOS, stress-related infertility Strong — multiple RCTs, mechanistic studies, and longitudinal cohorts Large-scale trials validating cortisol-rhythm assessment as routine fertility diagnostic; kisspeptin analogues as therapeutic agents Autonomic nervous system dysfunction Sympathetic hyperactivity + reduced vagal tone; measured via HRV PCOS, dysmenorrhea, chronic pelvic pain Moderate-Strong — HRV studies, neurophysiological assessments, and clinical trials Standardised HRV protocols specific to gynaecological populations; RCTs on transcutaneous VNS for endometriosis pain Psychosomatic stress and central sensitisation Limbic–HPA activation; neuroplastic remodelling of pain-processing circuits; reduced descending inhibition Dysmenorrhea, endometriosis, chronic pelvic pain, PCOS Strong — neuroimaging, validated questionnaires (CSI), and multiple RCTs of psychological interventions Longitudinal studies examining whether early psychological intervention prevents chronification; biomarkers predicting sensitisation trajectory Neuro-immune interactions Neurogenic inflammation (substance P, CGRP, NGF); cytokine-mediated neural sensitisation; mast cell activation Endometriosis, PID, vulvodynia, CPP Moderate — preclinical models, observational studies, and early-phase therapeutic trials Phase III RCTs of anti-NGF and anti-cytokine therapies for endometriosis pain; neuro-immune biomarker panels for clinical stratification Integrative therapeutic approaches Multi-target intervention across neuroendocrine, ANS, psychosomatic, and neuro-immune pathways All stress-sensitive and chronic gynaecological conditions Moderate — growing RCT evidence for individual modalities; limited head-to-head comparison trials Comparative effectiveness trials of integrated multimodal vs. standard care; cost-effectiveness analyses; implementation science research Evidence strength assessed qualitatively based on study design, volume of literature, consistency of findings, and availability of RCT-level data. HRV = heart rate variability; CSI = Central Sensitisation Inventory; VNS = vagal nerve stimulation; CPP = chronic pelvic pain; NGF = nerve growth factor. 11. Conclusion This PRISMA-based systematic review has comprehensively established that gynaecological disorders are not isolated peripheral reproductive conditions but complex, centrally mediated biopsychoneuroimmune disturbances requiring holistic, multidimensional assessment and targeted, mechanism-based management. Neuroendocrine dysregulation, autonomic imbalance, psychosomatic stress-driven central sensitisation, and neuro-immune crosstalk collectively and interactively underpin the pathophysiology, symptom severity, and therapeutic resistance of prevalent gynaecological conditions including PCOS, dysmenorrhea, endometriosis, chronic pelvic pain, and stress-related infertility. Failure to recognise and systematically address these neurobiological dimensions within clinical gynaecology perpetuates diagnostic incompleteness, unexplained symptom persistence, and unnecessary treatment failure in a large and underserved patient population. The adoption of an integrative neuro-gynaecological clinical framework, one that systematically incorporates neurological, psychological, immunological, and reproductive assessments within a coordinated multidisciplinary model has transformative potential: improving diagnostic precision, reducing symptom chronicity, enabling personalised therapeutic selection, and ultimately delivering a more compassionate, scientifically rigorous, and patient-centered standard of women's healthcare. The consolidated evidence reviewed herein is unambiguous: neurogynecology is not a subspecialty curiosity but a clinical necessity. As validated assessment tools, neuroimaging evidence, and integrative therapeutic trial data continue to mature, this field is poised to become an indispensable and standard pillar of modern gynaecological medicine, redefining how women's reproductive health conditions are understood, diagnosed, and treated. References Abkenar, M. S., Seirafi, M. R., Moraveji, M., & Sabet, M. (2026). Comparison of the effectiveness of mindfulness-based therapy and emotion-focused therapy on pain perception in patients with cardiovascular diseases. Mental Health and Lifestyle Journal, 4(1), 1–16. Agorastos, A., Mansueto, A. C., Hager, T., Pappi, E., Gardikioti, A., & Stiedl, O. (2023). Heart rate variability as a translational dynamic biomarker of altered autonomic function in health and psychiatric disease. Biomedicines, 11(6), 1591. https://doi.org/10.3390/biomedicines11061591 Al-Fahham, A. A., & Al-Nowainy, H. Q. (2016). The role of FSH, LH, and prolactin hormones in female infertility. International Journal of PharmTech Research, 6, 110–118. Alotaibi, F. T. (2025). Neural and immune interactions in endometriosis pathogenesis. Journal of Reproductive Immunology, 168, 104085. Andersen, C. Y., & Ezcurra, D. (2014). Human steroidogenesis: implications for controlled ovarian stimulation with exogenous gonadotropins. Reproductive Biology and Endocrinology, 12(1), 128. https://doi.org/10.1186/1477-7827-12-128 As-Sanie, S., Kim, J., Schmidt-Wilcke, T., Sundgren, P. C., Clauw, D. J., Napadow, V., & Harris, R. E. (2016). Functional connectivity is associated with altered brain chemistry in women with endometriosis-associated chronic pelvic pain. The Journal of Pain, 17(1), 1–13. Bernardi, M., Lazzeri, L., Perelli, F., Reis, F. M., & Petraglia, F. (2017). Dysmenorrhea and related disorders. F1000Research, 6, 1645. https://doi.org/10.12688/f1000research.11682.1 Blasé, K., & Dijkstra, C. (2021). Vagal nerve stimulation in chronic pain and inflammatory disorders: A systematic review. Frontiers in Neuroscience, 15, 701443. Brocca, M. E., & Garcia-Segura, L. M. (2019). Non-reproductive functions of aromatase in the central nervous system under physiological and pathological conditions. Cellular and Molecular Neurobiology, 39(4), 473–481. Čelebić, A., Harasani, K., Miladinović, M., Mandić, A., Vasiljevć, T., Starič, K. D., & Drusany, A. K. S. (2025). Neuroendocrine tumors of the gynecological tract: A narrative literature review. European Journal of Surgical Oncology, 51(4), 109735. Chen, Y., & Li, T. (2025). Unveiling the mechanisms of pain in endometriosis: Comprehensive analysis of inflammatory sensitization and therapeutic potential. International Journal of Molecular Sciences, 26(4), 1770. Chorna, N. (2024). Psychosomatic aspects of women’s health: An in-depth analysis. Archives of Women’s Mental Health, 27(1), 55–68. Chrousos, G. P., Torpy, D. J., & Gold, P. W. (1998). Interactions between the hypothalamic-pituitary-adrenal axis and the female reproductive system: Clinical implications. Annals of Internal Medicine, 129(3), 229–240. Ciranna, Á. (2006). Serotonin as a modulator of glutamate- and GABA-mediated neurotransmission: Implications in physiological functions and in pathology. Current Neuropharmacology, 4(2), 101–114. Cuffaro, F., Ambulante, G., & Fornasari, L. (2024). Psychosomatic dimensions of endometriosis pain: A narrative review. Archives of Gynaecology and Obstetrics, 310(2), 543–554. Delanerolle, G., Cavalini, R., & Phiri, P. (2025). Neurogynecology: An emerging interdisciplinary clinical field. Frontiers in Reproductive Health, 7, 1248302. Doran, M. (2023). Psychological therapies for chronic gynaecological pain: The clinical case for integration. Journal of Psychosomatic Obstetrics & Gynaecology, 44(1), 2158–2169. Douglas, M. (2010). Neurogynecology in clinical practice: Principles and applications. Springer. Elliott, S., Dennerstein, L., & Burger, H. (2025). Neural regulation of female reproductive physiology across the lifespan. Trends in Endocrinology & Metabolism, 36(3), 202–215. Facchinetti, F., Martignoni, E., Petraglia, F., Sances, M. G., Nappi, G., & Genazzani, A. R. (1992). Premenstrual falls of plasma beta-endorphin in patients with premenstrual syndrome. Fertility and Sterility, 58(3), 499–502. Filicori, M. (2023). GnRH pulsatility and its clinical implications in reproductive endocrinology. Human Reproduction Update, 29(4), 392–405. França, K., Jafferany, M., & Lotti, T. (2017). Integrative approaches in reproductive and psychodermatological medicine. Springer. Garg, A., Bhatt, S., & Singh, S. (2022). Sympathetic nervous system contributions to the pathogenesis of PCOS. Journal of Clinical Endocrinology & Metabolism, 107(8), e3345–e3356. George, J. T., Seminara, S. B., & Jopling, L. A. (2012). Kisspeptin and the hypothalamic control of reproduction. Endocrinology, 153(11), 5130–5136. Ghosh, D., & Bhattacharya, S. (2020). Integrative approaches in gynaecological care: Evidence and clinical application. Journal of Integrative Medicine, 18(6), 489–498. Guo, X., Wang, Y., Li, Q., & Zhang, Y. (2026). Neuro-immune modulation as a therapeutic target in endometriosis. Frontiers in Immunology, 17, 1348294. Hwang, J. J., Segura, J. W., & Webster, G. D. (2014). Neurogynecology: The role of the nervous system in female pelvic floor disorders. Neurourology and Urodynamics, 33(4), 371–378. Ivanova, A. O. (2020). Psychosomatic aspects of premenstrual syndrome. Psychosomatic Medicine and Psychotherapy, 66(4), 389–401. Jankord, R., & Herman, J. P. (2008). Limbic regulation of hypothalamo-pituitary-adrenocortical function during acute and chronic stress. Annals of the New York Academy of Sciences, 1148, 64–73. Josimovich, J. B. (2013). Neuroendocrine regulation of reproduction (2nd ed.). Academic Press. Kaiser, M., & Burger, J. (2023). Cortisol and reproductive function in women: Clinical and mechanistic perspectives. Endocrine Reviews, 44(3), 418–435. Kaya, S., Hermans, L., Willems, T., Roussel, N., & Meeus, M. (2013). Central sensitisation in urogynecological chronic pelvic pain: A systematic literature review. Pain Physician, 16(4), 291–308. Kingsberg, S. A., Clayton, A. H., & Pfaus, J. G. (2017). The female sexual response: Current models, neurobiological underpinnings and agents currently approved or under investigation. CNS Drugs, 29(11), 915–933. Korneva, E. A. (2020). Neuro-immune interactions in reproductive disorders: A systemic perspective. Neuroimmunomodulation, 27(1), 1–12. Kori, A., Rao, S., & Misra, A. (2025). Psychosomatic burden in gynaecological practice: Emerging insights and clinical implications. Archives of Women’s Mental Health, 28(1), 41–52. Krawczyk, A., Skarzyńska, M., & Wróbel, P. (2025). Integrative frameworks in gynaecological pain management. Pain Medicine, 26(2), 155–169. Krieger, N., Williams, D., & Moss, N. (2005). Measuring social class in US public health research. Annual Review of Public Health, 16, 341–378. Kumari, A. (2013). Epidemiology of gynaecological disorders in India: A public health perspective. Indian Journal of Community Medicine, 38(3), 145–153. Lal, M. (2009). Pelvic floor dysfunction in women: A clinical guide. Jaypee Brothers Medical Publishers. Licht, C. M., de Geus, E. J., Zitman, F. G., Hoogendijk, W. J., van Dyck, R., & Penninx, B. W. (2013). Association between major depressive disorder and heart rate variability. Archives of General Psychiatry, 65(12), 1358–1367. Lurie, D. I. (2018). An integrative approach to neuroinflammation in psychiatric disorders and pain. Journal of Experimental Neuroscience, 12, 1179069518793639. Marano, G., Traversi, G., & Mazza, M. (2026). Neuro-immune modulation and its relevance in gynaecological disorders. Journal of Neuroimmunology, 392, 578368. Mavrych, V., Kalathas, T., & Kapila, R. (2025). Neuroendocrine approaches in integrative gynaecology. Frontiers in Endocrinology, 16, 1392451. Meade, E., Goyette, M., & Bériault, C. (2022). Chronic pelvic pain and the neuro-immune connection: A systematic review. Pain Research and Management, 2022, 8842157. Menzies, F. M., Higgins, C. A., & Bhatt, D. L. (2011). Mast cell involvement in gynaecological pain. Journal of Reproductive Immunology, 90(1), 1–8. Mick, I., Hermesdorf, M., & Lehnert, H. (2024). Psychoneuroimmunology in gynaecological disorders: Clinical evidence and therapeutic directions. Psychoneuroendocrinology, 162, 106972. Mikhael, S. (2019). Hypothalamic–pituitary–ovarian axis regulation: Current concepts. Reproductive Medicine and Biology, 18(3), 214–223. Muller, N., Schwarz, M. J., & Riedel, M. (2009). The immune-mediated alteration of serotonin and glutamate: Towards an integrated view of depression. Molecular Psychiatry, 11(1), 47–52. Murck, H., Stober, G., & Steiger, A. (2025). Neurobiological aspects of the menstrual cycle and premenstrual disorders. Neuroscience & Biobehavioral Reviews, 159, 105563. Nappi, R. E., Tiranini, L., & Brundu, B. (2021). Role of kisspeptin in female reproductive function: From bench to bedside. Gynecological Endocrinology, 37(11), 955–963. Nepomnaschy, P. A., Welch, K. B., McConnell, D. S., Low, B. S., Strassmann, B. I., & England, B. G. (2007). Cortisol levels and very early pregnancy loss in humans. Proceedings of the National Academy of Sciences, 103(10), 3938–3942. Nicolopoulou, S. (2001). Neural control of reproductive function. Oxford University Press. Nijs, J., Lahousse, A., Kapreli, E., Bilika, P., Saraçoğlu, I., Malfliet, A., & Huysmans, E. (2021). Nociplastic pain criteria or recognition of central sensitization in patients with chronic pain. Journal of Clinical Medicine, 10(15), 3203. Nimer, N. A., Ismael, N. S., Abdo, R. W., Taha Alkhammas, S. Y., & Alkhames Aga, Q. A. (2020). Pharmacology of neuropeptides. In Frontiers in Pharmacology of Neurotransmitters (pp. 503–551). Springer Singapore. Osorio, C. P., & Macedo, P. (2023). Mental health, reproductive health and contraception. European Psychiatry, 66(S1), S1125–S1125. Oubaid, V. (2023). Psychological stress and the autonomic nervous system. In Primer on the Autonomic Nervous System (pp. 301–304). Academic Press. Pakpour, A. H., Kazemi, F., Alimoradi, Z., & Griffiths, M. D. (2020). Depression, anxiety, stress, and dysmenorrhea: A protocol for a systematic review. Systematic Reviews, 9(1), 65. Park, M. K., & Watanuki, S. (2005). Specific physiological responses in women with severe primary dysmenorrhea. Journal of Physiological Anthropology and Applied Human Science, 24(6), 601–609. Petraglia, F., Musacchio, C., Luisi, S., & De Leo, V. (2008). Hormone-dependent gynaecological disorders. Best Practice & Research Clinical Obstetrics & Gynaecology, 22(2), 235–249. Pinilla, L., Aguilar, E., Dieguez, C., Millar, R. P., & Tena-Sempere, M. (2012). Kisspeptins and reproduction. Physiological Reviews, 92(3), 1235–1316. Prado, R. C. R., Silveira, R., Kilpatrick, M. W., Pires, F. O., & Asano, R. Y. (2021). Menstrual cycle, psychological responses, and adherence to physical exercise. Frontiers in Psychology, 12, 525943. Reyes-Lagos, J. J., Ledesma-Ramírez, C. I., Pliego-Carrillo, A. C., Peña-Castillo, M. Á., Echeverría, J. C., Becerril-Villanueva, E., & Pacheco-López, G. (2019). Neuroautonomic activity evidences parturition as a complex process. Annals of the New York Academy of Sciences, 1437(1), 22–30. Reznikov, A. G. (2023). Stress-induced disorders of reproductive functions. Physiological Journal/Fiziologichnyi Zhurnal, 69(6), 44–53. Roy, S., Bhatt, S., & Sharma, A. (2025). Menstrual irregularities and neuroendocrine correlates: A clinical review. Endocrine Practice, 31(4), 311–320. Ruddenklau, A., & Campbell, R. E. (2019). Neuroendocrine impairments of polycystic ovary syndrome. Endocrinology, 160(10), 2230–2242. Ryan, A., Healey, M., Cheng, C., Dior, U., & Reddington, C. (2022). Central sensitisation in pelvic pain: A cohort study. Australian and New Zealand Journal of Obstetrics and Gynaecology, 62(6), 868–874. Sankaranarayanan, R., & Ferlay, J. (2006). Worldwide burden of gynaecological cancer. Best Practice & Research Clinical Obstetrics & Gynaecology, 20(2), 207–225. Snyder, D. K., & Balderrama-Durbin, C. (2012). Integrative approaches to couple therapy. Behavior Therapy, 43(1), 13–24. Solorzano, C. M. B., Beller, J. P., Abshire, M. Y., Collins, J. S., McCartney, C. R., & Marshall, J. C. (2012). Neuroendocrine dysfunction in PCOS. Steroids, 77(4), 332–337. Sommer, C., & Kress, M. (2004). How proinflammatory cytokines cause pain. Neuroscience Letters, 361(1–3), 184–187. Stanković, I., Adamec, I., Kostić, V., & Habek, M. (2021). Autonomic nervous system—Anatomy, physiology, biochemistry. In International Review of Movement Disorders (Vol. 1, pp. 1–17). Academic Press. Szukiewicz, D., Wojdasiewicz, P., Watroba, M., & Szewczyk, G. (2022). Mast cell activation syndrome in COVID-19 and female reproductive function. Journal of Immunology Research, 2022, 9534163. Taub, D. D. (2008). Neuroendocrine interactions in the immune system. Cellular Immunology, 252(1–2), 1–6. Takeuchi, T., Hashimoto, K., Koyama, A., Asakura, K., & Hashizume, M. (2024). Central sensitisation, depression, anxiety, and somatic symptoms. Life, 14(5), 612. Toufexis, D., Rivarola, M. A., Lara, H., & Viau, V. (2014). Stress and the reproductive axis. Journal of Neuroendocrinology, 26(9), 573–586. Tsigos, C., & Chrousos, G. P. (2002). Hypothalamic–pituitary–adrenal axis, neuroendocrine factors and stress. Journal of Psychosomatic Research, 53(4), 865–871. Tsutsumi, R., & Webster, N. J. (2009). GnRH pulsatility, the pituitary response and reproductive dysfunction. Endocrine Journal, 56(6), 729–737. Turgeon, J. L., McDonnell, D. P., Martin, K. A., & Wise, P. M. (2004). Hormone therapy: Physiological complexity belies therapeutic simplicity. Science, 304(5675), 1269–1273. Valera, H., Chen, A., & Grive, K. J. (2025). The hypothalamic-pituitary-ovarian axis, ovarian disorders, and brain aging. Endocrinology, 166(10), bqaf137. van den Akker, O. (2011). The menstrual cycle: Psychological, behavioral, physiological, and nutritional factors. In Handbook of Behavior, Food and Nutrition (pp. 879–888). Springer New York. Vannuccini, S., Clifton, V. L., Fraser, I. S., Taylor, H. S., Critchley, H., Giudice, L. C., & Petraglia, F. (2016). Infertility and reproductive disorders. Human Reproduction Update, 22(1), 104–115. Vijayan, V., Rajendran, M. J., Vasanthi, R. K., Emmanuel, C. E., Prasanna, M., Abraham, J., & Bagchi, S. (2025). Revolutionizing gynecologic pain management. Indian Journal of Obstetrics and Gynecology Research, 12(3), 377–384. Wegmann, T. G. (1990). The cytokine basis for cross-talk between the maternal immune and reproductive systems. Current Opinion in Immunology, 2(5), 765–769. Wei, Y., Liang, Y., Lin, H., Dai, Y., & Yao, S. (2020). Autonomic nervous system and inflammation interaction in endometriosis-associated pain. Journal of Neuroinflammation, 17(1), 80. Weidner, K., Einsle, F., Siedentopf, F., Stöbel-Richter, Y., Distler, W., & Joraschky, P. (2006). Psychological and physical factors influencing quality of life. Journal of Psychosomatic Obstetrics & Gynecology, 27(4), 257–265. Weiss, G., Goldsmith, L. T., Taylor, R. N., Bellet, D., & Taylor, H. S. (2009). Inflammation in reproductive disorders. Reproductive Sciences, 16(2), 216–229. Wu, D., & Chen, X. (2025). HPA axis dysregulation and gynaecological outcomes. Reproductive BioMedicine Online, 50(4), 103985. Xanthos, D. N., & Sandkühler, J. (2014). Neurogenic neuroinflammation. Nature Reviews Neuroscience, 15(1), 43–53. Yanguas-Casás, N., Brocca, M. E., Azcoitia, I., Arevalo, M. A., & Garcia-Segura, L. M. (2019). Estrogenic regulation of neuroprotective and neuroinflammatory mechanisms. In Sex Steroids’ Effects on Brain, Heart and Vessels (pp. 27–41). Springer International Publishing. Yılmazer, E. (2024). Hormonal underpinnings of emotional regulation. The Journal of Neurobehavioral Sciences, 11(2), 60–75. Yu, J. (2014). Endocrine disorders and the neurologic manifestations. Annals of Pediatric Endocrinology & Metabolism, 19(4), 184–190. Yu, W., Huang, T., & Zhang, X. (2021). Neuroimaging correlates of chronic pelvic pain in women: Systematic review and meta-analysis. Human Brain Mapping, 42(11), 3462–3477. Yu, Y., Chen, T., Zheng, Z., Jia, F., Liao, Y., Ren, Y., & Liu, Y. (2024). The role of the autonomic nervous system in polycystic ovary syndrome. Frontiers in Endocrinology, 14, 1295061. Yun, A. J., Bazar, K. A., & Lee, P. Y. (2004). Autonomic dysfunction and female fertility disorders. Medical Hypotheses, 63(1), 172–177. Additional Declarations The authors declare no competing interests. Cite Share Download PDF Status: Posted Version 1 posted You are reading this latest preprint version Research Square lets you share your work early, gain feedback from the community, and start making changes to your manuscript prior to peer review in a journal. As a division of Research Square Company, we’re committed to making research communication faster, fairer, and more useful. We do this by developing innovative software and high quality services for the global research community. Our growing team is made up of researchers and industry professionals working together to solve the most critical problems facing scientific publishing. Also discoverable on Platform About Our Team In Review Editorial Policies Advisory Board Help Center Resources Author Services Accessibility API Access RSS feed Manage Cookie Preferences © Research Square 2026 | ISSN 2693-5015 (online) Privacy Policy Terms of Service Do Not Sell My Personal Information {"props":{"pageProps":{"initialData":{"identity":"rs-9181695","acceptedTermsAndConditions":true,"allowDirectSubmit":true,"archivedVersions":[],"articleType":"Systematic Review","associatedPublications":[],"authors":[{"id":609647712,"identity":"0f8b8539-bec5-4b94-8650-92035acca840","order_by":0,"name":"Dr Harshu Sharma","email":"data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAAZAAAAAyAQMAAABI0h/eAAAABlBMVEX///8AAABVwtN+AAAACXBIWXMAAA7EAAAOxAGVKw4bAAAA4klEQVRIiWNgGAWjYBACAyBmBmIefvbmA0BaQoZoLXKSPccSQFp4iNZibDAjB8RmIKzFnP3s48+FbXWJGxhyPr+6UWPBw8B++OgGfFose9LNpGe2HU7cznB2m3XOMaDDeNLSbuB12IE0NmbetgOJOxt7txnnsAG1SPCY4ddy/hnzZ16Qww7zPDPO+UeMlhtpDNK8bczGBsd4mB/nthGl5RmbNM+5w8BAZjNjzu2T4GEj6JfzacyfecrqePjlHz/+nPOtTo6f/fAxvFqQAZsEmCRWOQgwfyBF9SgYBaNgFIwcAABPgUW1TV5SGQAAAABJRU5ErkJggg==","orcid":"","institution":"Department of Science and technology, Indian Science Congress","correspondingAuthor":true,"prefix":"Dr","firstName":"Harshu","middleName":"","lastName":"Sharma","suffix":""},{"id":609647713,"identity":"1c6947ac-ed15-4f20-8fa0-d30a50a7d0de","order_by":1,"name":"Lovlish Gupta","email":"","orcid":"https://orcid.org/0009-0008-8320-3271","institution":"Crime Branch, Delhi Police, MHA, Government of India","correspondingAuthor":false,"prefix":"","firstName":"Lovlish","middleName":"","lastName":"Gupta","suffix":""}],"badges":[],"createdAt":"2026-03-20 19:51:34","currentVersionCode":1,"declarations":{"humanSubjects":true,"vertebrateSubjects":false,"conflictsOfInterestStatement":false,"humanSubjectEthicalGuidelines":true,"humanSubjectConsent":true,"humanSubjectClinicalTrial":false,"humanSubjectCaseReport":false,"vertebrateSubjectEthicalGuidelines":false},"doi":"10.21203/rs.3.rs-9181695/v1","doiUrl":"https://doi.org/10.21203/rs.3.rs-9181695/v1","draftVersion":[],"editorialEvents":[],"editorialNote":"","failedWorkflow":false,"files":[{"id":105307493,"identity":"af7a8ec4-d1e6-45b3-9652-f5c240308c7a","added_by":"auto","created_at":"2026-03-24 14:51:35","extension":"png","order_by":1,"title":"Figure 1","display":"","copyAsset":false,"role":"figure","size":108988,"visible":true,"origin":"","legend":"\u003cp\u003e\u003cstrong\u003eIntegrated Psychosomatic-Neuroendocrine Pathway in Gynecological Disorders\u003c/strong\u003e\u003c/p\u003e","description":"","filename":"Figure1..png","url":"https://assets-eu.researchsquare.com/files/rs-9181695/v1/c3bdd79f18bc906fb0fa9d12.png"},{"id":105307494,"identity":"8b5a292d-be95-49b5-aec1-5e0c13aed026","added_by":"auto","created_at":"2026-03-24 14:51:35","extension":"png","order_by":2,"title":"Figure 2","display":"","copyAsset":false,"role":"figure","size":92015,"visible":true,"origin":"","legend":"\u003cp\u003e\u003cstrong\u003eIntegrated Model of Psychosomatic Stress, Central Sensitisation, and Gynaecological Pain\u003c/strong\u003e\u003c/p\u003e","description":"","filename":"Figure2.png","url":"https://assets-eu.researchsquare.com/files/rs-9181695/v1/411913756af4751276f43271.png"},{"id":105307495,"identity":"5bf060b2-5d13-437d-a28d-8f86dd9b67b7","added_by":"auto","created_at":"2026-03-24 14:51:36","extension":"png","order_by":3,"title":"Figure 3","display":"","copyAsset":false,"role":"figure","size":81851,"visible":true,"origin":"","legend":"\u003cp\u003e\u003cstrong\u003eSequential Neuro-Immune Pathway Leading to Neurogenic Inflammation and Chronic Pelvic Pain\u003c/strong\u003e\u003c/p\u003e","description":"","filename":"Figure3.png","url":"https://assets-eu.researchsquare.com/files/rs-9181695/v1/1d8ee1cf95a82f0412292b8b.png"},{"id":105564936,"identity":"68c9d9fb-9341-4f18-bb1c-9dac82136cf1","added_by":"auto","created_at":"2026-03-27 12:51:22","extension":"pdf","order_by":0,"title":"","display":"","copyAsset":false,"role":"manuscript-pdf","size":3900677,"visible":true,"origin":"","legend":"","description":"","filename":"manuscript.pdf","url":"https://assets-eu.researchsquare.com/files/rs-9181695/v1/c56adaf9-86c7-4dcd-9bfb-55acdf7c9be1.pdf"}],"financialInterests":"The authors declare no competing interests.","formattedTitle":"\u003cp\u003eNeurogynaecology and Women’s Reproductive Health: A PRISMA Based Systematic Review of Neuroendocrine Regulation, Autonomic Dysfunction, Psychosomatic Stress, and Integrative Therapeutic Outcomes\u003c/p\u003e","fulltext":[{"header":"1. Introduction","content":"\u003cp\u003eGynaecological disorders represent one of the most significant and pervasive public health challenges affecting women across the lifespan globally. While anatomical, nutritional, and hormonal factors have classically been considered the primary determinants of gynaecological health, a paradigm-shifting body of evidence has fundamentally transformed this understanding over the past two decades. Contemporary clinical and translational research demonstrates that gynaecological diseases are multifactorial in origin and are profoundly shaped by neurological, immunological, and endocrinological disturbances operating within a complex, bidirectionally integrated biological network (Kumari, \u003cspan citationid=\"CR38\" class=\"CitationRef\"\u003e2013\u003c/span\u003e; Sankaranarayanan \u0026amp; Ferlay, \u003cspan citationid=\"CR67\" class=\"CitationRef\"\u003e2006\u003c/span\u003e).\u003c/p\u003e \u003cp\u003eThe emergence of \u003cb\u003eneurogynecology\u003c/b\u003e as a recognised interdisciplinary field reflects this scientific evolution. Central and peripheral neural systems are now understood to not merely regulate reproductive physiology but to actively determine the pathophysiology of gynaecological diseases through neuroendocrine, autonomic, and neuroinflammatory mechanisms (Hwang et al., \u003cspan citationid=\"CR27\" class=\"CitationRef\"\u003e2014\u003c/span\u003e; Douglas, \u003cspan citationid=\"CR18\" class=\"CitationRef\"\u003e2010\u003c/span\u003e). This understanding challenges the traditional organ-centric model of gynaecological care, which focused principally on anatomical abnormalities, hormonal assays, and structural pathology (Fran\u0026ccedil;a et al., \u003cspan citationid=\"CR22\" class=\"CitationRef\"\u003e2017\u003c/span\u003e). Table\u0026nbsp;\u003cspan refid=\"Tab1\" class=\"InternalRef\"\u003e1\u003c/span\u003e \u003cb\u003epresents the five principal neuro-gynaecological biological systems and their respective reproductive roles.\u003c/b\u003e\u003c/p\u003e \u003cp\u003e \u003cdiv class=\"gridtable\"\u003e\u003ctable float=\"Yes\" id=\"Tab1\" border=\"1\"\u003e \u003ccaption language=\"En\"\u003e \u003cdiv class=\"CaptionNumber\"\u003eTable 1\u003c/div\u003e \u003cdiv class=\"CaptionContent\"\u003e \u003cp\u003eNeuro-Gynaecological Biological Systems and Their Reproductive Roles\u003c/p\u003e \u003c/div\u003e \u003c/caption\u003e \u003ccolgroup cols=\"6\"\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c1\" colnum=\"1\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c2\" colnum=\"2\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c3\" colnum=\"3\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c4\" colnum=\"4\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c5\" colnum=\"5\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c6\" colnum=\"6\"\u003e\u003c/div\u003e \u003cthead\u003e \u003ctr\u003e \u003cth align=\"left\" colname=\"c1\"\u003e \u003cp\u003eBiological System\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c2\"\u003e \u003cp\u003eKey Components\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c3\"\u003e \u003cp\u003eMechanism of Action\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c4\"\u003e \u003cp\u003eReproductive Functions Affected\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c5\"\u003e \u003cp\u003eAssociated Disorders\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c6\"\u003e \u003cp\u003eClinical Significance\u003c/p\u003e \u003c/th\u003e \u003c/tr\u003e \u003c/thead\u003e \u003ctbody\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eNeurological System\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eBrainstem, limbic system (amygdala, hippocampus), hypothalamus, peripheral nerves\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003eNeural modulation of reproductive hormones and end-organ function via neuroendocrine signalling\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003eMenstrual cycle regulation, ovulation, and fertility\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003ePCOS, stress-related infertility, irregular menstruation\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003eCentral to neuroendocrine coordination; disruption triggers reproductive dysfunction\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eEndocrine System\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eHypothalamic\u0026ndash;Pituitary\u0026ndash;Ovarian (HPO) Axis and Hypothalamic\u0026ndash;Pituitary\u0026ndash;Adrenal (HPA) Axis\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003ePulsatile hormonal signalling via GnRH, FSH, LH, oestrogen, and progesterone; cortisol modulation under stress\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003eOvulation, follicular development, menstrual cyclicity, steroidogenesis\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003eOvulatory disorders, PCOS, functional hypothalamic amenorrhea\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003eCore regulatory axis; HPA\u0026ndash;HPO crosstalk is a primary mechanism in stress-induced reproductive failure\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eAutonomic Nervous System\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eSympathetic and parasympathetic (vagal) divisions; pelvic plexus\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003eNeural control of pelvic vascular tone, ovarian steroidogenesis, and uterine contractility via adrenergic/cholinergic pathways\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003eUterine contractility, ovarian blood flow, cervical function\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003eDysmenorrhea, chronic pelvic pain, PCOS\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003eSympathetic hyperactivity and vagal withdrawal are measurable and targetable contributors to gynaecological pathology\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eImmune System\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eCytokines (IL-1β, IL-6, TNF-α), mast cells, macrophages, T lymphocytes, neuropeptides\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003eBidirectional neuro-immune signalling; inflammatory cascade amplified by neurogenic mediators\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003eTissue homeostasis, inflammatory regulation, wound healing\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003eEndometriosis, pelvic inflammatory disease, infertility\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003eNeuro-immune crosstalk sustains chronic inflammation and drives therapeutic resistance\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003ePsychosomatic System\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eLimbic stress circuits (amygdala, prefrontal cortex), HPA axis, pain-processing networks\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003eBrain\u0026ndash;body interaction via cortisol, central sensitisation, and autonomic dysregulation\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003eMenstrual regularity, pain perception, fertility, quality of life\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003eAnxiety-related infertility, central sensitisation syndromes\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003ePsychosomatic factors are independent pathogenic drivers, not secondary symptoms \u0026mdash; their assessment is clinically mandatory\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003c/tbody\u003e \u003c/colgroup\u003e \u003ctfoot\u003e \u003ctr\u003e\u003ctd colspan=\"6\"\u003e\u003cem\u003eNote. Sources\u003c/em\u003e: Brocca \u0026amp; Garcia-Segura (\u003cspan citationid=\"CR9\" class=\"CitationRef\"\u003e2019\u003c/span\u003e\u003cem\u003e);\u003c/em\u003e Nicolopoulou (\u003cspan citationid=\"CR52\" class=\"CitationRef\"\u003e2001\u003c/span\u003e\u003cem\u003e);\u003c/em\u003e Yu et al. (\u003cspan citationid=\"CR93\" class=\"CitationRef\"\u003e2024\u003c/span\u003e); Nepomnaschy et al. (\u003cspan citationid=\"CR51\" class=\"CitationRef\"\u003e2007\u003c/span\u003e); Lal (\u003cspan citationid=\"CR39\" class=\"CitationRef\"\u003e2009\u003c/span\u003e\u003cem\u003e).\u003c/em\u003e\u003c/td\u003e\u003c/tr\u003e \u003c/tfoot\u003e \u003c/table\u003e\u003c/div\u003e \u003c/p\u003e \u003cp\u003eConditions including PCOS, primary and secondary dysmenorrhea, endometriosis, chronic pelvic pain, and stress-related menstrual irregularities are now understood as \u003cb\u003ebiopsychoneuroimmune disorders\u003c/b\u003e, conditions in which stress-mediated neural signalling, autonomic nervous system dysregulation, and neuroendocrine disruption are central, not peripheral, pathogenic factors (Licht et al., \u003cspan citationid=\"CR40\" class=\"CitationRef\"\u003e2013\u003c/span\u003e; Van den Akker, \u003cspan citationid=\"CR80\" class=\"CitationRef\"\u003e2011\u003c/span\u003e; Murck et al., \u003cspan citationid=\"CR49\" class=\"CitationRef\"\u003e2025\u003c/span\u003e). Failure to recognise and address these dimensions within routine clinical practice is a primary contributor to treatment resistance, unexplained symptom persistence, and reduced quality of life in women with chronic gynaecological conditions.\u003c/p\u003e \u003cp\u003eDespite the accumulating evidence base, neuro-gynaecological assessment remains substantially underrepresented in clinical gynaecology. Most evaluations continue to rely predominantly on hormonal assays and imaging, systematically overlooking neurological, autonomic, and psychosomatic contributors. This diagnostic gap partly explains the high prevalence of women with chronic gynaecological conditions who fail to achieve sustained symptom relief with conventional therapies alone. The present systematic review was therefore designed to consolidate and critically appraise the existing evidence on neuro-gynaecological mechanisms, evaluate their clinical significance, and provide a structured framework for integrative assessment and management of women's reproductive health conditions. Table\u0026nbsp;\u003cspan refid=\"Tab2\" class=\"InternalRef\"\u003e2\u003c/span\u003e \u003cb\u003ehighlights the key conceptual and practical distinctions between traditional gynaecology and the neuro-gynaecological framework, illustrating the rationale for this paradigm shift.\u003c/b\u003e\u003c/p\u003e \u003cp\u003e \u003cdiv class=\"gridtable\"\u003e\u003ctable float=\"Yes\" id=\"Tab2\" border=\"1\"\u003e \u003ccaption language=\"En\"\u003e \u003cdiv class=\"CaptionNumber\"\u003eTable 2\u003c/div\u003e \u003cdiv class=\"CaptionContent\"\u003e \u003cp\u003eConceptual Comparison: Traditional Gynaecology versus the Neuro-Gynaecological Framework\u003c/p\u003e \u003c/div\u003e \u003c/caption\u003e \u003ccolgroup cols=\"3\"\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c1\" colnum=\"1\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c2\" colnum=\"2\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c3\" colnum=\"3\"\u003e\u003c/div\u003e \u003cthead\u003e \u003ctr\u003e \u003cth align=\"left\" colname=\"c1\"\u003e \u003cp\u003eDimension\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c2\"\u003e \u003cp\u003eTraditional Gynaecology\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c3\"\u003e \u003cp\u003eNeuro-Gynaecological Framework\u003c/p\u003e \u003c/th\u003e \u003c/tr\u003e \u003c/thead\u003e \u003ctbody\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cb\u003eConceptual Basis\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eOrgan-centric; disease arises from localised anatomical or hormonal pathology\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003eBiopsychoneuroimmune; disease arises from convergent dysfunction across neural, endocrine, immune, and reproductive systems\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cb\u003eDiagnostic Approach\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003ePelvic imaging (ultrasound, MRI) and hormonal assays (FSH, LH, oestrogen, AMH)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003eExpanded multimodal assessment: neuroendocrine profiling\u0026thinsp;+\u0026thinsp;autonomic function (HRV) + pain centralisation index\u0026thinsp;+\u0026thinsp;psychological screening\u0026thinsp;+\u0026thinsp;inflammatory biomarkers\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cb\u003eDisease Model\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eSingle-system, peripherally localised pathology\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003eMultisystem; central neural dysregulation drives peripheral manifestations\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cb\u003eExplanation for Treatment Resistance\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eInadequate hormonal suppression or surgical completeness\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003eUnaddressed central sensitisation, psychosomatic contributors, and neuro-immune inflammation\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cb\u003eTreatment Paradigm\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eHormonal pharmacotherapy, surgical correction, analgesics\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003eIntegrative multidisciplinary: pharmacological\u0026thinsp;+\u0026thinsp;neuromodulatory\u0026thinsp;+\u0026thinsp;psychological\u0026thinsp;+\u0026thinsp;autonomic-regulating\u0026thinsp;+\u0026thinsp;neuro-immune modulating\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cb\u003ePain Explanation\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eProportional to observable peripheral pathology (lesion size, inflammation)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003ePain severity reflects central sensitisation status \u0026mdash; may far exceed anatomical findings\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cb\u003eExpected Outcomes\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eSymptom reduction through peripheral correction\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003eHolistic improvement: reproductive function\u0026thinsp;+\u0026thinsp;pain relief\u0026thinsp;+\u0026thinsp;psychological wellbeing\u0026thinsp;+\u0026thinsp;quality of life\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cb\u003ePatient Stratification\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eBy hormonal profile and imaging stage\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003eBy autonomic balance, stress biomarkers, pain sensitisation score, and psychosocial risk profile\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003c/tbody\u003e \u003c/colgroup\u003e \u003ctfoot\u003e \u003ctr\u003e\u003ctd colspan=\"3\"\u003e\u003cem\u003eNote. This comparison illustrates the expanded conceptual and clinical scope that the neuro-gynaecological framework offers over conventional gynaecological practice.\u003c/em\u003e\u003c/td\u003e\u003c/tr\u003e \u003c/tfoot\u003e \u003c/table\u003e\u003c/div\u003e \u003c/p\u003e"},{"header":"2. Rationale, Objectives and Hypothesis","content":"\u003cp\u003e\u003cstrong\u003e2.1 Rationale and Significance:\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eThe rationale for this systematic review arises from two converging clinical imperatives. First, neurogynecology remains substantially underrepresented in routine clinical practice despite a growing evidence base linking neurological processes to gynaecological disorders. Second, the organ-centric model of gynaecological care has demonstrably failed a significant proportion of patients, those with treatment-resistant chronic pain, unexplained infertility, and disproportionate symptom severity, precisely because it does not account for the central neural, autonomic, and psychosomatic determinants of disease. A comprehensive, methodologically rigorous synthesis of evidence is therefore urgently needed to support the clinical translation of neuro-gynaecological science into routine practice.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003e2.2 Objectives\u0026nbsp;\u003c/strong\u003e\u003c/p\u003e\n\u003col\u003e\n \u003cli\u003eTo systematically review and synthesise peer-reviewed literature on neuro-gynaecological interactions in women\u0026apos;s reproductive health.\u003c/li\u003e\n \u003cli\u003eTo critically analyse neuroendocrine, autonomic, psychosomatic, and neuro-immune mechanisms implicated in the pathophysiology of gynaecological disorders.\u003c/li\u003e\n \u003cli\u003eTo evaluate the clinical efficacy of integrative, multidisciplinary neuro-gynaecological therapeutic approaches.\u003c/li\u003e\n \u003cli\u003eTo identify current research gaps and propose evidence-informed priorities for future neuro-gynaecological investigation and clinical translation.\u003c/li\u003e\n\u003c/ol\u003e\n\u003cp\u003e\u003cstrong\u003e2.3 Central Hypothesis\u0026nbsp;\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eThis review is guided by the central hypothesis that gynaecological disorders are not isolated peripheral reproductive conditions but complex, centrally mediated biopsychoneuroimmune disturbances, and that their diagnosis and treatment require systematic integration of neurological, psychological, immunological, and reproductive assessments within a multidisciplinary clinical framework.\u003c/p\u003e"},{"header":"3. Methodology","content":"\u003cp\u003eThis systematic review was conducted in strict accordance with the \u003cb\u003ePreferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) 2020 guidelines\u003c/b\u003e to ensure methodological rigour, transparency, and reproducibility of the evidence synthesis process. A narrative systematic review design was adopted in preference to meta-analysis, given the methodological heterogeneity of available studies across outcome measures, populations, and study designs.\u003c/p\u003e \u003cdiv id=\"Sec6\" class=\"Section2\"\u003e \u003ch2\u003e3.1. Data Source\u003c/h2\u003e \u003cp\u003eSystematic database searches were conducted across three major electronic bibliographic databases: \u003cb\u003ePubMed/MEDLINE, Scopus\u003c/b\u003e, and \u003cb\u003eGoogle Scholar.\u003c/b\u003e Reference lists of all included systematic reviews and relevant primary studies were additionally screened manually to capture eligible studies not retrieved through database searches.\u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec7\" class=\"Section2\"\u003e \u003ch2\u003e3.2. Search Strategy\u003c/h2\u003e \u003cp\u003eStructured searches employed MeSH terms and free-text keywords combined with Boolean operators (AND, OR, NOT). Principal search terms included: \u003cem\u003e\"Neurogynecology,\" \"neuroendocrine regulation,\" \"hypothalamic\u0026ndash;pituitary\u0026ndash;ovarian axis,\" \"hypothalamic\u0026ndash;pituitary\u0026ndash;adrenal axis,\" \"autonomic nervous system,\" \"heart rate variability,\" \"psychosomatic stress,\" \"central sensitisation,\" \"PCOS,\" \"polycystic ovarian syndrome,\" \"dysmenorrhea,\" \"endometriosis,\" \"chronic pelvic pain,\" \"neuro-immune interactions,\" \"neurogenic inflammation,\" \"integrative women\u0026rsquo;s healthcare,\" and \"mind\u0026ndash;body intervention.\"\u003c/em\u003e\u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec8\" class=\"Section2\"\u003e \u003ch2\u003e3.3. Inclusion and Exclusion Criteria\u003c/h2\u003e \u003cp\u003e \u003cstrong\u003eInclusion\u003c/strong\u003e \u003cp\u003e(1) Peer-reviewed original research articles, systematic reviews, and narrative reviews in the English language; (2) Clinical, observational, experimental, neuroimaging, heart rate variability, and psychosomatic studies; (3) Studies examining neurological, neuroendocrine, autonomic, psychosomatic, or neuro-immune aspects of gynaecological disorders; (4) Studies reporting quantitative or qualitative outcomes relevant to neuro-gynaecological mechanisms or integrative therapeutic interventions; (5) Published primarily between 2000 and 2026, with foundational earlier studies included where relevant.\u003c/p\u003e \u003c/p\u003e \u003cp\u003e \u003cstrong\u003eExclusion\u003c/strong\u003e \u003cp\u003e(1) Case reports or case series with insufficient data for systematic appraisal; (2) non-peer-reviewed literature, conference abstracts, and grey literature without verifiable methodology; (3) Animal studies without demonstrated translational relevance to human gynaecological pathology; (4) Duplicate publications from the same dataset.\u003c/p\u003e \u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec9\" class=\"Section2\"\u003e \u003ch2\u003e3.4. PRISMA Study Selection\u003c/h2\u003e \u003cp\u003eThe study selection process followed PRISMA 2020 recommendations. A total of approximately 1,840 records were identified across the three databases. After deduplication, approximately 1,210 records were screened by title and abstract. Full-text review was conducted for approximately 186 records, with 89 studies ultimately meeting all inclusion criteria and contributing to the qualitative evidence synthesis. \u003cb\u003eThe PRISMA selection summary is presented below in\u003c/b\u003e Table \u003cspan refid=\"Tab3\" class=\"InternalRef\"\u003e3\u003c/span\u003e.\u003c/p\u003e \u003cp\u003e \u003cdiv class=\"gridtable\"\u003e\u003ctable float=\"Yes\" id=\"Tab3\" border=\"1\"\u003e \u003ccaption language=\"En\"\u003e \u003cdiv class=\"CaptionNumber\"\u003eTable 3\u003c/div\u003e \u003cdiv class=\"CaptionContent\"\u003e \u003cp\u003ePRISMA Study Selection Summary\u003c/p\u003e \u003c/div\u003e \u003c/caption\u003e \u003ccolgroup cols=\"2\"\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c1\" colnum=\"1\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c2\" colnum=\"2\"\u003e\u003c/div\u003e \u003cthead\u003e \u003ctr\u003e \u003cth align=\"left\" colname=\"c1\"\u003e \u003cp\u003ePRISMA Selection Stage\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c2\"\u003e \u003cp\u003eRecord Count / Description\u003c/p\u003e \u003c/th\u003e \u003c/tr\u003e \u003c/thead\u003e \u003ctbody\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eDatabase Search (PubMed, Scopus, Google Scholar)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003ePreliminary records identified: ~1,840\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eAfter deduplication\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eRecords screened: ~1,210\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eAfter title and abstract screening\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eFull-text articles assessed for eligibility: ~186\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eAfter full-text exclusion (case reports, non-English, non-peer-reviewed, no clinical relevance)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eStudies included in qualitative synthesis: 89\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003ePublication year range\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e2000\u0026ndash;2026 (with emphasis on post-2015 literature)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eStudy designs included\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eSystematic reviews, RCTs, observational studies, experimental studies, neuroimaging studies, HRV studies, and psychosomatic research\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003c/tbody\u003e \u003c/colgroup\u003e \u003ctfoot\u003e \u003ctr\u003e\u003ctd colspan=\"2\"\u003e\u003cem\u003eNote. Precise record counts are approximate, reflecting the systematic search conducted across PubMed, Scopus, and Google Scholar using the described search strategy.\u003c/em\u003e\u003c/td\u003e\u003c/tr\u003e \u003c/tfoot\u003e \u003c/table\u003e\u003c/div\u003e \u003c/p\u003e \u003c/div\u003e"},{"header":"4. Findings: Neuroendocrine Regulation in Gynaecological Disorders","content":"\u003cp\u003eThe hypothalamic\u0026ndash;pituitary\u0026ndash;ovarian (HPO) axis constitutes the central neuroendocrine architecture of female reproductive physiology, coordinating hormonal signals that govern menstrual cyclicity, ovulation, follicular maturation, and steroidogenesis. Critically, the HPO axis does not function in isolation: it is intimately integrated with the hypothalamic\u0026ndash;pituitary\u0026ndash;adrenal (HPA) axis, the autonomic nervous system, and higher cortical and limbic brain structures. The reviewed evidence confirms that disruption of this integrated neuroendocrine architecture underlies a spectrum of common gynaecological conditions (Josimovich, \u003cspan citationid=\"CR30\" class=\"CitationRef\"\u003e2013\u003c/span\u003e; Wu et al., 2025). Table\u0026nbsp;\u003cspan refid=\"Tab4\" class=\"InternalRef\"\u003e4\u003c/span\u003e \u003cb\u003ecomprehensively delineates the principal neuroendocrine components, their mechanisms of dysregulation, and gynaecological consequences.\u003c/b\u003e\u003c/p\u003e \u003cp\u003e \u003cdiv class=\"gridtable\"\u003e\u003ctable float=\"Yes\" id=\"Tab4\" border=\"1\"\u003e \u003ccaption language=\"En\"\u003e \u003cdiv class=\"CaptionNumber\"\u003eTable 4\u003c/div\u003e \u003cdiv class=\"CaptionContent\"\u003e \u003cp\u003eNeuroendocrine Components: Physiological Roles, Mechanisms of Dysregulation, and Gynaecological Consequences\u003c/p\u003e \u003c/div\u003e \u003c/caption\u003e \u003ccolgroup cols=\"5\"\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c1\" colnum=\"1\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c2\" colnum=\"2\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c3\" colnum=\"3\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c4\" colnum=\"4\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c5\" colnum=\"5\"\u003e\u003c/div\u003e \u003cthead\u003e \u003ctr\u003e \u003cth align=\"left\" colname=\"c1\"\u003e \u003cp\u003eNeuroendocrine Component\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c2\"\u003e \u003cp\u003ePhysiological Role\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c3\"\u003e \u003cp\u003eMechanism of Dysregulation\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c4\"\u003e \u003cp\u003eHormonal Consequences\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c5\"\u003e \u003cp\u003eGynaecological Significance\u003c/p\u003e \u003c/th\u003e \u003c/tr\u003e \u003c/thead\u003e \u003ctbody\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cb\u003eHPO Axis (GnRH\u0026ndash;LH\u0026ndash;FSH cascade)\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eCentral regulator of menstrual cyclicity, folliculogenesis, and ovulation\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003eDisruption of pulsatile signalling between hypothalamus, anterior pituitary, and ovaries under chronic stress or metabolic load\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003eAltered GnRH amplitude and frequency; aberrant LH:FSH ratio\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003eMenstrual irregularities, ovulatory dysfunction, unexplained infertility; core regulatory axis for all reproductive outcomes\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cb\u003eHPA Axis (CRH\u0026ndash;ACTH\u0026ndash;Cortisol)\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eStress response, systemic homeostasis, anti-inflammatory regulation\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003eChronic stress-induced hyperactivation; excess cortisol suppresses hypothalamic GnRH neurones via direct negative feedback\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003eElevated CRH, ACTH, and cortisol; suppressed gonadotropins\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003eFunctional hypothalamic amenorrhea, anovulation, PCOS exacerbation; stress is a primary, reversible cause of reproductive failure\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cb\u003eLimbic\u0026ndash;Hypothalamic Pathway\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eIntegration of emotional, behavioural, and environmental signals into endocrine output\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003eAmygdala and hippocampal hyperactivation under psychological stress directly modulates GnRH neurone firing\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003eDysregulated GnRH secretion patterns\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003eDirect anatomical and functional link between emotional states and menstrual regularity; explains stress-induced cycle disruption\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cb\u003eOvarian Steroidogenesis Under Stress\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eProduction of oestrogen and progesterone essential for cycle maintenance and endometrial preparation\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003eCortisol directly inhibits follicular development and gonadal steroid biosynthesis via glucocorticoid receptors\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003eReduced oestradiol and progesterone; impaired folliculogenesis\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003eDelayed ovulation, luteal phase defects, implantation failure; identifiable through integrated hormonal profiling\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cb\u003eNeuroendocrine Basis of PCOS\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eRegulation of ovarian androgen production through gonadotropin balance\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003eElevated GnRH pulse frequency preferentially drives LH over FSH; sympathetic hyperactivity amplifies androgen production\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003eElevated LH:FSH ratio; excess theca cell androgen output\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003eHyperandrogenism, anovulation, polycystic morphology; PCOS is fundamentally a neuroendocrine \u0026mdash; not solely ovarian \u0026mdash; disorder\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cb\u003eProlactin and Neurohormonal Modulation\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eModulates lactation, reproductive hormone balance, and neuroimmune function\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003eStress-induced hyperprolactinaemia suppresses GnRH via ultra-short feedback loop\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003eReduced LH and FSH; disrupted ovulatory surge\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003eInfertility, luteal phase defects; elevated prolactin functions as a neurohormonal stress biomarker in reproductive evaluation\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cb\u003eKisspeptin Signalling\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eUpstream gatekeeper of GnRH secretion; integrates metabolic and stress signals into reproductive regulation\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003eImpaired kisspeptin neurone activity under chronic stress, nutritional deficit, or metabolic disorder\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003eReduced GnRH release; suppressed gonadotropin cascade\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003eDelayed puberty, amenorrhea, stress-induced infertility; kisspeptin is an emerging translational diagnostic and therapeutic target\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cb\u003eBeta-Endorphin Pathway\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eEndogenous opioid modulation of pain perception and hypothalamic neuroendocrine activity\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003eStress- and pain-induced beta-endorphin release inhibits hypothalamic GnRH neurones and modulates descending pain pathways\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003eSuppressed GnRH and gonadotropin secretion under chronic pain or stress\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003eOvulatory dysfunction in chronic pain syndromes; directly links dysmenorrhea and chronic pelvic pain to hormonal dysregulation\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003c/tbody\u003e \u003c/colgroup\u003e \u003ctfoot\u003e \u003ctr\u003e\u003ctd colspan=\"5\"\u003e\u003cem\u003eNote. Sources\u003c/em\u003e: Petraglia et al. (\u003cspan citationid=\"CR59\" class=\"CitationRef\"\u003e2008\u003c/span\u003e); Chrousos et al. (\u003cspan citationid=\"CR13\" class=\"CitationRef\"\u003e1998\u003c/span\u003e); Reznikov (\u003cspan citationid=\"CR63\" class=\"CitationRef\"\u003e2023\u003c/span\u003e\u003cem\u003e);\u003c/em\u003e Tsutsumi \u0026amp; Webster (\u003cspan citationid=\"CR77\" class=\"CitationRef\"\u003e2009\u003c/span\u003e\u003cem\u003e);\u003c/em\u003e Pinilla et al. (\u003cspan citationid=\"CR60\" class=\"CitationRef\"\u003e2012\u003c/span\u003e); Valera et al. (\u003cspan citationid=\"CR79\" class=\"CitationRef\"\u003e2025\u003c/span\u003e); Ruddenklau \u0026amp; Campbell (\u003cspan citationid=\"CR65\" class=\"CitationRef\"\u003e2019\u003c/span\u003e\u003cem\u003e).\u003c/em\u003e\u003c/td\u003e\u003c/tr\u003e \u003c/tfoot\u003e \u003c/table\u003e\u003c/div\u003e \u003c/p\u003e \u003cdiv id=\"Sec11\" class=\"Section2\"\u003e \u003ch2\u003e4.1. Hypothalamic Control and GnRH Pulsatility\u003c/h2\u003e \u003cp\u003eThe hypothalamus functions as the principal neuroendocrine integrator of the reproductive axis, translating neural signals, emotional stimuli, metabolic cues, and environmental stressors into coherent, timed endocrine responses. GnRH neurones in the arcuate nucleus and preoptic area release GnRH in a critically timed pulsatile pattern that is indispensable for normal pituitary gonadotropin secretion. Alterations in GnRH pulse frequency or amplitude directly impair LH and FSH release, disrupting ovarian function. Limbic inputs from the amygdala and hippocampus directly modulate hypothalamic GnRH neurones, establishing a direct and clinically measurable link between emotional states and reproductive function (George et al., \u003cspan citationid=\"CR24\" class=\"CitationRef\"\u003e2012\u003c/span\u003e).\u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec12\" class=\"Section2\"\u003e \u003ch2\u003e4.2. Stress-Induced HPA Axis Activation and Reproductive Suppression\u003c/h2\u003e \u003cp\u003eChronic psychological or physiological stress triggers sustained HPA axis activation, generating sequential secretion of CRH, ACTH, and cortisol. Excess cortisol exerts potent inhibitory effects on the HPO axis by suppressing GnRH pulsatility and impairing ovarian steroidogenesis via glucocorticoid receptor-mediated inhibition of follicular development (Toufexis et al., \u003cspan citationid=\"CR75\" class=\"CitationRef\"\u003e2014\u003c/span\u003e; Kaiser et al., 2023). This neuroendocrine cascade produces functional hypothalamic amenorrhea, menstrual irregularities, delayed ovulation, and unexplained infertility in women without primary ovarian pathology \u0026mdash; demonstrating the primacy of central neuroendocrine regulation in reproductive health.\u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec13\" class=\"Section2\"\u003e \u003ch2\u003e4.3. Neuroendocrine Dysregulation in PCOS\u003c/h2\u003e \u003cp\u003ePCOS is characterised by a fundamentally neuroendocrine pathogenesis. Aberrant GnRH pulse frequency preferentially drives LH secretion over FSH, stimulating ovarian theca cells to produce excess androgens and resulting in hyperandrogenism, anovulation, and polycystic ovarian morphology. Sympathetic nervous system hyperactivity and enhanced stress responsiveness exacerbate these neuroendocrine disturbances (Ruddenklau \u0026amp; Campbell, \u003cspan citationid=\"CR65\" class=\"CitationRef\"\u003e2019\u003c/span\u003e). Elevated cortisol and aberrant beta-endorphin signalling further disrupt HPO axis feedback. These findings establish PCOS as a complex neuroendocrine condition centrally driven by dysregulated eural regulation, not a primary ovarian disorder (Solorzano et al., \u003cspan citationid=\"CR69\" class=\"CitationRef\"\u003e2012\u003c/span\u003e; Garg et al., \u003cspan citationid=\"CR23\" class=\"CitationRef\"\u003e2022\u003c/span\u003e).\u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec14\" class=\"Section2\"\u003e \u003ch2\u003e4.4. Neurohormonal Modulation: Prolactin, Kisspeptin, and Beta-Endorphins\u003c/h2\u003e \u003cp\u003eNeurohormones including prolactin, kisspeptin, and beta-endorphins exert critical modulatory roles across the reproductive axis. Stress-induced hyperprolactinaemia suppresses GnRH secretion, contributing to luteal phase defects and infertility. Kisspeptin neurones function as upstream gatekeepers of GnRH release and are exquisitely sensitive to metabolic and stress signals \u0026mdash; their dysregulation underlies amenorrhea and stress-induced infertility, positioning kisspeptin as an emerging diagnostic and therapeutic biomarker (Al-Fahham \u0026amp; Al-Nowainy, \u003cspan citationid=\"CR3\" class=\"CitationRef\"\u003e2016\u003c/span\u003e; Nappi et al., \u003cspan citationid=\"CR50\" class=\"CitationRef\"\u003e2021\u003c/span\u003e). Beta-endorphins released during chronic pain suppress hypothalamic activity, directly linking dysmenorrhea and chronic pelvic pain to hormonal dysregulation.\u003c/p\u003e \u003c/div\u003e"},{"header":"5. Findings: Autonomic Nervous System Dysfunction in Gynaecological Disorders","content":"\u003cp\u003eThe autonomic nervous system (ANS) comprising sympathetic, parasympathetic, and enteric divisions, plays an indispensable and clinically underappreciated role in female reproductive physiology. Via adrenergic and cholinergic innervation of pelvic organs, the ANS directly regulates ovarian steroidogenesis, uterine contractility, cervical secretion, and pelvic vascular tone (Stanković et al., \u003cspan citationid=\"CR71\" class=\"CitationRef\"\u003e2021\u003c/span\u003e). A growing body of neurophysiological evidence demonstrates that \u003cb\u003eautonomic dysregulation\u003c/b\u003e \u0026mdash; characterised by sympathetic hyperactivity and reduced parasympathetic (vagal) tone \u0026mdash; is a measurable, reproducible, and clinically significant contributor to the pathophysiology of multiple gynaecological conditions. Heart rate variability (HRV), a validated non-invasive biomarker of sympathovagal balance, has emerged as a key diagnostic and monitoring tool in neuro-gynaecological research (Agorastos et al., \u003cspan citationid=\"CR2\" class=\"CitationRef\"\u003e2023\u003c/span\u003e). Table\u0026nbsp;\u003cspan refid=\"Tab5\" class=\"InternalRef\"\u003e5\u003c/span\u003e \u003cb\u003esystematically presents the ANS abnormalities identified across major gynaecological conditions and their clinical implications.\u003c/b\u003e\u003c/p\u003e \u003cp\u003e \u003cdiv class=\"gridtable\"\u003e\u003ctable float=\"Yes\" id=\"Tab5\" border=\"1\"\u003e \u003ccaption language=\"En\"\u003e \u003cdiv class=\"CaptionNumber\"\u003eTable 5\u003c/div\u003e \u003cdiv class=\"CaptionContent\"\u003e \u003cp\u003eAutonomic Nervous System Dysregulation in Gynaecological Disorders: Mechanisms, Biomarkers, and Clinical Implications\u003c/p\u003e \u003c/div\u003e \u003c/caption\u003e \u003ccolgroup cols=\"5\"\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c1\" colnum=\"1\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c2\" colnum=\"2\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c3\" colnum=\"3\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c4\" colnum=\"4\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c5\" colnum=\"5\"\u003e\u003c/div\u003e \u003cthead\u003e \u003ctr\u003e \u003cth align=\"left\" colname=\"c1\"\u003e \u003cp\u003eANS Component\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c2\"\u003e \u003cp\u003eGynaecological Condition\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c3\"\u003e \u003cp\u003eMechanism of ANS Dysregulation\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c4\"\u003e \u003cp\u003eMeasurable Biomarker / Finding\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c5\"\u003e \u003cp\u003eClinical Implication\u003c/p\u003e \u003c/th\u003e \u003c/tr\u003e \u003c/thead\u003e \u003ctbody\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cb\u003eSympathetic hyperactivity\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003ePCOS\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003eElevated catecholamine tone drives ovarian noradrenergic signalling, increasing ovarian androgen production and disrupting folliculogenesis\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003eIncreased muscle sympathetic nerve activity (MSNA); elevated plasma norepinephrine; abnormal HRV (reduced HF power)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003eANS-targeted therapies (e.g., moxibustion, exercise, alpha-blockers) improve hormonal profiles; HRV monitoring guides treatment response\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cb\u003eSympathetic hyperactivity\u0026thinsp;+\u0026thinsp;reduced vagal tone\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eDysmenorrhea\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003eAdrenergic stimulation increases uterine vascular resistance and prostaglandin-mediated myometrial hypercontractility; reduced vagal tone impairs endogenous analgesia\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003eReduced RMSSD and HF/LF ratio on HRV analysis; elevated prostaglandin F2α; increased pain catastrophising\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003eHRV-guided biofeedback and parasympathetic-activating interventions (yoga, controlled breathing) reduce menstrual pain intensity and duration\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cb\u003eAutonomic imbalance (sympathetic dominance)\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eChronic pelvic pain\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003eSustained sympathetic activity amplifies nociceptive afferent signalling from pelvic viscera; reduced vagal tone diminishes endogenous pain inhibition via cholinergic anti-inflammatory pathway\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003eImpaired HRV; elevated salivary alpha-amylase (sympathetic marker); allodynia on quantitative sensory testing\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003eVagal nerve stimulation and parasympathetic activation reduce pelvic pain intensity; HRV serves as treatment monitoring tool\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cb\u003eAutonomic neuropathy of pelvic innervation\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eEndometriosis-associated pain\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003eAbnormal sympathetic and sensory nerve innervation of ectopic lesions creates aberrant neural microenvironment sustaining neurogenic inflammation\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003eDense SP- and CGRP-positive nerve fibres in lesions on immunohistochemistry; elevated neuropeptides in peritoneal fluid\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003eTargeting neural components of lesions alongside hormonal suppression; neuromodulatory approaches address pain refractory to standard therapy\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cb\u003eImpaired HPA\u0026ndash;ANS integration\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eStress-related menstrual disorders\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003eChronic stress simultaneously activates HPA and SNS, resulting in compounded suppression of HPO axis and sensitisation of visceral pain pathways\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003eBlunted cortisol awakening response; reduced HRV; disrupted menstrual cycle regularity\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003eIntegrated stress management (MBSR, biofeedback) simultaneously targets HPA and ANS dysregulation; more effective than isolated hormonal intervention\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003c/tbody\u003e \u003c/colgroup\u003e \u003ctfoot\u003e \u003ctr\u003e\u003ctd colspan=\"5\"\u003e\u003cem\u003eNote. Sources\u003c/em\u003e: Yu et al. (\u003cspan citationid=\"CR93\" class=\"CitationRef\"\u003e2024\u003c/span\u003e); Yun et al. (\u003cspan citationid=\"CR94\" class=\"CitationRef\"\u003e2004\u003c/span\u003e); Wei et al. (\u003cspan citationid=\"CR84\" class=\"CitationRef\"\u003e2020\u003c/span\u003e); Agorastos et al. (\u003cspan citationid=\"CR2\" class=\"CitationRef\"\u003e2023\u003c/span\u003e); Stanković et al. (\u003cspan citationid=\"CR71\" class=\"CitationRef\"\u003e2021\u003c/span\u003e).\u003c/td\u003e\u003c/tr\u003e \u003c/tfoot\u003e \u003c/table\u003e\u003c/div\u003e \u003c/p\u003e \u003cdiv id=\"Sec16\" class=\"Section2\"\u003e \u003ch2\u003e5.1. Sympathetic Hyperactivity in PCOS\u003c/h2\u003e \u003cp\u003eMultiple lines of evidence converge in establishing sympathetic nervous system hyperactivity as a pathogenic contributor to PCOS beyond the classically described hormonal and metabolic features. Elevated ovarian sympathetic nerve density, increased catecholamine levels, and reduced HRV, indicative of impaired parasympathetic tone, have been documented in women with PCOS (Yu et al., \u003cspan citationid=\"CR93\" class=\"CitationRef\"\u003e2024\u003c/span\u003e). Noradrenergic signalling within the ovary directly stimulates theca cell androgen production and inhibits follicular maturation, providing a mechanistic link between ANS dysregulation and the endocrine phenotype of PCOS. Interventions targeting sympathetic hyperactivity, including aerobic exercise, electroacupuncture, and alpha-adrenergic receptor modulation, have demonstrated improvements in both hormonal profiles and metabolic parameters.\u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec17\" class=\"Section2\"\u003e \u003ch2\u003e5.2. ANS Dysregulation in Dysmenorrhea and Chronic Pelvic Pain\u003c/h2\u003e \u003cp\u003ePrimary dysmenorrhea is associated with measurable autonomic imbalance, characterised by sympathetic dominance and reduced vagal tone during the menstrual phase. This autonomic shift increases uterine vascular resistance, promotes prostaglandin-mediated myometrial hypercontractility, and reduces the activation threshold of pelvic nociceptors. HRV analysis consistently demonstrates reduced parasympathetic indices \u0026mdash; including RMSSD and HF power \u0026mdash; in women with severe dysmenorrhea compared with controls, with the degree of autonomic imbalance correlating significantly with pain severity and psychological distress (Park \u0026amp; Watanuki, \u003cspan citationid=\"CR58\" class=\"CitationRef\"\u003e2005\u003c/span\u003e). In chronic pelvic pain, sustained sympathetic activity amplifies nociceptive afferent signalling from pelvic viscera, while concurrent vagal withdrawal diminishes the cholinergic anti-inflammatory pathway, perpetuating a self-reinforcing cycle of inflammation and pain.\u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec18\" class=\"Section2\"\u003e \u003ch2\u003e5.3. Autonomic Dysfunction and Endometriosis\u003c/h2\u003e \u003cp\u003eEndometriosis is characterised by aberrant autonomic innervation of ectopic lesions, including elevated densities of sympathetic and sensory nerve fibres (Wei et al., \u003cspan citationid=\"CR84\" class=\"CitationRef\"\u003e2020\u003c/span\u003e). This neural microenvironment perpetuates neurogenic inflammation through neuropeptide release, while the adrenergic overstimulation of immune cells within lesions promotes cytokine production and further neural sensitisation. The co-existence of peripheral autonomic dysfunction and central sensitisation in endometriosis explains the characteristic dissociation between lesion burden and pain severity that is frequently encountered clinically.\u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec19\" class=\"Section2\"\u003e \u003ch2\u003e5.4. Heart Rate Variability as a Neuro-Gynaecological Biomarker\u003c/h2\u003e \u003cp\u003eHRV analysis offers a clinically accessible, non-invasive, and validated window into ANS function in gynaecological patients. Reduced HRV \u0026mdash; specifically low frequency/high frequency (LF/HF) ratio elevation and suppressed RMSSD \u0026mdash; has been documented across PCOS, dysmenorrhea, endometriosis, and chronic pelvic pain populations. HRV correlates significantly with pain severity, psychological distress, and hormonal dysregulation, positioning it as a multidimensional biomarker of neuro-gynaecological dysfunction. HRV-guided biofeedback, which uses real-time autonomic feedback to train resonance breathing and vagal tone enhancement, functions as both a diagnostic and therapeutic tool in neuro-gynaecological practice (Agorastos et al., \u003cspan citationid=\"CR2\" class=\"CitationRef\"\u003e2023\u003c/span\u003e).\u003c/p\u003e \u003c/div\u003e"},{"header":"6. Psychosomatic Stress and Central Sensitisation","content":"\u003cp\u003ePsychosomatic stress is a critical and increasingly well-evidenced determinant of women's reproductive health, operating through complex bidirectional interactions between psychological processes, neural circuitry, endocrine regulation, and immune function. Psychological stress, anxiety, depressive disorders, and emotional trauma are robustly established as significant contributors to the onset, persistence, and severity of gynaecological disorders (Chorna, \u003cspan citationid=\"CR12\" class=\"CitationRef\"\u003e2024\u003c/span\u003e). Within the neuro-gynaecological framework, these psychosocial factors exert pathophysiological influence primarily through dysregulation of central neural pathways and the development of \u003cb\u003ecentral sensitisation\u003c/b\u003e \u0026mdash; a condition characterised by amplified pain perception, lowered pain thresholds, and maladaptive neuroplastic remodelling of spinal and supraspinal pain-processing circuits (Delanerolle et al., \u003cspan citationid=\"CR16\" class=\"CitationRef\"\u003e2025\u003c/span\u003e). Figure\u0026nbsp;\u003cspan refid=\"Fig1\" class=\"InternalRef\"\u003e1\u003c/span\u003e \u003cb\u003eillustrates the integrated psychosomatic\u0026ndash;neuroendocrine pathways converging on gynaecological dysfunction.\u003c/b\u003e\u003c/p\u003e \u003cp\u003e \u003c/p\u003e \u003cp\u003eChronic psychosomatic stress activates limbic structures including the amygdala and hippocampus, which communicate directly with the hypothalamus to modulate neuroendocrine output (Jankord \u0026amp; Herman, \u003cspan citationid=\"CR29\" class=\"CitationRef\"\u003e2008\u003c/span\u003e). Sustained HPA axis activation results in prolonged cortisol secretion that disrupts GnRH pulsatility, impairs ovarian steroidogenesis, and progressively destabilises the HPO axis (Tsigos \u0026amp; Chrousos, \u003cspan citationid=\"CR76\" class=\"CitationRef\"\u003e2002\u003c/span\u003e). As a consequence, oestrogen and progesterone synthesis become irregular, contributing to menstrual disturbances, ovulatory dysfunction, and heightened vulnerability to stress-sensitive gynaecological conditions. These findings establish psychosomatic stress not as a secondary co-morbidity but as a \u003cb\u003eprimary, centrally acting driver of reproductive dysregulation.\u003c/b\u003e Figure\u0026nbsp;\u003cspan refid=\"Fig2\" class=\"InternalRef\"\u003e2\u003c/span\u003e \u003cb\u003edepicts the integrated model through which psychosomatic stress drives central sensitisation and chronic gynaecological pain.\u003c/b\u003e\u003c/p\u003e \u003cp\u003e \u003c/p\u003e \u003cp\u003eCentral sensitisation involves heightened excitability within the central nervous system, wherein repeated or prolonged nociceptive input leads to maladaptive neuroplastic changes in the spinal dorsal horn and supraspinal pain-processing regions. Psychological stress accelerates this sensitisation by enhancing excitatory neurotransmission (glutamate, substance P) while simultaneously impairing inhibitory pathways mediated by GABA and serotonin (Ciranna, \u003cspan citationid=\"CR14\" class=\"CitationRef\"\u003e2006\u003c/span\u003e). Functional neuroimaging studies have demonstrated altered activation in the anterior cingulate cortex, insular cortex, thalamus, and prefrontal cortex in women with chronic pelvic pain, confirming the central neural origin of disproportionate gynaecological pain (As-Sanie et al., \u003cspan citationid=\"CR6\" class=\"CitationRef\"\u003e2016\u003c/span\u003e; Yu et al., \u003cspan citationid=\"CR92\" class=\"CitationRef\"\u003e2021\u003c/span\u003e). Table\u0026nbsp;\u003cspan refid=\"Tab6\" class=\"InternalRef\"\u003e6\u003c/span\u003e. \u003cb\u003eprovides a systematic overview of psychosomatic mechanisms and their clinical dimensions.\u003c/b\u003e\u003c/p\u003e \u003cp\u003e \u003cdiv class=\"gridtable\"\u003e\u003ctable float=\"Yes\" id=\"Tab6\" border=\"1\"\u003e \u003ccaption language=\"En\"\u003e \u003cdiv class=\"CaptionNumber\"\u003eTable 6\u003c/div\u003e \u003cdiv class=\"CaptionContent\"\u003e \u003cp\u003ePsychosomatic Mechanisms in Gynaecological Disorders: Neural, Endocrine, and Clinical Dimensions\u003c/p\u003e \u003c/div\u003e \u003c/caption\u003e \u003ccolgroup cols=\"6\"\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c1\" colnum=\"1\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c2\" colnum=\"2\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c3\" colnum=\"3\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c4\" colnum=\"4\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c5\" colnum=\"5\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c6\" colnum=\"6\"\u003e\u003c/div\u003e \u003cthead\u003e \u003ctr\u003e \u003cth align=\"left\" colname=\"c1\"\u003e \u003cp\u003ePsychosomatic Factor\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c2\"\u003e \u003cp\u003eNeural Mechanism\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c3\"\u003e \u003cp\u003eNeuroendocrine Effect\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c4\"\u003e \u003cp\u003eNeurophysiological Change\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c5\"\u003e \u003cp\u003eGynaecological Manifestation\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c6\"\u003e \u003cp\u003eClinical Implication\u003c/p\u003e \u003c/th\u003e \u003c/tr\u003e \u003c/thead\u003e \u003ctbody\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cb\u003ePsychological stress (acute and chronic)\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eLimbic activation (amygdala, hippocampus) \u0026rarr; HPA axis engagement \u0026rarr; sympathetic arousal\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003eExcess cortisol disrupts GnRH pulsatility; elevated CRH suppresses gonadotropin release\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003eDysregulated HPO axis activity; altered pain modulation threshold\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003eMenstrual irregularities, anovulation, stress-sensitive dysmenorrhea\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003eStress is a primary, modifiable reproductive risk factor \u0026mdash; cortisol profiling and stress assessment should be routine in gynaecological workup\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cb\u003eAnxiety disorders\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eHeightened excitatory neural activity; amygdala hyperreactivity; reduced prefrontal inhibitory control\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003eAltered GnRH pulse frequency; exaggerated sympathoadrenal response\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003eHormonal fluctuations; heightened visceral hypersensitivity\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003eDysmenorrhea, irregular menstrual cycles, worsened premenstrual symptoms\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003eValidated anxiety screening (GAD-7) should be integrated into standard gynaecological history-taking\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cb\u003eMajor depressive disorder\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eSerotonin, dopamine, and norepinephrine deficits reduce hypothalamic drive; limbic hypoactivation\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003eImpaired hypothalamic GnRH pulsatility; HPO axis suppression and reduced ovarian steroidogenesis\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003eDisrupted gonadotropin release; blunted hormonal feedback sensitivity\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003eInfertility, amenorrhea, reduced libido, impaired treatment adherence\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003eDepression independently impairs reproductive function; pharmacological and psychological treatment of depression can restore menstrual cyclicity\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cb\u003eEmotional trauma / PTSD\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003ePersistent amygdala sensitisation; dysregulated hypothalamic\u0026ndash;limbic circuitry; HPA axis dysregulation\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003eChronic cortisol elevation with blunted diurnal cortisol rhythm; neuroendocrine instability\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003eAltered stress reactivity; impaired pain inhibitory pathways\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003eOvulatory dysfunction, recurrent pregnancy loss, heightened pain sensitivity\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003eTrauma-sensitive clinical assessment; PTSD screening in women with unexplained infertility or treatment-refractory pelvic pain\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cb\u003eCentral sensitisation\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eSpinal dorsal horn neuroplastic remodelling; reduced descending inhibition (GABA, serotonin); enhanced excitatory neurotransmission (glutamate, substance P)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003eNeurotransmitter imbalance perpetuates pain irrespective of peripheral pathology status\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003eHyper-responsive pain circuits; lowered pain threshold; wind-up phenomenon\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003eChronic pelvic pain, severe dysmenorrhea, endometriosis pain disproportionate to lesion burden\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003eCentral sensitisation must be assessed with validated tools (CSI, painDETECT); its presence mandates centrally acting treatment strategies\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cb\u003eAutonomic dysfunction (psychosomatic-driven)\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eSustained sympathetic overactivity and parasympathetic withdrawal under chronic emotional stress\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003eAdrenergic\u0026ndash;endocrine crosstalk produces hormonal instability; cholinergic anti-inflammatory deficit\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003eIncreased pain transmission; impaired emotional regulation; prolonged inflammatory response\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003ePelvic pain disorders, stress-exacerbated menstrual symptoms\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003eHRV analysis quantifies autonomic imbalance; vagal nerve stimulation and mind\u0026ndash;body therapies restore autonomic balance\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003c/tbody\u003e \u003c/colgroup\u003e \u003ctfoot\u003e \u003ctr\u003e\u003ctd colspan=\"6\"\u003e\u003cem\u003eNote. Sources\u003c/em\u003e: Facchinetti et al. (\u003cspan citationid=\"CR20\" class=\"CitationRef\"\u003e1992\u003c/span\u003e); Weidner et al. (\u003cspan citationid=\"CR85\" class=\"CitationRef\"\u003e2006\u003c/span\u003e); Bernardi et al. (\u003cspan citationid=\"CR7\" class=\"CitationRef\"\u003e2017\u003c/span\u003e); Pakpour et al. (\u003cspan citationid=\"CR57\" class=\"CitationRef\"\u003e2020\u003c/span\u003e); Yun et al. (\u003cspan citationid=\"CR94\" class=\"CitationRef\"\u003e2004\u003c/span\u003e); Takeuchi et al. (\u003cspan citationid=\"CR74\" class=\"CitationRef\"\u003e2024\u003c/span\u003e).\u003c/td\u003e\u003c/tr\u003e \u003c/tfoot\u003e \u003c/table\u003e\u003c/div\u003e \u003c/p\u003e \u003cdiv id=\"Sec21\" class=\"Section2\"\u003e \u003ch2\u003e6.1. Dysmenorrhea and Psychosomatic Interaction\u003c/h2\u003e \u003cp\u003eDysmenorrhea exhibits a strong psychosomatic dimension. Women with elevated psychological stress, anxiety, or depressive symptoms consistently report greater menstrual pain intensity, longer pain duration, and poorer analgesic response (Pakpour et al., \u003cspan citationid=\"CR57\" class=\"CitationRef\"\u003e2020\u003c/span\u003e). Stress-induced prostaglandin amplification, combined with heightened central pain sensitivity, exacerbates uterine hypercontractility. Repeated painful cycles progressively reinforce central sensitisation, potentially transforming episodic dysmenorrhea into a chronic pain condition \u0026mdash; a transition that is both clinically significant and preventable with early psychosomatic intervention.\u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec22\" class=\"Section2\"\u003e \u003ch2\u003e6.2. Endometriosis, Depression, and Central Pain Amplification\u003c/h2\u003e \u003cp\u003eEndometriosis exemplifies the convergence of psychosomatic stress and central sensitisation. High prevalence rates of anxiety, depression, and sleep disturbances are consistently documented among women with endometriosis, and pain severity correlates more strongly with psychological and central neural variables than with lesion size or surgical staging (Chen \u0026amp; Li, \u003cspan citationid=\"CR11\" class=\"CitationRef\"\u003e2025\u003c/span\u003e; Cuffaro et al., \u003cspan citationid=\"CR15\" class=\"CitationRef\"\u003e2024\u003c/span\u003e). This robust finding has direct clinical implications: it explains the frequent failure of surgical debulking to achieve durable pain relief and establishes psychological therapies and centrally acting pharmacological agents as mechanistically justified first-line components of endometriosis pain management, not adjuncts.\u003c/p\u003e \u003c/div\u003e"},{"header":"7. Neuro-Immune Interactions in Gynaecological Disorders","content":"\u003cp\u003eNeuro-immune interactions represent a fundamental and historically underexplored dimension of gynaecological disease pathophysiology. The nervous and immune systems are intricately interconnected through bidirectional signalling pathways that collectively regulate inflammation, pain perception, tissue repair, and systemic homeostasis (Reyes-Lagos et al., \u003cspan citationid=\"CR62\" class=\"CitationRef\"\u003e2019\u003c/span\u003e). In gynaecology, dysregulation of this neuro-immune axis plays a central role in the development and chronification of pelvic pain, endometriosis, dysmenorrhea, and inflammatory reproductive disorders. Table\u0026nbsp;\u003cspan refid=\"Tab7\" class=\"InternalRef\"\u003e7\u003c/span\u003e \u003cb\u003edelineates the components and mechanisms of neuro-immune interactions in gynaecological pathology.\u003c/b\u003e\u003c/p\u003e \u003cp\u003e \u003cdiv class=\"gridtable\"\u003e\u003ctable float=\"Yes\" id=\"Tab7\" border=\"1\"\u003e \u003ccaption language=\"En\"\u003e \u003cdiv class=\"CaptionNumber\"\u003eTable 7\u003c/div\u003e \u003cdiv class=\"CaptionContent\"\u003e \u003cp\u003eNeuro-Immune Mechanisms and Neurogenic inflammation in Gynaecological Disorders\u003c/p\u003e \u003c/div\u003e \u003c/caption\u003e \u003ccolgroup cols=\"6\"\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c1\" colnum=\"1\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c2\" colnum=\"2\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c3\" colnum=\"3\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c4\" colnum=\"4\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c5\" colnum=\"5\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c6\" colnum=\"6\"\u003e\u003c/div\u003e \u003cthead\u003e \u003ctr\u003e \u003cth align=\"left\" colname=\"c1\"\u003e \u003cp\u003eComponent\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c2\"\u003e \u003cp\u003eKey Mediators\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c3\"\u003e \u003cp\u003eSource\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c4\"\u003e \u003cp\u003eMechanism of Action\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c5\"\u003e \u003cp\u003ePathophysiological Effects\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c6\"\u003e \u003cp\u003eClinical Significance\u003c/p\u003e \u003c/th\u003e \u003c/tr\u003e \u003c/thead\u003e \u003ctbody\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cb\u003eNeurogenic inflammation\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eSubstance P, CGRP, neurokinins\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003ePrimary afferent sensory fibres innervating pelvic organs\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003eNeuropeptide release in response to stress, injury, or persistent nociception \u0026rarr; vascular permeability \u0026uarr;, immune cell recruitment\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003eAmplified local inflammation; vasodilation; mast cell and macrophage activation; sustained pro-inflammatory microenvironment\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003eMajor driver of chronic pelvic inflammation; explains pain persistence after lesion resolution\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cb\u003eCytokine-mediated neural sensitisation\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eIL-1β, IL-6, TNF-α\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003eActivated immune cells (mast cells, macrophages, T lymphocytes)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003eCytokines lower nociceptor activation threshold and enhance spinal synaptic pain transmission; penetrate CNS to alter mood and stress response\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003ePeripheral and central sensitisation; progressive hyperalgesia; psychosomatic pain amplification\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003eElevated pro-inflammatory cytokines are measurable biomarkers of neuro-immune dysregulation in endometriosis and CPP\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cb\u003eBidirectional neuro-immune signalling\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eNeuropeptides, neurotransmitters, stress hormones, growth factors (NGF)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003eBidirectional nervous\u0026ndash;immune system communication\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003eNeural signals modulate immune cell activity; immune mediators alter neural excitability and pain processing\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003eAmplified inflammation exceeding tissue injury; pain severity decoupled from anatomical extent\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003eKey pathogenic mechanism explaining poor correlation between lesion burden and symptom severity in endometriosis\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cb\u003eMast cell\u0026ndash;nerve fibre interaction\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eHistamine, tryptase, cytokines, prostaglandins\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003eMast cells co-localised with pelvic nerve fibres\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003eStress-related neuropeptides activate adjacent mast cells; histamine and tryptase sensitise nociceptors and sustain inflammation\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003eNeuronal sensitisation; localised inflammatory flares; stress-triggered symptom exacerbation\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003ePsychosomatic stress directly activates neuro-immune pathway via mast cells; stress reduction is a neuro-immune therapeutic target\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cb\u003eAutonomic neuro-immune modulation\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eSympathetic catecholamines; vagal acetylcholine (cholinergic anti-inflammatory pathway)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003eAutonomic nervous system (SNS and PNS)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003eSNS activation \u0026rarr; pro-inflammatory cytokines \u0026uarr;; PNS (vagal) activation \u0026rarr; NF-κB suppression \u0026rarr; cytokine release \u0026darr;\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003eSympathetic dominance drives and sustains pelvic inflammation; vagal withdrawal removes endogenous anti-inflammatory brake\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003eVagal nerve stimulation activates cholinergic anti-inflammatory pathway; clinically reduces inflammatory burden in pelvic conditions\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cb\u003eImmune-driven nerve growth\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eNerve growth factor (NGF), BDNF, neurotrophin-3\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003eActivated immune cells within pelvic lesions\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003eNGF stimulates axonal sprouting and nociceptor sensitisation within endometriotic and inflamed pelvic tissue\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003eIncreased nerve fibre density; heightened sensory input; hyperalgesia independent of structural injury\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003eAnti-NGF therapies under clinical investigation for endometriosis pain; nerve density correlates with pain severity\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003c/tbody\u003e \u003c/colgroup\u003e \u003c/table\u003e\u003c/div\u003e \u003c/p\u003e \u003cp\u003e \u003cem\u003eSources\u003c/em\u003e: Xanthos \u0026amp; Sandk\u0026uuml;hler (\u003cspan citationid=\"CR88\" class=\"CitationRef\"\u003e2014\u003c/span\u003e\u003cem\u003e);\u003c/em\u003e Nimer et al. (\u003cspan citationid=\"CR54\" class=\"CitationRef\"\u003e2020\u003c/span\u003e); Sommer \u0026amp; Kress (\u003cspan citationid=\"CR70\" class=\"CitationRef\"\u003e2004\u003c/span\u003e\u003cem\u003e);\u003c/em\u003e Guo et al. (\u003cspan citationid=\"CR26\" class=\"CitationRef\"\u003e2026\u003c/span\u003e); Yanguas-Cas\u0026aacute;s et al. (\u003cspan citationid=\"CR89\" class=\"CitationRef\"\u003e2019\u003c/span\u003e).\u003c/p\u003e \u003cdiv id=\"Sec24\" class=\"Section2\"\u003e \u003ch2\u003e7.1. Neurogenic Inflammation\u003c/h2\u003e \u003cp\u003eNeurogenic inflammation is a key mechanism through which neural signalling amplifies immune activation in gynaecological tissues (Xanthos \u0026amp; Sandk\u0026uuml;hler, \u003cspan citationid=\"CR88\" class=\"CitationRef\"\u003e2014\u003c/span\u003e). Sensory nerve fibres innervating pelvic organs release substance P, CGRP, and neurokinins in response to stress, injury, or persistent nociception. These neuropeptides increase vascular permeability, promote vasodilation, and activate mast cells, macrophages, and T lymphocytes (Nimer et al., \u003cspan citationid=\"CR54\" class=\"CitationRef\"\u003e2020\u003c/span\u003e), creating a pro-inflammatory microenvironment that perpetuates pain and tissue sensitisation. Pro-inflammatory cytokines \u0026ndash; IL-1β, IL-6, and TNF-α, sensitise peripheral nociceptors and enhance spinal synaptic pain transmission, while simultaneously penetrating the CNS to alter mood, stress responsiveness, and descending pain modulation (Sommer \u0026amp; Kress, \u003cspan citationid=\"CR70\" class=\"CitationRef\"\u003e2004\u003c/span\u003e). Figure\u0026nbsp;\u003cspan refid=\"Fig3\" class=\"InternalRef\"\u003e3\u003c/span\u003e \u003cb\u003eillustrates the sequential neuro-immune pathway leading to neurogenic inflammation and chronic pelvic pain.\u003c/b\u003e\u003c/p\u003e \u003cp\u003e \u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec25\" class=\"Section2\"\u003e \u003ch2\u003e7.2. Endometriosis as a Neuro-immune Disorder\u003c/h2\u003e \u003cp\u003eEndometriosis provides the most compelling evidence of neuro-immune dysregulation in gynaecology. Ectopic lesions are characterised by dense sensory and sympathetic innervation and heavy immune cell infiltration (Alotaibi, \u003cspan citationid=\"CR4\" class=\"CitationRef\"\u003e2025\u003c/span\u003e). Immune cells secrete NGF and cytokines that stimulate axonal sprouting and nociceptor sensitisation; sensory nerve fibres within lesions release neuropeptides that amplify local inflammation \u0026mdash; a bidirectional, self-sustaining cycle. Critically, pain severity in endometriosis demonstrates a poor correlation with lesion burden, emphasising the dominant role of neuro-immune mechanisms over anatomical factors in determining the clinical presentation.\u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec26\" class=\"Section2\"\u003e \u003ch2\u003e7.3. Mast Cells, Stress, and Pelvic Pain\u003c/h2\u003e \u003cp\u003eMast cells occupy a pivotal position at the neural\u0026ndash;immune interface in gynaecological disorders (Menzies et al., \u003cspan citationid=\"CR45\" class=\"CitationRef\"\u003e2011\u003c/span\u003e; Szukiewicz et al., \u003cspan citationid=\"CR72\" class=\"CitationRef\"\u003e2022\u003c/span\u003e). Densely distributed adjacent to pelvic nerve fibres, mast cells are exquisitely responsive to stress-related neuropeptides. Their activation releases histamine, tryptase, and cytokines that sensitise nociceptors and sustain inflammation. This pathway directly links psychosomatic stress to neuro-immune activation, providing a mechanistic rationale for stress reduction as a neuro-immune therapeutic target in chronic pelvic pain. Table\u0026nbsp;\u003cspan refid=\"Tab8\" class=\"InternalRef\"\u003e8\u003c/span\u003e \u003cb\u003econsolidates the neuro-immune features, pathophysiology, and therapeutic implications for key gynaecological conditions.\u003c/b\u003e\u003c/p\u003e \u003cp\u003e \u003cdiv class=\"gridtable\"\u003e\u003ctable float=\"Yes\" id=\"Tab8\" border=\"1\"\u003e \u003ccaption language=\"En\"\u003e \u003cdiv class=\"CaptionNumber\"\u003eTable 8\u003c/div\u003e \u003cdiv class=\"CaptionContent\"\u003e \u003cp\u003eNeuro-Immune Dysregulation in Gynaecological Conditions: Pathophysiology and Therapeutic Implications\u003c/p\u003e \u003c/div\u003e \u003c/caption\u003e \u003ccolgroup cols=\"5\"\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c1\" colnum=\"1\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c2\" colnum=\"2\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c3\" colnum=\"3\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c4\" colnum=\"4\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c5\" colnum=\"5\"\u003e\u003c/div\u003e \u003cthead\u003e \u003ctr\u003e \u003cth align=\"left\" colname=\"c1\"\u003e \u003cp\u003eGynaecological Condition\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c2\"\u003e \u003cp\u003eNeuro-Immune Features\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c3\"\u003e \u003cp\u003ePathophysiological Mechanism\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c4\"\u003e \u003cp\u003eClinical Outcome\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c5\"\u003e \u003cp\u003eEvidence-Based Therapeutic Implications\u003c/p\u003e \u003c/th\u003e \u003c/tr\u003e \u003c/thead\u003e \u003ctbody\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cb\u003eEndometriosis\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eDense sensory and sympathetic innervation of ectopic lesions; heavy immune cell infiltration (macrophages, NK cells, mast cells)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003eCytokines stimulate NGF-driven axonal sprouting; neuropeptides amplify immune activation; self-sustaining neuro-immune inflammatory cycle\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003eSevere, often progressive chronic pelvic pain disproportionate to lesion size; central sensitisation in majority of patients\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003eHormonal suppression\u0026thinsp;+\u0026thinsp;neuromodulation\u0026thinsp;+\u0026thinsp;anti-NGF/anti-cytokine strategies; psychological therapy targeting central sensitisation is evidence-based\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cb\u003eChronic pelvic pain (CPP)\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003ePersistent neuro-immune co-activation; elevated peritoneal cytokines and neuropeptides; central and peripheral sensitisation\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003eSustained cytokine release amplifies nociceptive signalling; repeated immune activation promotes irreversible neuroplastic changes in spinal cord\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003ePain chronicity, widespread hyperalgesia, allodynia, fatigue, and sleep disturbance; progressive reduction in analgesic efficacy\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003eMultimodal therapy is mandatory: neuromodulation\u0026thinsp;+\u0026thinsp;anti-inflammatory strategies\u0026thinsp;+\u0026thinsp;psychological intervention (CBT) + autonomic regulation (VNS, biofeedback)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cb\u003eDysmenorrhea (primary and secondary)\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eNeurogenic inflammation; elevated prostaglandins and neuropeptide activity; autonomic imbalance\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003eNeuropeptide-mediated vascular and immune responses intensify uterine hypercontractility; repeated pain cycles progressively reinforce central sensitisation\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003eIncreasing menstrual pain severity over time; transition from episodic to chronic pain; analgesic tolerance\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003eEarly intervention with anti-inflammatory therapy\u0026thinsp;+\u0026thinsp;centrally acting agents in those with elevated CSI scores; mindfulness reduces central amplification\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cb\u003ePCOS-associated low-grade inflammation\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eChronic systemic low-grade inflammation; elevated CRP, IL-6, TNF-α; sympathetic hyperactivity\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003eElevated androgens and insulin resistance activate immune cells; SNS hyperactivity sustains neuro-immune dysregulation; adipose tissue amplifies cytokine burden\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003eMetabolic complications, infertility, worsening hormonal imbalance, mood disorders\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003eLifestyle intervention (anti-inflammatory diet, aerobic exercise) + stress reduction\u0026thinsp;+\u0026thinsp;insulin sensitisers; autonomic modulation as adjunct to hormonal therapy\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cb\u003ePelvic inflammatory disease (PID) / Vulvodynia\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eElevated cytokines and neuropeptides in pelvic tissues; central sensitisation in vulvodynia\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003eNeurogenic inflammation and immune activation cause persistent tissue sensitisation beyond the acute infectious phase\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003eChronic pain, dyspareunia, recurrent inflammation, impaired sexual function\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003eTargeting cytokine pathways alongside antimicrobial treatment for PID; topical anaesthetics\u0026thinsp;+\u0026thinsp;CBT\u0026thinsp;+\u0026thinsp;pelvic physiotherapy for vulvodynia with central sensitisation\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003c/tbody\u003e \u003c/colgroup\u003e \u003c/table\u003e\u003c/div\u003e \u003c/p\u003e \u003cp\u003e \u003cem\u003eSources\u003c/em\u003e: Muller et al. (\u003cspan citationid=\"CR48\" class=\"CitationRef\"\u003e2009\u003c/span\u003e); Vannuccini et al. (\u003cspan citationid=\"CR81\" class=\"CitationRef\"\u003e2016\u003c/span\u003e); Weiss et al. (\u003cspan citationid=\"CR86\" class=\"CitationRef\"\u003e2009\u003c/span\u003e); Chen \u0026amp; Li (\u003cspan citationid=\"CR11\" class=\"CitationRef\"\u003e2025\u003c/span\u003e\u003cem\u003e);\u003c/em\u003e Marano et al. (\u003cspan citationid=\"CR42\" class=\"CitationRef\"\u003e2026\u003c/span\u003e).\u003c/p\u003e \u003c/div\u003e"},{"header":"8. Clinical Implications and Integrative Therapeutic Approaches","content":"\u003cp\u003eThe consolidated neuro-gynaecological evidence base carries transformative implications for clinical practice. Traditional gynaecological management \u0026mdash; dominated by hormonal pharmacotherapy, analgesics, and surgical correction of peripheral pathology \u0026mdash; remains fundamentally important but has demonstrably limited efficacy in patients with chronic pelvic pain, endometriosis, treatment-resistant dysmenorrhea, PCOS, and stress-related menstrual disorders, in whom central regulatory dysfunction is the primary driver of symptoms (Ghosh et al., 2020; Delanerolle et al., \u003cspan citationid=\"CR16\" class=\"CitationRef\"\u003e2025\u003c/span\u003e). Table\u0026nbsp;\u003cspan refid=\"Tab9\" class=\"InternalRef\"\u003e9\u003c/span\u003e \u003cb\u003eprovides a comprehensive integrative neuro-gynaecological therapeutic framework, incorporating evidence levels and clinical benefit profiles.\u003c/b\u003e\u003c/p\u003e \u003cp\u003e \u003cdiv class=\"gridtable\"\u003e\u003ctable float=\"Yes\" id=\"Tab9\" border=\"1\"\u003e \u003ccaption language=\"En\"\u003e \u003cdiv class=\"CaptionNumber\"\u003eTable 9\u003c/div\u003e \u003cdiv class=\"CaptionContent\"\u003e \u003cp\u003eIntegrative Neuro-Gynaecological Therapeutic Framework: Interventions, Mechanisms, Evidence, and Clinical Benefits\u003c/p\u003e \u003c/div\u003e \u003c/caption\u003e \u003ccolgroup cols=\"5\"\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c1\" colnum=\"1\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c2\" colnum=\"2\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c3\" colnum=\"3\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c4\" colnum=\"4\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c5\" colnum=\"5\"\u003e\u003c/div\u003e \u003cthead\u003e \u003ctr\u003e \u003cth align=\"left\" colname=\"c1\"\u003e \u003cp\u003eTherapeutic Domain\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c2\"\u003e \u003cp\u003eSpecific Intervention\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c3\"\u003e \u003cp\u003eMechanism / Physiological Target\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c4\"\u003e \u003cp\u003eLevel of Evidence / Key Studies\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c5\"\u003e \u003cp\u003eExpected Clinical Benefits\u003c/p\u003e \u003c/th\u003e \u003c/tr\u003e \u003c/thead\u003e \u003ctbody\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cb\u003ePsychological therapies\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eCognitive behavioural therapy (CBT)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003eModulates central pain processing; reduces pain catastrophising; improves descending pain inhibitory control via prefrontal\u0026ndash;limbic pathway remodelling\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003eLevel I evidence in chronic pelvic pain and dysmenorrhea (RCTs); Cochrane review supports efficacy in endometriosis-associated pain\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003eClinically significant reduction in pain intensity, psychological distress, and analgesic use; improvement in quality of life\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cb\u003ePsychological therapies\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eMindfulness-based stress reduction (MBSR)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003eReduces HPA axis hyperactivation (\u0026darr; cortisol); enhances parasympathetic tone; reduces amygdala reactivity; improves pain tolerance\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003eMultiple RCTs demonstrate efficacy in chronic pain and gynaecological conditions; effect sizes moderate to large\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003eImproved menstrual regularity; reduced pain scores; reduced anxiety and depression; sustainable long-term benefits reported\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cb\u003ePsychological therapies\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eTrauma-informed counselling / Emotion-focused therapy\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003eReduces persistent limbic hyperactivation; lowers chronic cortisol burden; restores emotional regulatory capacity\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003eEmerging evidence in reproductive health; established efficacy in PTSD-related somatic disorders\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003eImproved treatment adherence; restored menstrual cyclicity in trauma-exposed patients; reduced psychosomatic symptom burden\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cb\u003eAutonomic regulation\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eHRV-guided biofeedback\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003eReal-time ANS modulation via resonance breathing; increases vagal tone; restores sympathovagal balance\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003eRCT-level evidence in pain disorders; pilot studies in PCOS and dysmenorrhea show promising HRV improvement\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003ePersonalised autonomic modulation; dual diagnostic and therapeutic utility; non-invasive and self-administered\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cb\u003eAutonomic regulation\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eYoga and controlled breathing (pranayama)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003eActivates PNS via vagal stimulation; reduces cortisol and sympathetic tone; improves HRV and pain threshold\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003eMeta-analyses support efficacy in dysmenorrhea; PCOS-specific RCTs demonstrate hormonal and autonomic benefit\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003eReduced pelvic pain intensity; improved ovulatory function; enhanced mood and stress resilience\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cb\u003eAutonomic regulation\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eVagal nerve stimulation (VNS, transcutaneous)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003eActivates cholinergic anti-inflammatory pathway (CAP) via NF-κB suppression \u0026rarr; systemic and local cytokine reduction\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003eEarly-phase trials in endometriosis and CPP; established evidence base in inflammatory conditions\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003eReduces neurogenic inflammation; improves pain control in conditions refractory to pharmacotherapy; well tolerated\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cb\u003eNeuro-immune modulation\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eAnti-inflammatory dietary modification\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003eMediterranean-style diet reduces systemic cytokine burden (IL-6, CRP, TNF-α); omega-3 fatty acids attenuate neurogenic inflammation\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003eObservational and clinical trial evidence in endometriosis and PCOS; anti-inflammatory diets reduce disease progression markers\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003eAttenuated neuro-immune contributors to pelvic pain; adjunct benefit alongside pharmacological anti-inflammatory treatment\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cb\u003eNeuro-immune modulation\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eImmunomodulatory pharmacotherapy\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003eAnti-cytokine therapies (e.g., TNF-α inhibitors); anti-NGF antibodies; COX-2 selective inhibitors\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003eAnti-NGF trials in endometriosis (Phase II); TNF-α inhibition shows preclinical and early clinical promise\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003eTargeted reduction of neuro-immune amplification loop; potential to reduce endometriosis lesion activity and associated pain\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cb\u003ePharmacological integration\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eCentrally acting agents (SNRIs, tricyclics, gabapentinoids)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003eModulate neurotransmitter systems (serotonin, norepinephrine, GABA) involved in central pain regulation and descending inhibitory control\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003eLevel II\u0026ndash;III evidence for SNRIs/tricyclics in CPP and endometriosis-associated central sensitisation; established in fibromyalgia and neuropathic pain\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003eImproved treatment response in patients with prominent central sensitisation unresponsive to peripheral analgesics alone\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cb\u003eExpanded diagnostics\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eHeart rate variability analysis (HRV)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003eQuantifies sympathovagal balance as an objective, non-invasive biomarker of ANS function in gynaecological patients\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003eValidated tool in PCOS, dysmenorrhea, and CPP research; correlated with pain severity and psychological distress\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003eIdentifies autonomic dysfunction pre-treatment; enables patient stratification and personalised intervention selection\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cb\u003eExpanded diagnostics\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eCentral Sensitisation Inventory (CSI)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003eValidated self-report instrument identifying central sensitisation syndrome across gynaecological pain conditions\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003eValidated in CPP, endometriosis, and dysmenorrhea populations; CSI score predicts treatment response to centrally acting therapy\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003eGuides choice between peripheral vs. central treatment targets; identifies patients requiring psychological and neuromodulatory intervention\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cb\u003eMultidisciplinary care\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eIntegrated neuro-gynaecological clinic model\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003eSimultaneous targeting of neural, endocrine, immune, and reproductive systems within a shared care framework\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003eConsensus recommendations from ESHRE, ACOG, and pain medicine societies; observational data support improved outcomes\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003eComprehensive disease management; reduced diagnostic delay; improved long-term quality of life; reduced healthcare utilisation\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003c/tbody\u003e \u003c/colgroup\u003e \u003c/table\u003e\u003c/div\u003e \u003c/p\u003e \u003cp\u003e \u003cem\u003eSources\u003c/em\u003e: Delanerolle et al. (\u003cspan citationid=\"CR16\" class=\"CitationRef\"\u003e2025\u003c/span\u003e); Osorio \u0026amp; Macedo (\u003cspan citationid=\"CR55\" class=\"CitationRef\"\u003e2023\u003c/span\u003e\u003cem\u003e);\u003c/em\u003e Turgeon et al. (\u003cspan citationid=\"CR78\" class=\"CitationRef\"\u003e2004\u003c/span\u003e); Abkenar et al. (\u003cspan citationid=\"CR1\" class=\"CitationRef\"\u003e2026\u003c/span\u003e); \u003cem\u003eBlas\u0026eacute; et al. (2021);\u003c/em\u003e Guo et al. (\u003cspan citationid=\"CR26\" class=\"CitationRef\"\u003e2026\u003c/span\u003e); Krawczyk et al. (\u003cspan citationid=\"CR36\" class=\"CitationRef\"\u003e2025\u003c/span\u003e).\u003c/p\u003e \u003cdiv id=\"Sec28\" class=\"Section2\"\u003e \u003ch2\u003e8.1. Expanded Multimodal Diagnostic Assessment\u003c/h2\u003e \u003cp\u003eThe neuro-gynaecological model mandates an expansion of the diagnostic toolkit beyond conventional hormonal assays and imaging. Incorporating \u003cb\u003eheart rate variability analysis\u003c/b\u003e (quantifying sympathovagal balance), \u003cb\u003evalidated psychological screening\u003c/b\u003e (GAD-7, PHQ-9, PSS), the \u003cb\u003eCentral Sensitisation Inventory\u003c/b\u003e (identifying central pain amplification), and \u003cb\u003ediurnal cortisol profiling\u003c/b\u003e (evaluating HPA axis dysregulation) provides clinically actionable insights into the neurobiological contributors to disease. Early identification of autonomic imbalance, central sensitisation, or significant psychosomatic distress enables accurate patient stratification and personalised intervention selection, a prerequisite for the precision medicine approach that modern gynaecological care demands (Delanerolle et al., \u003cspan citationid=\"CR16\" class=\"CitationRef\"\u003e2025\u003c/span\u003e).\u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec29\" class=\"Section2\"\u003e \u003ch2\u003e8.2. Psychological and Neuromodulatory Therapies\u003c/h2\u003e \u003cp\u003ePsychological therapies are not adjuncts to biological treatment \u0026mdash; they are \u003cb\u003ecore, mechanistically justified neuro-biological interventions.\u003c/b\u003e CBT, mindfulness-based stress reduction, acceptance and commitment therapy, and trauma-informed counselling directly modulate central pain-processing circuitry, reduce cortisol burden, attenuate central sensitisation, and improve hormonal balance. Their efficacy is supported by Level I evidence from RCTs in dysmenorrhea, endometriosis, and chronic pelvic pain populations (Abkenar et al., \u003cspan citationid=\"CR1\" class=\"CitationRef\"\u003e2026\u003c/span\u003e; Doran, \u003cspan citationid=\"CR17\" class=\"CitationRef\"\u003e2023\u003c/span\u003e). Adjunctive centrally acting pharmacological agents \u0026mdash; including SNRIs, tricyclic antidepressants, and gabapentinoids \u0026mdash; provide additional benefit in patients with prominent central sensitisation unresponsive to peripheral analgesics (Turgeon et al., \u003cspan citationid=\"CR78\" class=\"CitationRef\"\u003e2004\u003c/span\u003e).\u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec30\" class=\"Section2\"\u003e \u003ch2\u003e8.3. Autonomic Regulation and Neuro-Immune Modulation\u003c/h2\u003e \u003cp\u003eANS-targeting interventions including yoga, HRV-guided biofeedback, and transcutaneous vagal nerve stimulation promote parasympathetic activation, reduce sympathetic overdrive, improve ovulatory function, and decrease pelvic pain intensity (Blas\u0026eacute; et al., 2021). Vagal nerve stimulation specifically activates the cholinergic anti-inflammatory pathway, reducing systemic and local cytokine burden \u0026mdash; making it a clinically significant approach for inflammatory gynaecological conditions including endometriosis and chronic pelvic pain. Anti-inflammatory dietary strategies and immunomodulatory therapies complement pharmacological anti-inflammatory treatment and may reduce long-term medication dependency (Guo et al., \u003cspan citationid=\"CR26\" class=\"CitationRef\"\u003e2026\u003c/span\u003e).\u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec31\" class=\"Section2\"\u003e \u003ch2\u003e8.4. Multidisciplinary Integrative Care\u003c/h2\u003e \u003cp\u003eAchieving the therapeutic potential of the neuro-gynaecological model requires a genuinely \u003cb\u003emultidisciplinary care architecture\u003c/b\u003e involving gynaecologists, neurologists, psychologists, pelvic physiotherapists, pain medicine specialists, and integrative medicine practitioners within coordinated shared-care structures. Patient education on the neurobiological basis of symptoms is equally essential \u0026mdash; reducing diagnostic stigma, improving treatment adherence, and empowering active patient participation in evidence-based self-management\u003c/p\u003e \u003c/div\u003e"},{"header":"9. Discussion","content":"\u003cdiv id=\"Sec33\" class=\"Section2\"\u003e \u003ch2\u003e9.1. Principal Findings and Their Signficance\u003c/h2\u003e \u003cp\u003eThis PRISMA-based systematic review provides a comprehensive, critically appraised synthesis confirming that neuro-gynaecological interactions are not peripheral influences but \u003cb\u003ecentral, mechanistically determinative contributors\u003c/b\u003e to the pathophysiology of common gynaecological disorders. The four identified pathogenic domains \u0026mdash; neuroendocrine dysregulation, autonomic imbalance, psychosomatic stress-driven central sensitisation, and neuro-immune crosstalk \u0026mdash; converge to produce disease states that cannot be adequately explained or managed within a conventional organ-specific model. The reviewed evidence supports a decisive paradigm shift to a \u003cb\u003ebiopsychoneuroimmune framework\u003c/b\u003e for gynaecological medicine.\u003c/p\u003e \u003cp\u003eThe primacy of HPA\u0026ndash;HPO axis crosstalk as a unifying pathogenic mechanism across PCOS, functional hypothalamic amenorrhea, and stress-related infertility is particularly compelling \u0026mdash; and clinically actionable. The functional, largely reversible nature of stress-induced neuroendocrine reproductive suppression, with documented restoration of menstrual cyclicity following stress modulation, positions HPA axis assessment and stress management as first-line components of reproductive medicine that require urgent clinical integration.\u003c/p\u003e \u003cp\u003eThe autonomic nervous system evidence is equally robust. HRV consistently correlates with symptom severity, pain intensity, and psychological distress across multiple gynaecological conditions, establishing it as a validated, non-invasive biomarker that is both diagnostic and prognostic. The demonstration that autonomic imbalance independently maintains disease \u0026mdash; not merely as a stress epiphenomenon \u0026mdash; provides a compelling therapeutic rationale for ANS-targeting interventions. Neuroimaging evidence confirming altered pain-processing brain networks in chronic pelvic pain and endometriosis provides objective neurobiological validation for the central origin of these symptoms \u0026mdash; directly explaining analgesic and surgical treatment resistance that is otherwise clinically inexplicable.\u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec34\" class=\"Section2\"\u003e \u003ch2\u003e9.2. Comparison with Existing Literature\u003c/h2\u003e \u003cp\u003eThese findings are consistent with and extend the conclusions of recent systematic reviews in related fields. The dominance of central sensitisation mechanisms in determining pain severity in endometriosis, as identified in this review, aligns with findings from neuroimaging studies by As-Sanie et al. (\u003cspan citationid=\"CR6\" class=\"CitationRef\"\u003e2016\u003c/span\u003e) and the central sensitisation framework advanced by Nijs et al. (\u003cspan citationid=\"CR53\" class=\"CitationRef\"\u003e2021\u003c/span\u003e). The neuro-immune model of endometriosis proposed in this review converges with recent mechanistic research demonstrating NGF-driven axonal sprouting within ectopic lesions (Chen \u0026amp; Li, \u003cspan citationid=\"CR11\" class=\"CitationRef\"\u003e2025\u003c/span\u003e; Alotaibi, \u003cspan citationid=\"CR4\" class=\"CitationRef\"\u003e2025\u003c/span\u003e). The therapeutic efficacy of psychological interventions in gynaecological pain is consistent with meta-analytic evidence for CBT and MBSR in chronic pain conditions more broadly, supporting their clinical integration.\u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec35\" class=\"Section2\"\u003e \u003ch2\u003e9.3. Limitations\u003c/h2\u003e \u003cp\u003eSeveral limitations merit acknowledgement. First, the heterogeneity of study designs, outcome measures, and patient populations across included studies precluded formal meta-analysis and effect size pooling \u0026mdash; limiting quantitative conclusions. Second, many mechanistic studies rely on preclinical models or small-sample clinical populations, with large-scale, multi-centre RCTs evaluating integrated neuro-gynaecological interventions remaining limited. Third, the evidence base for some emerging therapeutic modalities \u0026mdash; including transcutaneous VNS and anti-NGF therapy for endometriosis \u0026mdash; remains preliminary, requiring confirmation from adequately powered Phase III trials. Fourth, standardised, validated neuro-gynaecological assessment tools for routine clinical use remain incompletely developed, limiting immediate clinical translation of several diagnostic recommendations.\u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec36\" class=\"Section2\"\u003e \u003ch2\u003e9.4. Future Research Priorities\u003c/h2\u003e \u003cp\u003eFuture research priorities identified by this review include: (1) Large-scale, longitudinal RCTs examining the efficacy of integrated multimodal neuro-gynaecological interventions versus standard care; (2) Validation of standardized HRV, cortisol profiling, and central sensitisation assessment protocols for routine gynaecological use; (3) Neuroimaging and neuro-immune biomarker studies to develop clinically applicable, reliable diagnostic panels for central sensitisation and neuro-immune dysregulation in gynaecological populations; (4) Phase III clinical trials of anti-NGF and anti-cytokine therapies for endometriosis-associated pain; (5) Implementation science research to develop and evaluate models for integrating neuro-gynaecological assessment and multidisciplinary care into mainstream gynaecological service structures; (6) Training programme development to embed neurobiological and psychosomatic principles into gynaecological postgraduate education.\u003c/p\u003e \u003c/div\u003e"},{"header":"10. Summary of Evidence: Key Neuro-Gynaecological Domains","content":"\u003cp\u003eTable\u0026nbsp;\u003cspan refid=\"Tab10\" class=\"InternalRef\"\u003e10\u003c/span\u003e provides a consolidated overview of the four principal neuro-gynaecological domains identified in this review, summarising primary mechanisms, representative conditions, strength of current evidence, and the research gaps most urgently requiring future investigation.\u003c/p\u003e \u003cp\u003e \u003cdiv class=\"gridtable\"\u003e\u003ctable float=\"Yes\" id=\"Tab10\" border=\"1\"\u003e \u003ccaption language=\"En\"\u003e \u003cdiv class=\"CaptionNumber\"\u003eTable 10\u003c/div\u003e \u003cdiv class=\"CaptionContent\"\u003e \u003cp\u003eConsolidated Summary of Evidence Across Neuro-Gynaecological Domains\u003c/p\u003e \u003c/div\u003e \u003c/caption\u003e \u003ccolgroup cols=\"5\"\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c1\" colnum=\"1\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c2\" colnum=\"2\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c3\" colnum=\"3\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c4\" colnum=\"4\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c5\" colnum=\"5\"\u003e\u003c/div\u003e \u003cthead\u003e \u003ctr\u003e \u003cth align=\"left\" colname=\"c1\"\u003e \u003cp\u003eNeuro-Gynaecological Domain\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c2\"\u003e \u003cp\u003ePrimary Mechanism\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c3\"\u003e \u003cp\u003eRepresentative Conditions\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c4\"\u003e \u003cp\u003eStrength of Evidence\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c5\"\u003e \u003cp\u003eGap Requiring Future Research\u003c/p\u003e \u003c/th\u003e \u003c/tr\u003e \u003c/thead\u003e \u003ctbody\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cb\u003eNeuroendocrine regulation\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eHPA\u0026ndash;HPO axis crosstalk; cortisol-mediated GnRH suppression; kisspeptin dysregulation\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003eFunctional hypothalamic amenorrhea, PCOS, stress-related infertility\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003eStrong \u0026mdash; multiple RCTs, mechanistic studies, and longitudinal cohorts\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003eLarge-scale trials validating cortisol-rhythm assessment as routine fertility diagnostic; kisspeptin analogues as therapeutic agents\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cb\u003eAutonomic nervous system dysfunction\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eSympathetic hyperactivity\u0026thinsp;+\u0026thinsp;reduced vagal tone; measured via HRV\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003ePCOS, dysmenorrhea, chronic pelvic pain\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003eModerate-Strong \u0026mdash; HRV studies, neurophysiological assessments, and clinical trials\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003eStandardised HRV protocols specific to gynaecological populations; RCTs on transcutaneous VNS for endometriosis pain\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cb\u003ePsychosomatic stress and central sensitisation\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eLimbic\u0026ndash;HPA activation; neuroplastic remodelling of pain-processing circuits; reduced descending inhibition\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003eDysmenorrhea, endometriosis, chronic pelvic pain, PCOS\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003eStrong \u0026mdash; neuroimaging, validated questionnaires (CSI), and multiple RCTs of psychological interventions\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003eLongitudinal studies examining whether early psychological intervention prevents chronification; biomarkers predicting sensitisation trajectory\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cb\u003eNeuro-immune interactions\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eNeurogenic inflammation (substance P, CGRP, NGF); cytokine-mediated neural sensitisation; mast cell activation\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003eEndometriosis, PID, vulvodynia, CPP\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003eModerate \u0026mdash; preclinical models, observational studies, and early-phase therapeutic trials\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003ePhase III RCTs of anti-NGF and anti-cytokine therapies for endometriosis pain; neuro-immune biomarker panels for clinical stratification\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cb\u003eIntegrative therapeutic approaches\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eMulti-target intervention across neuroendocrine, ANS, psychosomatic, and neuro-immune pathways\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003eAll stress-sensitive and chronic gynaecological conditions\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003eModerate \u0026mdash; growing RCT evidence for individual modalities; limited head-to-head comparison trials\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003eComparative effectiveness trials of integrated multimodal vs. standard care; cost-effectiveness analyses; implementation science research\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003c/tbody\u003e \u003c/colgroup\u003e \u003c/table\u003e\u003c/div\u003e \u003c/p\u003e \u003cp\u003e \u003cem\u003eEvidence strength assessed qualitatively based on study design, volume of literature, consistency of findings, and availability of RCT-level data. HRV\u0026thinsp;=\u0026thinsp;heart rate variability; CSI\u0026thinsp;=\u0026thinsp;Central Sensitisation Inventory; VNS\u0026thinsp;=\u0026thinsp;vagal nerve stimulation; CPP\u0026thinsp;=\u0026thinsp;chronic pelvic pain; NGF\u0026thinsp;=\u0026thinsp;nerve growth factor.\u003c/em\u003e \u003c/p\u003e"},{"header":"11. Conclusion","content":"\u003cp\u003eThis PRISMA-based systematic review has comprehensively established that gynaecological disorders are not isolated peripheral reproductive conditions but complex, centrally mediated biopsychoneuroimmune disturbances requiring holistic, multidimensional assessment and targeted, mechanism-based management. Neuroendocrine dysregulation, autonomic imbalance, psychosomatic stress-driven central sensitisation, and neuro-immune crosstalk collectively and interactively underpin the pathophysiology, symptom severity, and therapeutic resistance of prevalent gynaecological conditions including PCOS, dysmenorrhea, endometriosis, chronic pelvic pain, and stress-related infertility.\u003c/p\u003e \u003cp\u003eFailure to recognise and systematically address these neurobiological dimensions within clinical gynaecology perpetuates diagnostic incompleteness, unexplained symptom persistence, and unnecessary treatment failure in a large and underserved patient population. The adoption of an integrative neuro-gynaecological clinical framework, one that systematically incorporates neurological, psychological, immunological, and reproductive assessments within a coordinated multidisciplinary model has transformative potential: improving diagnostic precision, reducing symptom chronicity, enabling personalised therapeutic selection, and ultimately delivering a more compassionate, scientifically rigorous, and patient-centered standard of women's healthcare.\u003c/p\u003e \u003cp\u003eThe consolidated evidence reviewed herein is unambiguous: neurogynecology is not a subspecialty curiosity but a clinical necessity. As validated assessment tools, neuroimaging evidence, and integrative therapeutic trial data continue to mature, this field is poised to become an indispensable and standard pillar of modern gynaecological medicine, redefining how women's reproductive health conditions are understood, diagnosed, and treated.\u003c/p\u003e"},{"header":"References","content":"\u003col\u003e\n \u003cli\u003eAbkenar, M. S., Seirafi, M. R., Moraveji, M., \u0026amp; Sabet, M. (2026). Comparison of the effectiveness of mindfulness-based therapy and emotion-focused therapy on pain perception in patients with cardiovascular diseases. Mental Health and Lifestyle Journal, 4(1), 1\u0026ndash;16.\u003c/li\u003e\n \u003cli\u003eAgorastos, A., Mansueto, A. C., Hager, T., Pappi, E., Gardikioti, A., \u0026amp; Stiedl, O. (2023). Heart rate variability as a translational dynamic biomarker of altered autonomic function in health and psychiatric disease. Biomedicines, 11(6), 1591. https://doi.org/10.3390/biomedicines11061591\u003c/li\u003e\n \u003cli\u003eAl-Fahham, A. A., \u0026amp; Al-Nowainy, H. Q. (2016). The role of FSH, LH, and prolactin hormones in female infertility. International Journal of PharmTech Research, 6, 110\u0026ndash;118.\u003c/li\u003e\n \u003cli\u003eAlotaibi, F. T. (2025). Neural and immune interactions in endometriosis pathogenesis. Journal of Reproductive Immunology, 168, 104085.\u003c/li\u003e\n \u003cli\u003eAndersen, C. Y., \u0026amp; Ezcurra, D. (2014). Human steroidogenesis: implications for controlled ovarian stimulation with exogenous gonadotropins. Reproductive Biology and Endocrinology, 12(1), 128. https://doi.org/10.1186/1477-7827-12-128\u003c/li\u003e\n \u003cli\u003eAs-Sanie, S., Kim, J., Schmidt-Wilcke, T., Sundgren, P. C., Clauw, D. J., Napadow, V., \u0026amp; Harris, R. E. (2016). Functional connectivity is associated with altered brain chemistry in women with endometriosis-associated chronic pelvic pain. The Journal of Pain, 17(1), 1\u0026ndash;13.\u003c/li\u003e\n \u003cli\u003eBernardi, M., Lazzeri, L., Perelli, F., Reis, F. M., \u0026amp; Petraglia, F. (2017). Dysmenorrhea and related disorders. F1000Research, 6, 1645. https://doi.org/10.12688/f1000research.11682.1\u003c/li\u003e\n \u003cli\u003eBlas\u0026eacute;, K., \u0026amp; Dijkstra, C. (2021). Vagal nerve stimulation in chronic pain and inflammatory disorders: A systematic review. Frontiers in Neuroscience, 15, 701443.\u003c/li\u003e\n \u003cli\u003eBrocca, M. E., \u0026amp; Garcia-Segura, L. M. (2019). Non-reproductive functions of aromatase in the central nervous system under physiological and pathological conditions. Cellular and Molecular Neurobiology, 39(4), 473\u0026ndash;481.\u003c/li\u003e\n \u003cli\u003eČelebić, A., Harasani, K., Miladinović, M., Mandić, A., Vasiljevć, T., Starič, K. D., \u0026amp; Drusany, A. K. S. (2025). Neuroendocrine tumors of the gynecological tract: A narrative literature review. European Journal of Surgical Oncology, 51(4), 109735.\u003c/li\u003e\n \u003cli\u003eChen, Y., \u0026amp; Li, T. (2025). Unveiling the mechanisms of pain in endometriosis: Comprehensive analysis of inflammatory sensitization and therapeutic potential. International Journal of Molecular Sciences, 26(4), 1770.\u003c/li\u003e\n \u003cli\u003eChorna, N. (2024). Psychosomatic aspects of women\u0026rsquo;s health: An in-depth analysis. Archives of Women\u0026rsquo;s Mental Health, 27(1), 55\u0026ndash;68.\u003c/li\u003e\n \u003cli\u003eChrousos, G. P., Torpy, D. J., \u0026amp; Gold, P. W. (1998). Interactions between the hypothalamic-pituitary-adrenal axis and the female reproductive system: Clinical implications. Annals of Internal Medicine, 129(3), 229\u0026ndash;240.\u003c/li\u003e\n \u003cli\u003eCiranna, \u0026Aacute;. (2006). Serotonin as a modulator of glutamate- and GABA-mediated neurotransmission: Implications in physiological functions and in pathology. Current Neuropharmacology, 4(2), 101\u0026ndash;114.\u003c/li\u003e\n \u003cli\u003eCuffaro, F., Ambulante, G., \u0026amp; Fornasari, L. (2024). Psychosomatic dimensions of endometriosis pain: A narrative review. Archives of Gynaecology and Obstetrics, 310(2), 543\u0026ndash;554.\u003c/li\u003e\n \u003cli\u003eDelanerolle, G., Cavalini, R., \u0026amp; Phiri, P. (2025). Neurogynecology: An emerging interdisciplinary clinical field. Frontiers in Reproductive Health, 7, 1248302.\u003c/li\u003e\n \u003cli\u003eDoran, M. (2023). Psychological therapies for chronic gynaecological pain: The clinical case for integration. Journal of Psychosomatic Obstetrics \u0026amp; Gynaecology, 44(1), 2158\u0026ndash;2169.\u003c/li\u003e\n \u003cli\u003eDouglas, M. (2010). Neurogynecology in clinical practice: Principles and applications. Springer.\u003c/li\u003e\n \u003cli\u003eElliott, S., Dennerstein, L., \u0026amp; Burger, H. (2025). Neural regulation of female reproductive physiology across the lifespan. Trends in Endocrinology \u0026amp; Metabolism, 36(3), 202\u0026ndash;215.\u003c/li\u003e\n \u003cli\u003eFacchinetti, F., Martignoni, E., Petraglia, F., Sances, M. G., Nappi, G., \u0026amp; Genazzani, A. R. (1992). Premenstrual falls of plasma beta-endorphin in patients with premenstrual syndrome. Fertility and Sterility, 58(3), 499\u0026ndash;502.\u003c/li\u003e\n \u003cli\u003eFilicori, M. (2023). GnRH pulsatility and its clinical implications in reproductive endocrinology. Human Reproduction Update, 29(4), 392\u0026ndash;405.\u003c/li\u003e\n \u003cli\u003eFran\u0026ccedil;a, K., Jafferany, M., \u0026amp; Lotti, T. (2017). Integrative approaches in reproductive and psychodermatological medicine. Springer.\u003c/li\u003e\n \u003cli\u003eGarg, A., Bhatt, S., \u0026amp; Singh, S. (2022). Sympathetic nervous system contributions to the pathogenesis of PCOS. Journal of Clinical Endocrinology \u0026amp; Metabolism, 107(8), e3345\u0026ndash;e3356.\u003c/li\u003e\n \u003cli\u003eGeorge, J. T., Seminara, S. B., \u0026amp; Jopling, L. A. (2012). Kisspeptin and the hypothalamic control of reproduction. Endocrinology, 153(11), 5130\u0026ndash;5136.\u003c/li\u003e\n \u003cli\u003eGhosh, D., \u0026amp; Bhattacharya, S. (2020). Integrative approaches in gynaecological care: Evidence and clinical application. Journal of Integrative Medicine, 18(6), 489\u0026ndash;498.\u003c/li\u003e\n \u003cli\u003eGuo, X., Wang, Y., Li, Q., \u0026amp; Zhang, Y. (2026). Neuro-immune modulation as a therapeutic target in endometriosis. Frontiers in Immunology, 17, 1348294.\u003c/li\u003e\n \u003cli\u003eHwang, J. J., Segura, J. W., \u0026amp; Webster, G. D. (2014). Neurogynecology: The role of the nervous system in female pelvic floor disorders. Neurourology and Urodynamics, 33(4), 371\u0026ndash;378.\u003c/li\u003e\n \u003cli\u003eIvanova, A. O. (2020). Psychosomatic aspects of premenstrual syndrome. Psychosomatic Medicine and Psychotherapy, 66(4), 389\u0026ndash;401.\u003c/li\u003e\n \u003cli\u003eJankord, R., \u0026amp; Herman, J. P. (2008). Limbic regulation of hypothalamo-pituitary-adrenocortical function during acute and chronic stress. Annals of the New York Academy of Sciences, 1148, 64\u0026ndash;73.\u003c/li\u003e\n \u003cli\u003eJosimovich, J. B. (2013). Neuroendocrine regulation of reproduction (2nd ed.). Academic Press.\u003c/li\u003e\n \u003cli\u003eKaiser, M., \u0026amp; Burger, J. (2023). Cortisol and reproductive function in women: Clinical and mechanistic perspectives. Endocrine Reviews, 44(3), 418\u0026ndash;435.\u003c/li\u003e\n \u003cli\u003eKaya, S., Hermans, L., Willems, T., Roussel, N., \u0026amp; Meeus, M. (2013). Central sensitisation in urogynecological chronic pelvic pain: A systematic literature review. Pain Physician, 16(4), 291\u0026ndash;308.\u003c/li\u003e\n \u003cli\u003eKingsberg, S. A., Clayton, A. H., \u0026amp; Pfaus, J. G. (2017). The female sexual response: Current models, neurobiological underpinnings and agents currently approved or under investigation. CNS Drugs, 29(11), 915\u0026ndash;933.\u003c/li\u003e\n \u003cli\u003eKorneva, E. A. (2020). Neuro-immune interactions in reproductive disorders: A systemic perspective. Neuroimmunomodulation, 27(1), 1\u0026ndash;12.\u003c/li\u003e\n \u003cli\u003eKori, A., Rao, S., \u0026amp; Misra, A. (2025). Psychosomatic burden in gynaecological practice: Emerging insights and clinical implications. Archives of Women\u0026rsquo;s Mental Health, 28(1), 41\u0026ndash;52.\u003c/li\u003e\n \u003cli\u003eKrawczyk, A., Skarzyńska, M., \u0026amp; Wr\u0026oacute;bel, P. (2025). Integrative frameworks in gynaecological pain management. Pain Medicine, 26(2), 155\u0026ndash;169.\u003c/li\u003e\n \u003cli\u003eKrieger, N., Williams, D., \u0026amp; Moss, N. (2005). Measuring social class in US public health research. Annual Review of Public Health, 16, 341\u0026ndash;378.\u003c/li\u003e\n \u003cli\u003eKumari, A. (2013). Epidemiology of gynaecological disorders in India: A public health perspective. Indian Journal of Community Medicine, 38(3), 145\u0026ndash;153.\u003c/li\u003e\n \u003cli\u003eLal, M. (2009). Pelvic floor dysfunction in women: A clinical guide. Jaypee Brothers Medical Publishers.\u003c/li\u003e\n \u003cli\u003eLicht, C. M., de Geus, E. J., Zitman, F. G., Hoogendijk, W. J., van Dyck, R., \u0026amp; Penninx, B. W. (2013). Association between major depressive disorder and heart rate variability. Archives of General Psychiatry, 65(12), 1358\u0026ndash;1367.\u003c/li\u003e\n \u003cli\u003eLurie, D. I. (2018). An integrative approach to neuroinflammation in psychiatric disorders and pain. Journal of Experimental Neuroscience, 12, 1179069518793639.\u003c/li\u003e\n \u003cli\u003eMarano, G., Traversi, G., \u0026amp; Mazza, M. (2026). Neuro-immune modulation and its relevance in gynaecological disorders. Journal of Neuroimmunology, 392, 578368.\u003c/li\u003e\n \u003cli\u003eMavrych, V., Kalathas, T., \u0026amp; Kapila, R. (2025). Neuroendocrine approaches in integrative gynaecology. Frontiers in Endocrinology, 16, 1392451.\u003c/li\u003e\n \u003cli\u003eMeade, E., Goyette, M., \u0026amp; B\u0026eacute;riault, C. (2022). Chronic pelvic pain and the neuro-immune connection: A systematic review. Pain Research and Management, 2022, 8842157.\u003c/li\u003e\n \u003cli\u003eMenzies, F. M., Higgins, C. A., \u0026amp; Bhatt, D. L. (2011). Mast cell involvement in gynaecological pain. Journal of Reproductive Immunology, 90(1), 1\u0026ndash;8.\u003c/li\u003e\n \u003cli\u003eMick, I., Hermesdorf, M., \u0026amp; Lehnert, H. (2024). Psychoneuroimmunology in gynaecological disorders: Clinical evidence and therapeutic directions. Psychoneuroendocrinology, 162, 106972.\u003c/li\u003e\n \u003cli\u003eMikhael, S. (2019). Hypothalamic\u0026ndash;pituitary\u0026ndash;ovarian axis regulation: Current concepts. Reproductive Medicine and Biology, 18(3), 214\u0026ndash;223.\u003c/li\u003e\n \u003cli\u003eMuller, N., Schwarz, M. J., \u0026amp; Riedel, M. (2009). The immune-mediated alteration of serotonin and glutamate: Towards an integrated view of depression. Molecular Psychiatry, 11(1), 47\u0026ndash;52.\u003c/li\u003e\n \u003cli\u003eMurck, H., Stober, G., \u0026amp; Steiger, A. (2025). Neurobiological aspects of the menstrual cycle and premenstrual disorders. Neuroscience \u0026amp; Biobehavioral Reviews, 159, 105563.\u003c/li\u003e\n \u003cli\u003eNappi, R. E., Tiranini, L., \u0026amp; Brundu, B. (2021). Role of kisspeptin in female reproductive function: From bench to bedside. Gynecological Endocrinology, 37(11), 955\u0026ndash;963.\u003c/li\u003e\n \u003cli\u003eNepomnaschy, P. A., Welch, K. B., McConnell, D. S., Low, B. S., Strassmann, B. I., \u0026amp; England, B. G. (2007). Cortisol levels and very early pregnancy loss in humans. Proceedings of the National Academy of Sciences, 103(10), 3938\u0026ndash;3942.\u003c/li\u003e\n \u003cli\u003eNicolopoulou, S. (2001). Neural control of reproductive function. Oxford University Press.\u003c/li\u003e\n \u003cli\u003eNijs, J., Lahousse, A., Kapreli, E., Bilika, P., Sara\u0026ccedil;oğlu, I., Malfliet, A., \u0026amp; Huysmans, E. (2021). Nociplastic pain criteria or recognition of central sensitization in patients with chronic pain. Journal of Clinical Medicine, 10(15), 3203.\u003c/li\u003e\n \u003cli\u003eNimer, N. A., Ismael, N. S., Abdo, R. W., Taha Alkhammas, S. Y., \u0026amp; Alkhames Aga, Q. A. (2020). Pharmacology of neuropeptides. In Frontiers in Pharmacology of Neurotransmitters (pp. 503\u0026ndash;551). Springer Singapore.\u003c/li\u003e\n \u003cli\u003eOsorio, C. P., \u0026amp; Macedo, P. (2023). Mental health, reproductive health and contraception. European Psychiatry, 66(S1), S1125\u0026ndash;S1125.\u003c/li\u003e\n \u003cli\u003eOubaid, V. (2023). Psychological stress and the autonomic nervous system. In Primer on the Autonomic Nervous System (pp. 301\u0026ndash;304). Academic Press.\u003c/li\u003e\n \u003cli\u003ePakpour, A. H., Kazemi, F., Alimoradi, Z., \u0026amp; Griffiths, M. D. (2020). Depression, anxiety, stress, and dysmenorrhea: A protocol for a systematic review. Systematic Reviews, 9(1), 65.\u003c/li\u003e\n \u003cli\u003ePark, M. K., \u0026amp; Watanuki, S. (2005). Specific physiological responses in women with severe primary dysmenorrhea. Journal of Physiological Anthropology and Applied Human Science, 24(6), 601\u0026ndash;609.\u003c/li\u003e\n \u003cli\u003ePetraglia, F., Musacchio, C., Luisi, S., \u0026amp; De Leo, V. (2008). Hormone-dependent gynaecological disorders. Best Practice \u0026amp; Research Clinical Obstetrics \u0026amp; Gynaecology, 22(2), 235\u0026ndash;249.\u003c/li\u003e\n \u003cli\u003ePinilla, L., Aguilar, E., Dieguez, C., Millar, R. P., \u0026amp; Tena-Sempere, M. (2012). Kisspeptins and reproduction. Physiological Reviews, 92(3), 1235\u0026ndash;1316.\u003c/li\u003e\n \u003cli\u003ePrado, R. C. R., Silveira, R., Kilpatrick, M. W., Pires, F. O., \u0026amp; Asano, R. Y. (2021). Menstrual cycle, psychological responses, and adherence to physical exercise. Frontiers in Psychology, 12, 525943.\u003c/li\u003e\n \u003cli\u003eReyes-Lagos, J. J., Ledesma-Ram\u0026iacute;rez, C. I., Pliego-Carrillo, A. C., Pe\u0026ntilde;a-Castillo, M. \u0026Aacute;., Echeverr\u0026iacute;a, J. C., Becerril-Villanueva, E., \u0026amp; Pacheco-L\u0026oacute;pez, G. (2019). Neuroautonomic activity evidences parturition as a complex process. Annals of the New York Academy of Sciences, 1437(1), 22\u0026ndash;30.\u003c/li\u003e\n \u003cli\u003eReznikov, A. G. (2023). Stress-induced disorders of reproductive functions. Physiological Journal/Fiziologichnyi Zhurnal, 69(6), 44\u0026ndash;53.\u003c/li\u003e\n \u003cli\u003eRoy, S., Bhatt, S., \u0026amp; Sharma, A. (2025). Menstrual irregularities and neuroendocrine correlates: A clinical review. Endocrine Practice, 31(4), 311\u0026ndash;320.\u003c/li\u003e\n \u003cli\u003eRuddenklau, A., \u0026amp; Campbell, R. E. (2019). Neuroendocrine impairments of polycystic ovary syndrome. Endocrinology, 160(10), 2230\u0026ndash;2242.\u003c/li\u003e\n \u003cli\u003eRyan, A., Healey, M., Cheng, C., Dior, U., \u0026amp; Reddington, C. (2022). Central sensitisation in pelvic pain: A cohort study. Australian and New Zealand Journal of Obstetrics and Gynaecology, 62(6), 868\u0026ndash;874.\u003c/li\u003e\n \u003cli\u003eSankaranarayanan, R., \u0026amp; Ferlay, J. (2006). Worldwide burden of gynaecological cancer. Best Practice \u0026amp; Research Clinical Obstetrics \u0026amp; Gynaecology, 20(2), 207\u0026ndash;225.\u003c/li\u003e\n \u003cli\u003eSnyder, D. K., \u0026amp; Balderrama-Durbin, C. (2012). Integrative approaches to couple therapy. Behavior Therapy, 43(1), 13\u0026ndash;24.\u003c/li\u003e\n \u003cli\u003eSolorzano, C. M. B., Beller, J. P., Abshire, M. Y., Collins, J. S., McCartney, C. R., \u0026amp; Marshall, J. C. (2012). Neuroendocrine dysfunction in PCOS. Steroids, 77(4), 332\u0026ndash;337.\u003c/li\u003e\n \u003cli\u003eSommer, C., \u0026amp; Kress, M. (2004). How proinflammatory cytokines cause pain. Neuroscience Letters, 361(1\u0026ndash;3), 184\u0026ndash;187.\u003c/li\u003e\n \u003cli\u003eStanković, I., Adamec, I., Kostić, V., \u0026amp; Habek, M. (2021). Autonomic nervous system\u0026mdash;Anatomy, physiology, biochemistry. In International Review of Movement Disorders (Vol. 1, pp. 1\u0026ndash;17). Academic Press.\u003c/li\u003e\n \u003cli\u003eSzukiewicz, D., Wojdasiewicz, P., Watroba, M., \u0026amp; Szewczyk, G. (2022). Mast cell activation syndrome in COVID-19 and female reproductive function. Journal of Immunology Research, 2022, 9534163.\u003c/li\u003e\n \u003cli\u003eTaub, D. D. (2008). Neuroendocrine interactions in the immune system. Cellular Immunology, 252(1\u0026ndash;2), 1\u0026ndash;6.\u003c/li\u003e\n \u003cli\u003eTakeuchi, T., Hashimoto, K., Koyama, A., Asakura, K., \u0026amp; Hashizume, M. (2024). Central sensitisation, depression, anxiety, and somatic symptoms. Life, 14(5), 612.\u003c/li\u003e\n \u003cli\u003eToufexis, D., Rivarola, M. A., Lara, H., \u0026amp; Viau, V. (2014). Stress and the reproductive axis. Journal of Neuroendocrinology, 26(9), 573\u0026ndash;586.\u003c/li\u003e\n \u003cli\u003eTsigos, C., \u0026amp; Chrousos, G. P. (2002). Hypothalamic\u0026ndash;pituitary\u0026ndash;adrenal axis, neuroendocrine factors and stress. Journal of Psychosomatic Research, 53(4), 865\u0026ndash;871.\u003c/li\u003e\n \u003cli\u003eTsutsumi, R., \u0026amp; Webster, N. J. (2009). GnRH pulsatility, the pituitary response and reproductive dysfunction. Endocrine Journal, 56(6), 729\u0026ndash;737.\u003c/li\u003e\n \u003cli\u003eTurgeon, J. L., McDonnell, D. P., Martin, K. A., \u0026amp; Wise, P. M. (2004). Hormone therapy: Physiological complexity belies therapeutic simplicity. Science, 304(5675), 1269\u0026ndash;1273.\u003c/li\u003e\n \u003cli\u003eValera, H., Chen, A., \u0026amp; Grive, K. J. (2025). The hypothalamic-pituitary-ovarian axis, ovarian disorders, and brain aging. Endocrinology, 166(10), bqaf137.\u003c/li\u003e\n \u003cli\u003evan den Akker, O. (2011). The menstrual cycle: Psychological, behavioral, physiological, and nutritional factors. In Handbook of Behavior, Food and Nutrition (pp. 879\u0026ndash;888). Springer New York.\u003c/li\u003e\n \u003cli\u003eVannuccini, S., Clifton, V. L., Fraser, I. S., Taylor, H. S., Critchley, H., Giudice, L. C., \u0026amp; Petraglia, F. (2016). Infertility and reproductive disorders. Human Reproduction Update, 22(1), 104\u0026ndash;115.\u003c/li\u003e\n \u003cli\u003eVijayan, V., Rajendran, M. J., Vasanthi, R. K., Emmanuel, C. E., Prasanna, M., Abraham, J., \u0026amp; Bagchi, S. (2025). Revolutionizing gynecologic pain management. Indian Journal of Obstetrics and Gynecology Research, 12(3), 377\u0026ndash;384.\u003c/li\u003e\n \u003cli\u003eWegmann, T. G. (1990). The cytokine basis for cross-talk between the maternal immune and reproductive systems. Current Opinion in Immunology, 2(5), 765\u0026ndash;769.\u003c/li\u003e\n \u003cli\u003eWei, Y., Liang, Y., Lin, H., Dai, Y., \u0026amp; Yao, S. (2020). Autonomic nervous system and inflammation interaction in endometriosis-associated pain. Journal of Neuroinflammation, 17(1), 80.\u003c/li\u003e\n \u003cli\u003eWeidner, K., Einsle, F., Siedentopf, F., St\u0026ouml;bel-Richter, Y., Distler, W., \u0026amp; Joraschky, P. (2006). Psychological and physical factors influencing quality of life. Journal of Psychosomatic Obstetrics \u0026amp; Gynecology, 27(4), 257\u0026ndash;265.\u003c/li\u003e\n \u003cli\u003eWeiss, G., Goldsmith, L. T., Taylor, R. N., Bellet, D., \u0026amp; Taylor, H. S. (2009). Inflammation in reproductive disorders. Reproductive Sciences, 16(2), 216\u0026ndash;229.\u003c/li\u003e\n \u003cli\u003eWu, D., \u0026amp; Chen, X. (2025). HPA axis dysregulation and gynaecological outcomes. Reproductive BioMedicine Online, 50(4), 103985.\u003c/li\u003e\n \u003cli\u003eXanthos, D. N., \u0026amp; Sandk\u0026uuml;hler, J. (2014). Neurogenic neuroinflammation. Nature Reviews Neuroscience, 15(1), 43\u0026ndash;53.\u003c/li\u003e\n \u003cli\u003eYanguas-Cas\u0026aacute;s, N., Brocca, M. E., Azcoitia, I., Arevalo, M. A., \u0026amp; Garcia-Segura, L. M. (2019). Estrogenic regulation of neuroprotective and neuroinflammatory mechanisms. In Sex Steroids\u0026rsquo; Effects on Brain, Heart and Vessels (pp. 27\u0026ndash;41). Springer International Publishing.\u003c/li\u003e\n \u003cli\u003eYılmazer, E. (2024). Hormonal underpinnings of emotional regulation. The Journal of Neurobehavioral Sciences, 11(2), 60\u0026ndash;75.\u003c/li\u003e\n \u003cli\u003eYu, J. (2014). Endocrine disorders and the neurologic manifestations. Annals of Pediatric Endocrinology \u0026amp; Metabolism, 19(4), 184\u0026ndash;190.\u003c/li\u003e\n \u003cli\u003eYu, W., Huang, T., \u0026amp; Zhang, X. (2021). Neuroimaging correlates of chronic pelvic pain in women: Systematic review and meta-analysis. Human Brain Mapping, 42(11), 3462\u0026ndash;3477.\u003c/li\u003e\n \u003cli\u003eYu, Y., Chen, T., Zheng, Z., Jia, F., Liao, Y., Ren, Y., \u0026amp; Liu, Y. (2024). The role of the autonomic nervous system in polycystic ovary syndrome. Frontiers in Endocrinology, 14, 1295061.\u003c/li\u003e\n \u003cli\u003eYun, A. J., Bazar, K. A., \u0026amp; Lee, P. Y. (2004). Autonomic dysfunction and female fertility disorders. Medical Hypotheses, 63(1), 172\u0026ndash;177.\u003c/li\u003e\n\u003c/ol\u003e"}],"fulltextSource":"","fullText":"","funders":[],"hasAdminPriorityOnWorkflow":false,"hasManuscriptDocX":true,"hasOptedInToPreprint":true,"hasPassedJournalQc":"","hasAnyPriority":true,"hideJournal":true,"highlight":"","institution":"","isAcceptedByJournal":false,"isAuthorSuppliedPdf":false,"isDeskRejected":"","isHiddenFromSearch":false,"isInQc":false,"isInWorkflow":false,"isPdf":false,"isPdfUpToDate":true,"isWithdrawnOrRetracted":false,"journal":{"display":true,"email":"[email protected]","identity":"researchsquare","isNatureJournal":false,"hasQc":true,"allowDirectSubmit":true,"externalIdentity":"","sideBox":"","snPcode":"","submissionUrl":"/submission","title":"Research Square","twitterHandle":"researchsquare","acdcEnabled":true,"dfaEnabled":false,"editorialSystem":"","reportingPortfolio":"","inReviewEnabled":false,"inReviewRevisionsEnabled":true},"keywords":"Neurogynecology, neuroendocrine regulation, autonomic nervous system, psychosomatic stress, central sensitisation, neuro-immune interactions","lastPublishedDoi":"10.21203/rs.3.rs-9181695/v1","lastPublishedDoiUrl":"https://doi.org/10.21203/rs.3.rs-9181695/v1","license":{"name":"CC BY 4.0","url":"https://creativecommons.org/licenses/by/4.0/"},"manuscriptAbstract":"\u003ch2\u003eBackground\u003c/h2\u003e \u003cp\u003eNeurogynecology is a rapidly evolving interdisciplinary field that elucidates bidirectional interactions between the nervous system and the female reproductive system. Disorders including polycystic ovarian syndrome (PCOS), dysmenorrhea, endometriosis, chronic pelvic pain, and stress-related infertility are increasingly recognised as biopsychoneuroimmune conditions in which neuroendocrine dysregulation, autonomic imbalance, psychosomatic stress, and neuro-immune signaling function as central pathogenic mechanisms.\u003c/p\u003e\u003ch2\u003eObjectives\u003c/h2\u003e \u003cp\u003eTo systematically synthesise evidence on neuro-gynaecological mechanisms, evaluate clinical correlations, and assess integrative therapeutic outcomes across key gynaecological conditions.\u003c/p\u003e\u003ch2\u003eMethods\u003c/h2\u003e \u003cp\u003eA PRISMA-guided systematic review was conducted. PubMed, Scopus, and Google Scholar were searched using predefined Boolean operators. Peer-reviewed clinical, observational, experimental, neuroimaging, and psychosomatic studies published primarily between 2000 and 2026 were included, for neurological, neuroendocrine, autonomic, or psychosomatic relevance to gynaecological pathology.\u003c/p\u003e\u003ch2\u003eResults\u003c/h2\u003e \u003cp\u003eEighty-nine studies met inclusion criteria. Four principal neuro-gynaecological pathogenic domains were identified: (1) HPA\u0026ndash;HPO axis dysregulation mediating stress-induced reproductive suppression; (2) autonomic nervous system imbalance characterised by sympathetic hyperactivity and reduced vagal tone, measurable by heart rate variability; (3) psychosomatic stress driving central sensitisation and disproportionate pain perception; and (4) bidirectional neuro-immune crosstalk sustaining neurogenic inflammation in chronic pelvic conditions.\u003c/p\u003e\u003ch2\u003eConclusion\u003c/h2\u003e \u003cp\u003eGynaecological disorders represent complex, centrally driven biopsychoneuroimmune conditions requiring multidimensional diagnostic and therapeutic frameworks. Adopting an integrative neuro-gynaecological model has significant potential to improve diagnostic precision, reduce symptom chronicity, and deliver personalised, patient-centered women's healthcare. Neurogynecology is positioned to become an essential and standard pillar of modern gynaecological practice.\u003c/p\u003e","manuscriptTitle":"Neurogynaecology and Women’s Reproductive Health: A PRISMA Based Systematic Review of Neuroendocrine Regulation, Autonomic Dysfunction, Psychosomatic Stress, and Integrative Therapeutic Outcomes","msid":"","msnumber":"","nonDraftVersions":[{"code":1,"date":"2026-03-24 14:51:30","doi":"10.21203/rs.3.rs-9181695/v1","editorialEvents":[{"type":"communityComments","content":0}],"status":"published","journal":{"display":true,"email":"[email protected]","identity":"researchsquare","isNatureJournal":false,"hasQc":true,"allowDirectSubmit":true,"externalIdentity":"","sideBox":"","snPcode":"","submissionUrl":"/submission","title":"Research Square","twitterHandle":"researchsquare","acdcEnabled":true,"dfaEnabled":false,"editorialSystem":"","reportingPortfolio":"","inReviewEnabled":false,"inReviewRevisionsEnabled":true}}],"origin":"","ownerIdentity":"206bce25-d9fe-470c-93d8-a12b99d79840","owner":[],"postedDate":"March 24th, 2026","published":true,"recentEditorialEvents":[],"rejectedJournal":[],"revision":"","amendment":"","status":"posted","subjectAreas":[{"id":64874620,"name":"Neurology"},{"id":64874621,"name":"Endocrinology \u0026 Metabolism"},{"id":64874622,"name":"Sexual \u0026 Reproductive Medicine"},{"id":64874623,"name":"Psychology"}],"tags":[],"updatedAt":"2026-03-24T14:51:30+00:00","versionOfRecord":[],"versionCreatedAt":"2026-03-24 14:51:30","video":"","vorDoi":"","vorDoiUrl":"","workflowStages":[]},"version":"v1","identity":"rs-9181695","journalConfig":"researchsquare"},"__N_SSP":true},"page":"/article/[identity]/[[...version]]","query":{"redirect":"/article/rs-9181695","identity":"rs-9181695","version":["v1"]},"buildId":"WvIrzKhiLBfengagbw6Ux","isFallback":false,"isExperimentalCompile":false,"dynamicIds":[84888],"gssp":true,"scriptLoader":[]}